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This  thesis  describes  the  development  of a  linked  1000th  scale  mimic  of  four 
distinct  unit  operations,  including  precipitation  and  centrifugation.  These 
operations  are  utilised  during  the  production  of  an  anti-snake  venom  Fab 
fragment.  A  new  approach  has  been  used  to  define  the  important  engineering 
parameters that impacted on the recovery process; the effect of these was verified 
by experimental work. The mimic requires only millilitre quantities of material to 
predict changes in the physical and biological properties of key components, such 
as  particle  size  and  antibody  activity.  The  potential  impact  of several  process 
changes on the characteristics of the feed stream and on purification steps further 
downstream has been assessed, which is not possible without a linked system.
Microfiltration  has  been  examined  as  a  possible  alternative  to  the  current 
centrifugal method of recovering the antibody particles. A small-scale stirred cell 
device  was  used  to  carry  out  a  number  of  operations  in  a  single  piece  of 
equipment;  these  included  separation,  concentration  and  buffer  exchange.  An 
overall  increase  in  the  yield  of  10%  was  observed.  This  was  attributed  to  the 
ability  of microfiltration  to  reduce  material  losses  by  integrating  a  number  of 
operations.
A  preliminary  investigation  has  been  conducted  into  the  possibility  of utilising 
Protein G affinity chromatography in place of the current four-step precipitation 
and  centrifugation  recovery  operation.  A  mathematical  model  capable  of 
predicting the size and shape of the breakthrough curves has been developed; the 
predicted  curves were  tested by comparison  with  breakthrough  curves  produced 
under  different  experimental  conditions.  The  initial  results  demonstrated  the 
feasibility  of utilising  affinity  chromatography  as  a  one  step  recovery  process. 
However the predicted breakthrough curves varied from the experimental curves 
suggesting that the mathematical model requires refinement.
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co = angular velocity = 27m (rps)
0 = half disc angle (rad)
Z = Sigma (m2)
|i = viscosity (mPa.s)
0 = volume of matrix (cm3)
$  = Power input per unit volume of suspension (WKg"1)
AP = pressure (bar)
APtm or TMP = transmembrane pressure (bar)
< |> v  = volume fraction of particles = n d  No / 6  (-)
Ap = density difference between the particle and the suspending fluid (gem'3)
A = filter area (m ) 
b = channel height (m)
B = Solubility constant (-)
C = particle concentration (Kg.m'3)
Co = initial protein concentration (mg/ml)
Ca = Camp number  (-)
Cb = bulk concentration of cells in the feed stream (Kg.m' )
Cm = concentration of solute in the mobile phase (mg/ml)
Cs = concentration of adsorbed solute at equilibrium (mg/ml)
Cw  = wall concentration of cells (Kg.m*3)
•y  i
D = diffusion coefficient (cm s ')
D = impeller diameter (m) 
d = particle diameter (m) 
ds = particle diameter (m)
Ef = evt = time integrated shear stress (Nm' )
Fo = initial flux  (L.m^.hr'1)
F i = correction factor applied to account for the presence of the spacer chalks (-)
*y
g = gravitational acceleration (m .s')
G = mean velocity gradient (-)
1  = ionic strength of solution (mols)
19J = flux (L.m"2.hr"1 )
K = mass transfer coefficient (Kg.m^.s*1 )
K| = forward rate constant (m3/Kg/hr)
K.| = reverse reaction rate constant (m3/Kg/hr)
K2 = backward rate constant (m3/Kg/hr')
Ka = association constant (Kg/m3)
Kb = Boltzman constant (J.K 1)
Kp = disassociation constant (Kg/m3) 
kp = proportionality constant (-)
L = channel length (m) 
n = impeller speed (rps)
No = particle number concentration (-)
Ncrit= rotational speed (rps)
Nr(j = rotational speed of laboratory rotating disc device (rps) 
p = density of the bulk suspension (Kgm*3)
P = power input (W)
Po = power number (-)
Pi = feed inlet pressure (bar)
P2 = retentate outlet pressure (bar)
P3 = permeate outlet pressure (bar)
P/ = liquid density (gem ')
Pp = particle density (gem'3)
1   1
Q = volumetric flowrate (m s ')
qm  = maximum monolayer capacity of the matrix (mg/ml) 
r = distance from the axis of rotation (m)
Ro = outer disc radius (m)
Ri = inner disc radius (m)
Rc = cake resistance (m.Kg*1 )
rcrit = critical radius of the structure (m)
re = equivalent min and max radius (m)
Rmax ^maximum radius (m)
R mjn = minimum radius (m)
rp = radius of the diffusing particle (m)
20Rt = sum of the membrane resistance (m.Kg'1)
Rt  =  total  hydrodynamic  resistance  defined  for  a  given  membrane  and  a  pure 
solvent (water) (m.Kg1 )
5 = solubility (-)
Se = equivalent settling distance (m)
T = absolute temperature (K) 
t = time (s)
T = torque (Nm)
V = volume (m3)
Vcrit  = tip-velocity (m.s'1)
Vf = volume of filtrate required to double the resistance to flow compared to the 
filter alone (L)
Vg = Stokes settling velocity (m .s1)
Vm ax = maximum volume filtered (L/m )
Vt = volume filtered (L)
w = channel width (m)
z = number of discs in the stack (-)
a  = effectiveness factor of collisions in forming aggregates (-)
21Abbreviations
dio / dO.l = particle size of 10% and less of the total volume of particles 
dso / d0.5 = particle size of 50% and less of the total volume of particles 
d% / d0.9 = particle size of 90% and less of the total volume of particles
221 Introduction
1.1  Background Of Protherics
The  estimated  annual  number of world-wide  deaths  from  snakebites  are  around 
100,000  (Smith,  2001).  In the  USA  alone  roughly  8000  people  are  bitten  each 
year.  The  incidence of snakebites  is rising as more and more people come  into 
contact with snakes, hence there is an increasing need for an effective anti-venom 
(Chippaux, 1998).
Snake venom  is composed of a complex  mixture  of proteins;  these  are  injected 
into  a victim  when  bitten.  The  venom’s  poisonous  action  depends  on  its  exact 
composition:
•  Some destroy red blood cells and prevent clotting
•  Some effect the nervous system and interfere with movement
•  Others are destructive to the tissue around the bite
DNA immunisation targeting specific venom toxin molecules has the potential to 
treat large groups of the population in the affected areas of the world.  However, 
the technique is in its infancy (Harrison, 2000) and it will be many years before a 
product becomes available on the market.  As such, a snakebite victim is currently 
treated through the use of antibodies developed against the venom, extracted from 
animal  serum  and  purified  for  human  use.  Traditionally  anti-venom  has  been 
produced by immunising animals, such as horses with a cocktail of venoms from 
across the board. Serum would be harvested from the animal and injected into the 
patient.  Due to the “foreign” nature of the anti-venom antibodies produced in this 
fashion allergic reactions by the patients are commonplace and could be fatal.
Protherics PLC (Wales, UK) has developed a new rattlesnake venom specific Fab 
fragment that is approved by the US Food and Drug Administration. It is expected
23to open up a market worth an estimated $35 million a year.  Since the action of the 
anti-venom is determined entirely by the Fab region, the Fc region of the antibody 
is removed during the purification process.  This results in a significant reduction 
in allergic responses due to the Fc fragment being highly glycoslylated.  Without 
the  Fc  region  the  patient’s  immune  system  cannot  readily  identify  the  Fab 
fragment as being “foreign” in nature.  Further reductions in the allergic reaction 
are  due  to  the  highly  purified  nature  of  the  anti-venom.  In  addition  a  Fab 
fragment, when compared to a whole antibody, can more quickly leave the blood 
stream; has faster diffusion rates into the affected tissues and the small Fab-venom 
complex  can  be  more  rapidly  cleared  from  the  body.  This  results  in  an  anti­
venom, that is more effective.
There are thirty-two species of rattlesnake and sixty five to seventy subspecies.  In 
order  for  the  anti-venom  to  be  effective  one  single  treatment  for  all  types  of 
rattlesnake  is  required.  Investigation  into  the  different  rattlesnake  venoms 
identified similarities in their composition.  Four species of snake were identified 
the venom from which when used to develop antibodies that are blended together, 
would give protection against all species.  These were:
•  Agkistrodon piscvorous (Western cottonmouth)
•  Crotalus atrox (Western diamondback)
•  Crotalus adamanteus (Eastern diamondback)
•  Crotalus scutulatus (Mojave rattlesnake)
The antibody fragments, administered via intravenous injection, work by binding 
to and thereby neutralising the venom toxins; facilitating their redistribution away 
from the target tissues and their elimination from the body.
The very first stage in the production of the anti-venom requires separate groups 
of sheep  to  be  immunised  with  each  different  type  of venom.  The  polyclonal 
antibody  Fab  fragments  against  each  type  of venom  are  then  isolated  from  the 
serum. The four products are then blended in equal quantities to produce one anti­
venom effective against all North American rattlesnake venoms.
24The sheep (kept in Australia) are immunised on a monthly schedule using venom 
collected in Arizona USA,  which has been processed into  sheep dose vials then 
freeze-dried  in  Wales,  UK.  The  venom  is  mixed  with  Freunds  adjuvant  (a 
solution of oils which increases the immune response) and injected into the sheep. 
Each sheep is bled once a month with each bleed producing 750-800mls of blood. 
The blood is clotted and centrifuged which leaves roughly 400mls of serum. This 
process takes twenty minutes after which the serum is pooled, dead end filtered, 
frozen and sent to Wales (UK) for purification.
251.2  Industrial Scale Purification Of Fab Fragments From Ovine
Serum
The entire industrial scale downstream purification process is shown in figure 1.1.
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Figure  1.1  Process  flow sheet for the purification of polyclonal  Fab fragments 
from ovine serum
The  following  section describes the  purpose of the  purification  steps; the initial 
step, which is not described  in detail, is the 0.2pm depth filtration of the thawed 
serum which removes cyro-precipitates.
261.2.1  Precipitation
Precipitation is a fast way of concentrating proteins from solution.  Under normal 
conditions proteins are associated with various levels of bound water. These form 
a hydration shell around the molecule.  The addition of highly charged ions (e.g. 
sulphate) to a protein solution has several effects:
1.  At low concentrations the solubility of the protein usually increases slightly. 
This effect is called salting in and is explained by the Debye-Huckel theory. 
This states that at low concentrations the protein becomes surrounded by the 
salt counter ions. This screening results in a decrease in the electrostatic free 
energy of the protein and an increase in the activity of the solvent, which in 
turn leads to an increase in solubility (Debye and Huckel, 1923).
2.  At  high  concentrations  the  attractive  forces  between  hydrophobic  areas 
increase  due  to  greater  induced  dipoles.  Also,  the  salt  ions  disrupt  the 
hydrogen  bonds  between  the  protein  and  water,  these  effects  result  in  the 
precipitation  of proteins  from  the  solution.  The  particulars  of precipitate 
formation and growth kinetics are detailed in section 1.3.1.
Protherics PLC use precipitation to salt out the immunoglobulins from the serum. 
Precipitation  is  a  good  first  step  choice  because  it  reduces  the  volume  of feed 
material and provides an acceptable level of initial purification.  An equal volume 
of 36%(w/v) liquid sodium sulphate solution is added to the serum, resulting in a 
final  concentration  of 18%(w/v)  sodium  sulphate.  This  solution  is  left  stirring 
overnight.  Sodium sulphate is used in preference of ammonium sulphate because 
ammonium sulphate is corrosive and toxic.  The immunoglobulins are precipitated 
out as a white paste whilst the majority of the albumin, the main contaminant at 
this stage, remains in solution.
Post precipitation disc stack centrifugation is used to separate the two phases.  The 
serum/sodium sulphate solution is pumped into the centrifuge which is spinning at 
7500rpm at a flow rate of 120 to 130L/hr. The supernatant flows out via the waste 
pipe  (albumin fraction).  The precipitate  is  desludged  at regular intervals  along 
with a hood flush of 18% (w/v) sodium sulphate.  Following the completion of the
27batch,  the  precipitated  IgG  is  resuspended  in  18%  (w/v)  sodium  sulphate  and 
centrifuged again in order to further reduce the levels of albumin contamination.
1.2.2  Centrifugation
Centrifugal  separation  is  a  sedimentation  operation  accelerated  by  centrifugal 
force.  As  such,  a  prerequisite  for  separation  is  a  density  difference  between 
phases.  This technique can be used to separate two liquid phases or a solid/liquid 
mixture. Protherics PLC utilise a continuous flow disc stack centrifuge (Westfalia 
separator serial number SAM R3036, type SAM, bowl  volume 6.9L with a max 
speed of 7500rpm, 6288g) to separate the precipitated antibodies from the proteins 
remaining in solution.
Precipitate solution:::
Centripetal  Pump
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Figure 1.2  A disc stack centrifuge
28The precipitate solution is pumped into the centrifuge (feed flow rate is between 
120-130L/hour) where it collects in the feed chamber at the bottom of the stack. 
During normal  operation  the  stack  is  spinning  at  7500rpm  this causes  the  solid 
precipitate to be thrown outwards and collect on the underside of the discs. It then 
slides down into the collection chamber, which is located by the discharge ports. 
The liquid part containing the unwanted proteins flows out the top of the machine 
to  waste.  At  a  time  interval,  set  by  the  percentage  solids  content  of the  feed 
stream,  pressurised  water  is  used  to  open  the  sliding  bowl  resulting  in  the 
collected  solid  being  ejected  into  a  clean  vessel.  If the  interval  is  too  long  a 
situation called breakthrough arises whereby the solid collection area becomes full 
and the solids begin to go out via waste.
1.2.3  Digestion
Following centrifugation the partially purified antibodies, consisting mainly of the 
IgG  sub type, are digested by the  addition  of papain.  Antibodies  are  Y  shaped 
proteins composed of two heavy chains and two light chains joined by disulphide 
linkages.  Digestion  with  papain  cleaves  the  antibody  into  two  regions:  the  Fc 
region  and  the  Fab  region.  The  Fc  region  is  so  called  because  it  is  readily 
crystallisable.  The  Fab  region  is  so  called  because  it  contains  the  antibody 
binding site.
Figure 1.3  Stylised representation of the sub-unit structure of an IgG antibody
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29The Fc region mediates some aspects of the immune response, but differences in 
the glycosylation pattern between species mean that foreign antibodies are easily 
recognised  by  a  patient’s  immune  system  as  being  foreign  in  origin.  For  this 
reason  when  antibodies  from  one  species  are  injected  into  another  an  allergic 
reaction  is  often  observed.  This  is  caused  by  the  patient’s  immune  system 
attacking  the  antibodies.  The  functions  of  the  Fc  region  are  not,  however, 
required  by  the  anti  venom.  The  binding of the  Fab  fragment to the  venom  is 
enough to neutralise it.
Protherics PLC utilise the unique action of the enzyme papain to cleave the heavy 
chain on the COOH* terminal side of the disulphide bond that links the heavy and 
light  chains.  This  results  in  the  formation  of two  Fab  fragments  and  one  Fc 
fragment.  The Fc fragment can then be purified out further downstream resulting 
in  a product which  has  been  modified  sufficiently to  reduce  recognition  by the 
patient’s  immune  system.  This  dramatically  reduces  the  risk  of  harmful  side 
effects.
A  solution  of  papain,  cysteine  and  EDTA  is  added  to  the  product  of  the 
centrifugation  stage.  This  solution  is  then  left  in  a  stirring  vessel  overnight  at 
37°C.  The following morning a sample is taken to the quality control laboratories 
where  Fast  Protein  Liquid  Chromatography  (FPLC)  is  used  to  determine  if the 
digestion is complete.  FPLC works by measuring the absorbance of the proteins 
contained in a solution.  The proteins are separated according to their molecular 
weight (IgG =  150-180000 kDa,  Albumin = 67000 kDa,  Fab = 45-50000 kDa). 
Fab and  Fc  fragments  appear as  one peak  (Fc  rides  on the  shoulder of the  Fab 
peak), whilst IgG forms another peak.  The solution has to contain less than  1% 
IgG.  If this is the case, the reaction is stopped by the addition of iodoacetamide. 
Iodoacetamide  works  by  binding  irreversibly  to  cysteine  and  other  side  chains 
neutralising the papain.
Filtration  is  used  to  remove  the  majority  of  the  insoluble  or  crystallised  Fc 
fragments. However the product solution now also contains a large concentration 
of other  chemicals  such  as  EDTA  and  soluble  Fc  fragments.  Ultrafiltration  is
30used to remove these chemicals, concentrate the product and change the buffer to 
one compatible with the next purification stages.  This is achieved by passing the 
solution across a filter with pores that are  small  enough to block the passage of 
Fab fragments but large enough to allow other contaminants to pass to waste.  At 
this stage the product is known as total Fab and is eighty percent pure.  It can be 
stored for up to eight weeks before final processing.
1.2.4  Ion Exchange
Ion  exchange  chromatography  is  used  to  separate  the  Fc  fragments  and  other 
blood proteins from the Fab fragments.  Separation on an  ion exchange  column 
depends  upon  the  reversible  binding  of charged  molecules  to  immobilised  ion 
exchange  groups  of an  opposite  charge.  There  are  two  types  of ion  exchange 
column:  cationic exchangers and anionic exchangers.  Cationic exchangers bind 
molecules with a net positive charge,  whilst anionic  exchangers bind molecules 
with a net negative charge.
The pH/ionic strength of the solution a protein is dissolved in effects its binding 
affinity.  By altering the pH or ionic strength of the solution, proteins can be given 
either a net positive or a net negative charge.  Different proteins have  different 
charges at different pH/ionic strength.  This phenomenon can be used to separate 
one protein from a solution containing many.
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Figure  1.4  Schematic representation of Ion Exchange chromatography (adapted 
from the Ion Exchange chromatography handbook, Pharmacia)
As the column has a finite capacity (column dimension 30cm diameter,  19-20cm 
bed height), the total  Fab produced to date must be divided up and loaded batch 
wise.  As the solution is passed over the matrix the unwanted proteins, such as the 
Fc  fragments and albumin,  bind  reversibly  whilst the  Fab fragments go  straight 
through and are collected.  The portion which remains bound to the column is then 
removed  by  washing  with  lOmM  phosphate,  1M  NaCl.  The  column  is  then 
cleaned  and  sanitised  by application  of 1M  sodium hydroxide.  Before  the next 
batch  can  be  processed  the  column  must  be  re-equilibrated  by  the  addition  of 
lOmM phosphate buffer.  This ensures that the matrix and the solution the Fab is 
contained in are compatible.
1.2.5  Affinity Chromatography
The final purification step is the separation of the component specific antibodies 
from  the  other  unspecific  antibodies.  Protherics  PLC  utilise  affinity 
chromatography to achieve this.
32This technique allows the purification of almost any bio-molecule on the basis of 
its biological function or individual chemical structure.  It is a type of adsorption 
chromatography  in  which  the  molecule  of interest  is  specifically  and  reversibly 
adsorbed  by  a  complementary  binding  substance  (ligand)  immobilised  on  an 
insoluble support (matrix).
Proteins 
recognising the 
affinity ligand 
bind
Proteins 
which do not 
recognise the 
ligand pass 
through • •
Bead with affinity ligand bound 
iiTeversibly to surface
Figure 1.5  Schematic representation of affinity chromatography
Successful  separation  requires  a  bio-specific  ligand  that  can  be  covalently 
attached to a chromatographic bed material, the matrix.
Protherics PLC utilise the snake venom specific for the anti-venom as the ligand. 
This is bound irreversibly to the matrix (Controlled pore glass, Millipore, Watford 
UK).  Thus,  as  each  component  recognises  a  different  type  of  venom,  each 
component of the anti-venom requires its own column (Column dimensions 30cm 
diameter,  28.5  to  32cm  bed  height).  This  means  that there  are  four columns  in 
total.  Once again the column has a finite capacity so the product is split into equal
33volumes  and  each  is  loaded  separately  batch  wise.  Separation  proceeds  as 
follows:
•  The column  is equilibrated with  lOOmM  Phosphate  buffer pH  7.5  at a  flow 
rate of 141 cm/hr.
•  The ion exchange purified Fab is added at a flow rate of 30cm/hr.  Antibodies 
specific  for the particular snake venom bind whilst everything else passes to 
waste.
•  The column  is washed with 0.9%  (w/v) NaCl  at a flow rate of 141 cm/hr to 
ensure that all the unbound proteins are washed away.
•  The  specific  Fab  molecules  are  eluted  from  the  column  by  the  addition  of 
lOOmM glycine-HCl pH 2.5 at a flow rate of 141 cm/hr.  The product is held in 
this solution for a minimum of two hours as this has been shown to inactivate 
certain groups of viruses (Omar, 1996).
This process is repeated for each batch. When the columns are not in use they are 
stored in a refrigerated area within a bacteriocidal solution.  The final stage is the 
blending and formulation of the final product.
1.2.6  Blending and Formulation
With  the  downstream  processing  complete,  the  final  step  is  the  blending  and 
formulation  of the  individual  components  into  a  solution  suitable  for  freeze- 
drying.  This solution is then concentrated so that each vial contains a consistent 
potency of product.
•  The four anti-venom components are equally blended together forming a pure 
product, which contains between lg/L to 3g/L.
•  Ultrafiltration concentrates the product to  12g/L and exchanges the buffer to 
sodium acetate, which is compatible with the next stage.
•  The product is passed through a 15nm viral filter.  This has been shown to be 
an effective viral  removal  step (O’Grady,  1996).  This gives Protherics PLC 
two validated steps for virus removal.
34•  Ultrafiltration exchanges the buffer for low salt phosphate, which is suitable 
for  freeze-drying.  This  causes  some  of the  Fab  to  precipitate  out  these  are 
removed by depth filtration.
•  Final ultrafiltration concentrates the product to 70g/L.
•  Contractors are used to freeze dry the product and place it in to vials.  One vial
holds  a  maximum  of  14mls.  The  bulk  formulated  solution  is  tested  by
external contractor for its potency to neutralise the venoms activity.  The vial
fill  volume  is calculated  such  that  vials  from  batch to  batch  always  contain 
sufficient neutralising potency to meet the final product specification.
1.2.7  Conclusion
Anti-venom prepared by this method is not cheap;  full treatment normally costs 
$10000.  From  a  process  engineering  perspective,  there  is  now  very  intense 
pressure on companies to establish techniques that can rapidly assess new process 
options to produce a potential  new drug candidate in sufficient quantities for its 
perceived  demand.  This  pressure  is  compounded  further  by  the  fact  that  such 
process  information  is  needed  often  early  in  the  life  cycle  of the  new  drug 
candidate.  Unfortunately  this  is  when  pilot  plant  trials  are  either  not  feasible, 
because the company has no access to suitable facilities, or not practical because 
only very small quantities of relevant materials are available for tests.
This thesis describes an engineering approach to the development and verification 
of small  scale  devices/processes  that  mimic  industrial  scale  operations.  This 
allows key unit operations and options to be investigated early on in the product 
development  life  cycle,  providing  the  process  engineer  with  invaluable 
information.  It  also  seeks  to  investigate  alternative  process  options  for  the 
production of the anti-venom.
351.3  Background Theory and Practice of Downstream Unit
Operations
This section details the research already conducted on the techniques of interest 
and the impact on this study.  It endeavours to cover the work related to and the 
concepts  important  to  the  running  and  mimicking  of each  purification  process 
utilised.  It also aims to provide an overview of the methods available for protein 
purification,  which  are  applicable  to  the  purification  of antibodies  from  ovine 
serum.
1.3.1  Precipitation
Precipitation has been used as a method to separate proteins for  130 years.  It  is 
well  established  in  the  separation  of  proteins  from  blood  plasma,  microbial 
extracts and plant extracts (Foster,  1994).  Precipitation exploits the differences in 
protein solubility in order to achieve separation. The proteins are precipitated as a 
non-crystalline solid.
Precipitation is often used near the start of a purification process for a variety of 
reasons.  These include:
•  Precipitation  methods  can  inexpensively  process  a  large  volume  of  crude 
material,  resulting  in  a  reduction  of the  volume  of material.  Although  the 
purification  factors of 3-10 that are typically achieved  are  low compared  to 
say  chromatographic  methods  (Bell,  et  al.  1983;  Chisti  and  Moo-young, 
1991).  The  ability  to  process  large  volumes  of  crude  material  mean  this 
method is a good first choice purification step.
•  The  process  is  easily  scale-able  allowing  processing  options  to  be  easily 
studied before the license is agreed.
•  Protein precipitates are compact and stable, thereby allowing the purification 
process to be held at an intermediate stage.
•  Precipitation  places  the  protein  into  an  environment  depleted  of proteolytic 
enzymes and other biologically active substances.
Since  part of this thesis  describes the  mimicking of the  precipitation  stage  it  is 
important  to  understand  the  factors  controlling  the  formation  and  growth  of
36precipitate  particles.  Knowledge  of  these  parameters  will  allow  an  accurate 
mimic of the process to be designed and operated.
Particle  formation  usually  consists  of two  phases;  an  induction phase  involving 
the formation of the nuclei, followed by a growth phase during which other solute 
molecules  attach to the  nuclei.  The  precipitate  particles  continue  to  grow until 
equilibrium is reached.  In order for particle formation to occur the soluble solute 
concentration must be greater than the normal equilibrium value.  As nucleation 
and  growth  are energy  consuming processes,  there  is  a need  for the  solution to 
attain  a  certain  level  of supersaturation.  It  is  the  excess  solute  concentration 
relative to the equilibrium solubility value that contributes the necessary energy.
The  formation  and  growth  of precipitate  particles  follows  a  set  series  of well 
defined stages.
Stage  1.  Addition of the precipitant, achievement of supersaturation and 
nuclei  formation.  Nucleation  times  can  range  from  a  few  seconds  to  several 
minutes depending on the type of precipitant and the specific protein. Parker and 
Dalgleish  (1977)  used  light  scattering  and  turbidity  measurements  in  order  to 
study the kinetics of this process.
Stage 2.  Perikinetic growth of nuclei to form primary precipitate particles. 
The  rate  of  growth  of  these  particles  will  be  determined  by  the  collision 
frequency.  Particles up to the size of 1  pm are not affected by mixing conditions, 
so collisions will be determined by diffusion, this is shown in equation 1.3.
^ 1  = K N 2  
dt
(equation  1.1)
Ka = 8 nDd
(equation  1.2)
37Where No is the particle number concentration, d is the particle diameter and D is 
the diffusion coefficient.
d = k > t
'Snfjd
(equation 1.3)
Where Kb  is the  Boltzman  constant,  T  is the  absolute temperature  and  p  is  the 
viscosity of the solution.
The above equations imply that there will be a greater rate of collisions and hence 
a  greater  growth  rate  at  higher temperatures.  They  also  imply  a  linear rate  of 
increase of particle volume, mass or molecular weight with time.
Stage 3.  Orthokinetic growth occurs once the particles have reached a size 
of 1  pm.  Fluid motion then causes the particles to collide and form macroscopic 
precipitate particles.
~ dN °  2  2
    =  —  aGd  N n
dt  3
=  — a $ vGN0
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(equation 1.4)
(equation 1.5)
Where < |> v  is the  volume  fraction of particles  which  equals  n d  No /  6,  a   is the 
effectiveness factor of collisions in forming aggregates and G is the mean velocity 
gradient.
These equations imply that the growth rate of the particles should increase with a 
larger mean velocity gradient and greater particle concentration.  They also imply 
that the size of particles should increase exponentially with time.
38Stage  4.  Batch  aging  and  conditioning.  Centrifugation  is  often  used  in 
order to separate the precipitate particles from solution.  For efficient separation 
the best particles are large, dense and strong.  Batch aging can produce particles 
with these attributes. This is where the precipitate is stirred in the tank for a given 
period of time.  The  average  size  of the  final  precipitate  will  be  a result of the 
balance between orthokinetic  growth and  hydrodynamic  shear induced  break up 
of particles.  Increasing  the  intensity  of mixing  will  result  in  smaller  particles. 
Larger  sized  particles  will  be  obtained  at  lower  shear  rates,  however  these 
particles  are  unlikely  to  be  very  strong  and  so  more  likely  to  break  up  when 
subjected to the high shear field found in equipment such as centrifuges.
Shear conditions within a reactor can be defined by the Camp number Gt, where 
G is the average shear rate, or mean velocity gradient and t is the time of exposure 
to  the  shear.  Bell  and  Dunnill  (1982a)  found  that  the  aggregate  strength  was 
dependent on the extent and duration of agitation.  They determined an optimum 
value of the aging parameter Gt of 105 (see figure 1.6).
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Figure 1.6  Effect of aging on the strength of particles (Bell and Dunnill 1982)
39Particles produced by this aging parameter were found to be the most resistant to 
shear break-up. This suggested that precipitates produced under low conditions of 
shear  should  be  aged  for  longer  in  order  to  strengthen  them.  The  improved 
strength at Gt values of 105 were thought to be due to rearrangement and infilling 
with  smaller  particles  giving  a  closer,  denser  and  more  stable  particle.  Other 
studies  by  Hoare  (1982)  and  Clarkson,  et  al.  (1996a)  confirmed  this  finding. 
Hoare (1982) examined the batch aging of ammonium sulphate precipitated casein 
and found that the maximum stable precipitate size was achieved at a Gt value of 
105.  While Clarkson, et al. (1996a) showed that bakers yeast protein precipitated 
with  ammonium  sulphate  had  a  reduction  in  fine  aggregates  of approximately 
1.5pm and an increase in the proportion of larger aggregates of 2 to 4pm at a Gt 
value of 105.
There  are  several  methods  of altering  protein  solubility,  bringing  about  protein 
precipitation:
•  Coagulation  by  heat  may  be  used  to  precipitate  out  unwanted  heat  labile 
proteins  from  a  solution  of more  stable  ones.  When  a  protein  reaches  a 
certain critical temperature it denatures allowing hydrophobic residues buried 
within  its  structure  to  interact  with  each  other  bringing  the  protein  out  of 
solution.
•  Isoelectric  precipitation  may  be  used  to  separate  pH  stable  proteins.  This 
method is based on the fact that at their isoelectric point proteins have no net 
charge.  This  results  in  a  reduction  in  the  repulsive  forces  between  protein 
molecules allowing them to contact each other forming an agglomeration.
•  Metal ions such as zinc or calcium can be used to precipitate proteins. These 
work by binding to the  surface  of the protein molecules again reducing the 
repulsion between the molecules.
•  High concentrations of non-ionic  polymers  (~20%w/v)  such as polyethylene 
glycol  tend  to  induce  precipitation  by  removal  of water  from  the  protein 
environment.
40•  Ionic polyelectrolytes induce precipitation, probably by a mixture of methods 
including  charge  patch  neutralization  and  polymer  bridging.  Very  low 
concentrations are required and the addition of excess quantities leads to re­
solubilisation  of  the  protein.  Reagents  used  include  polyethyleneimine, 
although that particular reagent is difficult to remove further downstream.
The  most  widely  used  method  of protein  precipitation  is  the  addition  of high 
concentrations of neutral salts. This process is known as “salting-out”.  At low salt 
concentrations proteins are very soluble as a result of polar interactions with the 
aqueous  solvent,  ionic  interactions  with  the  salt  present  and  to  some  extent 
repulsive  electrostatic  forces  between  like  charged  molecules  or  aggregates 
(Scopes,  1988).  This  effect  is  often  called  “salting  in”.  At  higher  salt 
concentrations solubility depends more on the hydrophobicity of the protein. The 
most hydrophobic and hence the least hydrated protein tend to be the first to come 
out of solution (Zhang, et al.  1995).  Each protein has a distribution of hydrophilic 
and  hydrophobic  residues  on  its  surface;  these  will  determine  its  solubility 
behavior.  When  hydrophobic  residues  are  forced  into  contact  with  an  aqueous 
environment,  water  molecules  become  bound  in  place  around  these  residues. 
When large amounts of salt are added, the salt molecules become solvated and, as 
water  molecules  become  scarce,  pull  away  the  bound  molecules  from  the 
hydrophobic residues.  The exposed residues can then interact to form a protein 
aggregate.  Once  these  reach  a  size  no  longer  favorable  to  the  soluble  phase, 
precipitation of the solid phase occurs (Foster, 1994).
Precipitation  reactions  generally  follow  the  Cohn  equation  (Chisti  and  Moo- 
young, 1991).
In S = B -K J
(equation  1.6)
Where S is the solubility and I is the ionic strength of solution.  The constants K 
and B represent the slope of the linear portion of the salting-out curve and the y
41intercept  respectively.  B  is  a  function  of both  pH  and  temperature  and  is  at  a 
minimum at the proteins iso-electric point. K is a function of the type of salt used 
and the individual protein.  The constants B and K have also been found to vary 
according to the mode and rate of addition of the precipitant (Foster, et al.  1976). 
This  implies that although the precipitate may be  in a stable  form this does not 
represent a true equilibrium state.
The differing reagents discussed above have different precipitation kinetics. These 
are discussed in a paper by Chan, et al. (1986).
The relative effectiveness of neutral salts in salting out, in particular the anions, is 
given  by  the  lyotrophic  or  Hofmeister  series  (Hofmeister,  1888;  Cacace,  et  al. 
1997):
Citrate > phosphate > sulphate > acetate ~ chloride > nitrate > thiocynate
The series is in order of decreasing effectiveness of anion to cause salting out and 
increasing likelihood of destabilising the protein.
One of the most commonly utilised  salts  is ammonium  sulphate  due to  its high 
solubility,  cheapness  and  stabilising  effect  on  some  enzymes.  However 
ammonium sulphate is corrosive and evolves ammonia at high pH. This makes it 
difficult to process at a large scale (Richardson, 1987).
The main factors, which determine protein solubility and therefore the extent of 
precipitation  are  listed  in  table  1.1.  The  effects  on  the  resulting  particles  of 
altering some of them are discussed afterwards.
42Protein Characteristics Solution properties
Size of molecule Solvent availability e.g. Water
Amino acid composition pH
Amino acid sequence Ionic strength
Number of ionisable residues Dielectric constant
Ratio of polar/non-polar residues Temperature
Distribution of polar/non-polar residues Specific ion effects
Dissociation constants
Protein conformation
Protein charge
Ion binding properties
Chemical nature of amino acids
Table 1.1  Factors determining the solubility of proteins from Foster (1994)
The effects of altering the pH  on the  solubility  of the protein  and the  resulting 
particle size of the precipitate are shown below.
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Figure 1.7  The effect of pH on soya protein solubility (Virkar, et al.  1982)
43Figure 1.8  Effect of pH on precipitate particle size (Chan, et al.  1986)
As can be seen the least solubility and highest particle size occur at roughly the 
same point.
The effect of ionic strength on protein solubility:
Solubility  of|3-
lactoglobulin
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Figure 1.9  The effect of ionic strength on protein solubility (Gronwall 1942) 
As can be seen there is a salting in effect at lower concentrations.
44It  can  be  concluded  from  previous  research  that  the  pH,  temperature,  ionic 
strength, the rate and mode of addition of the precipitant, the type of salt and the 
mixing conditions will all need to be kept similar between the scales of operation 
in order to achieve an accurate mimic.
1.3.2  Centrifugation
Centrifugal separation is a mechanical method of separating the components of a 
mixture of liquids or of liquid and solid particles.  Centrifugation takes advantage 
of the density  differences  between the  liquid phases  or solid and  liquid  phases. 
The material is accelerated in a centrifugal field, which acts in the same manner  as
a gravitational field.  The centrifugal field can however  be varied  by  adjusting  the
rotational  speed and equipment dimensions.  Commercial  centrifugal  equipment 
can reach an acceleration of 2 0 0 0 0  times gravity  ( 2 0 0 0 0  g), where as laboratory 
equipment can reach up to 360000 g.
13.2.1  Types of centrifuge
The  application  and  design  of  centrifugal  separators  has  been  reviewed  by 
Axelsson  (1985)  and  Brunner,  et  al.  (1988).  There  are  five  main  types  of 
centrifuge,  which  are  required  in  order  to  deal  with  the  variety  of  process 
materials produced.  The choice of separator depends on the characteristics of the 
process stream, including the particle  size, the difference in density between the 
solid and liquid phases, the solids content and the tendency for the process stream 
to form emulsions.  Centrifuges are mainly used for cell harvest and washing after 
fermentation  and  for  recovery  of  solid  particles  following  extraction, 
crystallisation or precipitation.
Tubular bowl
The simplistic design of the tubular bowl accounts for its ease of operation.  Fluid 
enters at the bottom and the solids sediment against the wall as the fluid flows up 
and out via an inner ring dam or centripetal pump.  The centrifuge is capable of 
operating  at  high  rotational  speeds.  This  leads  to  good  clarification  and  good 
dewatering.  There  is however no  automated  solids discharge;  solids have to be
45removed manually at the end of the run.  Therefore,  it is best used with process 
streams that have a low solids content and small batch volume.
Decanter/Scroll
This centrifuge design was derived from the tubular bowl. The main difference is 
that solids discharge is achieved via a conveyer screw which rotates at a different 
speed to the bowl.  This has the effect of concentrating solids in streams with high 
solids  content.  It  is  best  suited  to  process  streams,  which  contain  large  dense 
particles  due  to  the  low  centrifugal  forces  achievable  because  of the  imbalance 
inherent to the design.  This machine is attractive because it is capable of handling 
a high solids content and obtaining good dewatering.  It is mainly used for sludge 
dewatering in wastewater treatment.
Multichamber bowl
This centrifuge contains up to five concentric chambers. These have the effect of 
increasing the axial flow path and increasing the area available for sedimentation. 
Large  particles  sediment  out  in  the  inner  chamber,  whilst  smaller  particles 
sediment out in the outer chambers where there is a higher centrifugal force.  The 
effect of shear in the feed zone is decreased since it is flooded. Therefore material 
which enters the feed zone is accelerated slowly. This increases the performance 
of the  centrifuge  since  less  fine  particles  are  produced.  Discharge  of collected 
solids is manual but the increased size means that it can handle process streams 
with a higher solids content than a tubular bowl.
Carr Powerfuge
The  Carr  powerfuge  is  a  tubular  bowl  centrifuge  with  an  automated  solids 
discharge  mechanism.  The  bowl  is  constructed  of titanium,  which  can  tolerate 
higher g forces. As a result, the machine can operate at higher rotational speeds. 
Solids discharge is achieved by means of a scraper that moves into position near 
the bowl wall. Collected material is then removed from the walls and drops into a 
collection vessel whilst the centrifuge is spinning slowly.  The powerfuge can be 
both  cleaned  in  place  and  steamed  in  place  minimising  process  stream 
contamination.
46Disc Stack
The disc stack centrifuge is one of the most commonly employed machines for the 
separation  of biological  materials  in  the  biotechnology  industry.  Applications 
include the separation of cells from fermentation broth (Higgins, et al.  1978; Datar 
and Rosen,  1987), the removal of cell debris after cell disruption (Mosqueira, et 
al.  1981; Clarkson, et al.  1993a), the recovery of inclusion bodies (Jin, et al.  1994) 
and the recovery of precipitates (Bell, et al.  1983; Clarkson, et al.  1996b).
The disc  stack centrifuge consists of a bowl  containing a series of conical discs 
stacked one on top of the other.  The discs are  separated by spacer bars roughly 
1mm  in  height.  During  normal  operation  the  process  material  splits  into  thin 
layers  and  flows  between  the  discs.  Settling  solids  are  thrown  outwards  and 
collect on the underside of the discs and the bowl wall (figure  1.1 0).
Figure 1.10  Disc stack centrifugation
This  configuration  provides  a  large  settling  area  and  constant  flow  path,  which 
unlike tubular bowl centrifuges, is not reduced by the previously separated solids 
(Atkinson,  et  al.  1987).  The  flow  between  the  discs  is  usually  laminar,  which 
makes particle settling easier and reduces the settling distance (Axelsson,  1985). 
Solids discharge is achieved using a hydraulic bowl opening mechanism.
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47Important factors which affect the performance of the centrifuge are:
•  The properties of the material being separated
•  The centrifuge design and operating conditions
1.3.3  Recovery of biological solids
Centrifuges  encounter  some  problems  during  the  recovery  of biological  solids. 
These are mainly caused by small particle size, a low density difference between 
phases and shear or denaturation at air liquid interfaces.
Separating cells
A low density difference and high viscosity lead to separation difficulties. These 
are amplified by the small  size of some cells.  Bacteria range between  1  pm and 
3pm, yeast range between 4pm and 8 pm and fungi are bigger still, although fungi 
are easily sheared and so recovery is not necessarily easier.
Cell debris
Cells are mainly disrupted by either homogenisation or by a bead mill in order to 
release intracellular proteins.  Removal of the debris produced by these operations 
is  difficult  due  to,  for  example,  the  presence  of DNA  or the  small  size  of the 
debris  (Bonneijea,  1988)  but  it  is  very  important.  For  example,  affinity 
chromatography is a high resolution operation but the column is easily fouled, so 
cell  debris  is  usually  removed  before  this  step.  Homogenisation  of cells  also 
results  in debris with a broad  size distribution;  some particles may be  less than
0.2pm. This can cause problems.
Precipitates
As discussed in section  1.3.1  the density and size of precipitate particles depend 
on  the  protein,  the  precipitant  and  the  system  (Bell  and  Dunnill,  1982a  &  b). 
Typically  precipitate  particles range  in  size  from  5pm  to  25 pm,  although  some 
can be as small as  1pm (Clarkson, et al.  1993a).  The density difference between 
phases is usually in the order of 1  Okgm' 3 to  150kgm'3 therefore a low flow rate 
may  be  required.  This  will  result  in  an  increase  in  the  temperature  of the  feed 
stream  unless  the  centrifuge  has  bowl  cooling.  Other problems  are  due  to  the
48nature  of proteins,  which  cause  foaming  and  air  entrapment.  This  causes  low 
settling  velocities  and  denaturation.  High  shear  stresses  in  the  feed  zone  also 
cause precipitates to break-up (Boychyn, et al. 2001; Neal, et al. 2003).
Once separated, solid material must be discharged from the bowl.  The disc stack, 
scroll and Carr powerfuge are the only models with automated discharge.  In the 
other models the collected solids have to be removed manually.  Maybury (1999) 
states  that  feed  rates  calculated  theoretically  are  higher than  in  practice,  due  to 
hindered settling which occurs in process streams with a high percentage of solids. 
For process streams containing 0-2 percent of solids (v/v) two thirds the predicted 
flow should be used and for 5 percent solids half the predicted flow rate should be 
used  (Clarkson,  et  al.  1993b).  The  percentage  solids  content  is  very  important 
when  choosing  which  centrifuge  to  utilise,  since  only  certain  centrifuges  can 
handle certain solids load.  Figure  1.11  (Brunner and  Hemfort,  1988)  illustrates 
which centrifuges can handle what solids concentration.
Separable  solids  (vol  %)  0  20  40  60  80  100
Chamber  bowl  centrifuge  1
Solid  bowl  centrifuge  1
Self-cleaning  centrifuge
Nozzle  centrifuge ■
Decanter  centrifuge ■ ■ ■
Figure  1.11  Guide  to  suitable  centrifuge  design  with  respect  to  feed  solids 
concentration (Brumner and Hemfort, 1988)
491.3.4  Sigma theory
The £ concept is the most commonly used quantity to characterise centrifuges, it 
was  presented  by  Ambler  (1952  and  1959).  In  his  derivation  he  considered 
particles  with  a  critical  diameter  that  were  separated  to  50  percent.  Today 
however  the  most  commonly  used  definition  of the  critical  diameter  (dc)  is  a 
particle that is separated to  100 percent.  This does not influence the formulas for 
the  sigma  value  but  the  value  for  the  feed  flow  rate  (Q)  will  be  halved.  £  is 
defined as:
= r,.Z
Where,Vg is stokes settling velocity 
£ has the general expression:
Z =
Vco2re
The equation for critical diameter becomes
(equation 1.7)
(equation  1.8 )
dc =
,  V /2
1  %VQlhe„ r  S,
{P-P,)v<o\
r  V/ 2
(equation 1.9)
Where,  p  is  the  dynamic  viscosity  of fluid,  Pp  is  the  particle  density,  P/  is  the 
liquid density, se is the equivalent settling distance, g is gravity V is volume, co is 
angular velocity and re is the equivalent min and max radius.
50The derivation in equation 1.9 assumes the following:
•  Viscous drag is determining particle movement
•  The flow in disc bowls between the discs is laminar and symmetrical
•  The liquid rotates at the same speed as the bowl
•  There is no hindered settling
•  The particle always moves at its final settling velocity
Sigma theory allows a centrifuge to be described in terms of a separation area and 
is independent of process parameters.  The sigma value indicates the required area 
of a  gravity  settling  tank,  with  the  same  clarifying  capacity  as  the  centrifuge, 
under the same conditions.  Sigma is used as an index to compare the performance 
of  a  centrifuge  during  scale  up  and  between  centrifuges  of  different  types. 
Protherics PLC disc stack centrifuge has a sigma value of 8400m .
The  information  detailed  within  this  section  indicates  that  in  order to  mimic  a 
centrifuge the settling conditions need to be maintained and the shear conditions 
recreated.
13.5  Filtration
Filtration is a vacuum or pressure driven process that separates the components of 
a  feed  stream.  Separation  is  based  on  size  differences  rather  than  density 
differences,  through  the  use  of a  selectively  permeable  membrane.  This  is  of 
particular importance  in certain situations where centrifugation is not applicable
i.e. where there is only a small density difference between components.  Cheryan, 
et al.  (1988) contains an excellent review on the reasons for choosing filtration. 
Over  the  past  two  decades  there  have  been  significant  advances  in  membrane 
technology, such as increased control of pore size distribution, driven by the need 
for increasingly pure pharmaceutical products.  Separation technology has reached 
the stage now where it is no-longer limited to the separation of solutes differing in 
size by about ten fold (Van Reis,  et al.  1997).  As such, filtration is increasingly
51becoming  an  attractive  process  option  for  applications  which  would  have 
traditionally utilised centrifugation.
Membrane filtration has several applications within the bioprocess industry. These 
include:
•  Cell harvesting/recycling
•  Cell removal
•  Debris removal
•  Product sterilisation
During filtration the feed stream is either pumped perpendicular to the membrane 
or parallel to it.  Figure  1.12 depicts the two differing modes of operation.  If the 
feed  is  pumped  perpendicular  to  the  membrane,  then  the  operation  is  termed 
normal flow filtration (NFF) or dead end filtration.  During this type of operation 
a layer of particles builds up on the surface of the membrane. This is termed the 
cake.  This cake blocks the membrane pores and forms a barrier to filtration, in 
effect fouling the membrane.  This results in a decrease in the observed flux rate 
through  the  membrane  as  the  operation  progresses.  If the  flux  rate  is  to  be 
maintained, then the pressure will have to be altered to compensate for the fouling 
caused by the cake.
If the  feed  stream  is  pumped  parallel  to  the  surface  of the  membrane  then  the 
operation is termed tangential flow filtration (TFF).  TFF utilises high flow rates 
to  generate  shear  forces  at  the  membrane  surface.  These  act  to  “sweep”  the 
surface  of  the  membrane  clear  of  particles,  thereby  helping  to  reduce  cake 
formation and prolong higher flux rates.
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Figure  1.12  Diagrammatic  representation  of  Dead  end  filtration  (A)  and 
Tangential flow filtration (B)
The stirred cell depicted in figure  1.13 is a dead end filtration process that utilises 
a  stirrer bar  placed  close  to  the  surface  of the  membrane.  When  spinning,  the 
stirrer bar will  generate a shear field, without having to utilise a high flow rate. 
These devices have  been successfully  used to  increase the  flux  rate  for a given 
filtration system, but have not found widespread use in industry due to problems 
during scale up.  Lee,  et al.  (1995) utilised a stirred cell  for the concentration of 
recombinant yeast cells. The results showed that flux increased with disc rotation 
speed. The author attributed this to the fact that at higher speeds the observed cake 
build  up  was  minimal  and  hence  membrane  fouling  was  reduced.  Vogel  and 
Kroner  (1999)  also  utilised  a  stirred  cell  to  develop  a  novel  technique  for  the 
separation of animal cells.
stirrer bar
^membrane
Figure 1.13 Diagrammatic representation of the stirred cell filtration device
53Filtration  processes  are  normally  classified  according  to  the  dimensions  of the 
membrane pores and the size of the material to be separated.
Microfiltration
Microfiltration (MF) is generally used to recover particles between 0.05 and 10pm
in diameter.  It is a low-pressure operation with pressures typically not exceeding
^  1   |
2bar.  The  flux  rates  obtained  are  typically  greater  than  50L.m  .h*  .bar* . 
Examples  of material  removed  by  MF  processes  include  bacteria,  moulds  and 
yeast  (Winston  Ho  and  Sirkar,  1992).  Microfiltration  operations  can  be  run  in 
several  ways.  Which one is chosen depends upon the nature of the  feed  stream. 
They include, batch, fed-batch, feed and bleed, continuous and diafiltration.
Ultrafiltration
Ultrafiltration  (UF)  relies  on  the  same  principles  as  microfiltration,  but  is 
generally used during the recovery of particles and polymeric solutes between  1 0  
and  150kDa.  It is high pressure operation and may be run utilising pressures as
9  1
high as 5bar.  The flux rates obtained are typically between 10 and 50L.m .h* .bar* 
*.  One of the most common uses for UF is during diafiltration, when one buffer 
liquid is replaced by another. The membrane retains the protein of interest, whilst 
the old buffer flows to waste new buffer is added to system gradually replacing 
the old.  UF is also used to concentrate solutions by decreasing the volume of a 
process solution (Winston Ho and Sirkar, 1992).
1.3.5.1  Factors determining filtration performance
There  are  several  feed  related  parameters,  which  affect  the  performance  of the 
filtration process; the main ones are outlined below.
54Buffer composition
The  pH  and  ionic  strength  of the  buffering  solution  can  greatly  influence  the 
performance  of the  filtration  process.  By  altering a proteins  surface  charge,  the 
solubility of the protein may be affected.  At its iso-electric point a protein will 
have no net charge.  As a result, the degree of adsorption of the protein  into the 
surface of the membrane will be increased (Bowen and Gan,  1991; Hanemaaijer, 
et al.  1989).  It has also been observed that a maximum transmission is achieved at 
the protein’s iso-electric point, with a second maximum between the protein and 
the membrane’s iso-electric point (Bums and Zydney, 1999).
Particle properties
The  shape  and  compressibility  of  feed  stream  components  will  influence  the 
filtration.  The compressibility of a particle will affect the nature of the cake layer 
formed and impact on performance. The shape of the particle will determine the 
void volume within the bed, which again influences the flux rate.  Of particular 
importance is the size difference between solutes; this will determine the degree 
of separation achievable.
Viscosity
The viscosity of the feed stream determines its resistance to flow; an increase in 
viscosity results in lower flow rates and higher pressures to obtain an equivalent 
flux rate.
Temperature
The  temperature  of the  solution  can  affect  the  flux  in  two ways  (Kroner,  et  al. 
1984).  Increasing the temperature can lead to protein aggregation and hence an 
increase in fouling with concurrent decrease in flux.  Increasing the temperature 
will also decrease the viscosity. This will result in an increase in flux if all other 
parameters remain unchanged (Kroner, et al.  1984; Lojkine, et al.  1992).
551.3.5.2 System related factors
Operating mode
The actual  physical  membrane  is rarely the true  filtering medium.  In reality the 
true  filtering  medium  is  the  initial  thin  layer  of precipitate  that  forms  on  the 
surface of the membrane at the  start of the operation.  A consequence of this is 
that  this  initial  layer  is  of prime  importance  in  ensuring a satisfactory  filtration 
operation.
If full pressure is applied at the start of the process, as is the case with constant 
pressure  filtration where  the  flux  is  allowed  to  decline  over time,  then the  first 
layer of particles will be compacted into a tight mass that largely blocks the pores 
of the filter. This may result in a low flux rate for the rest of the filtration.  If the 
initial pressure is low, as in constant flux filtration, the initial precipitate layer will 
be open resulting in increased flux rates during the filtration. During constant flux 
filtration,  the  pressure  is  gradually  increased  in  order to  maintain  the  flux  rate 
throughout  the  process.  A  draw  back  of this  is  that  the  maximum  pressure  is 
applied  only  at  the  end  of the  process  so  the  whole  cycle  is  run  at  less  than 
maximum  capacity.  Studies  by  Field  et  al,  (1995)  and  Howell  (1995),  have 
suggested that operating in constant flux mode will result in higher flux rates and 
hence a better performing separation operation.
The advantages and disadvantages of the two types of operation depend to a large 
degree on the nature of the feed. If the particles are compressible then increasing 
the pressure  may  not necessarily  result  in  an  increase  in the  flux  rate.  With  a 
compressible  cake,  as  the  pressure  is  increased  so  the  resistance  of the  cake 
increases.  Eventually the  increase  in the resistance of the cake to  flow becomes 
more than the increase in the flow rate caused by the increase in pressure.  At this 
point  further increases  in pressure  will  have  no  effect and may even result in a 
decrease in flux.
56Process configuration
The membrane separation may be run in a number of different modes. The most 
common configurations are diafiltration, batch concentration and feed and bleed 
(Winston Ho and Sirkar,  1992).  Each configuration has its own advantages and 
disadvantages.  Which  one  is  used  depends  on  the  feed  stream  and  process 
requirements.
During diafiltration, buffer is added to the retentate tank as the process continues 
in order to replace  any  permeate  that  has been  removed.  Diafiltration  helps to 
overcome the low fluxes associated with high concentrations or to achieve greater 
removal of permeable species.
Batch  concentration  requires  the  minimum  membrane  area  and  is  the  most 
flexible.  However,  tank  volume  requirements  may  be  high,  the  equipment  may 
have a large footprint and the residence time can be excessive.  As the permeate is 
removed the concentration of retained species increases. This is particularly useful 
when dealing with large process volumes, as the volume of feed can be reduced.
During a feed and bleed process the permeate is removed as is a small portion of 
the  retentate.  The  remaining  retentate  is  passed  on  to  a  fresh  filter  for  further 
concentration;  this  helps  to  maintain  a  high  crossflow  velocity  and  reduce 
membrane fouling.
1.3.5.3  Transmembrane pressure
Increasing the pressure on the upstream side of the membrane, with reference to 
the downstream side, results in process fluid being forced through the membrane. 
The difference  in pressure between the two  sides of the membrane is known as 
transmembrane pressure (TMP) and for TFF is defined as:
57p -t-p 
TMP =  1   2  -P,
2  3
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Where Pi  is the feed inlet pressure, P2 is the retentate outlet pressure and P3 is the 
permeate outlet pressure.
During  the  filtration  process  any  material  retained  by  the  membrane  may  be 
deposited  on the  surface.  This phenomenon  is  called  concentration polarisation. 
At the same time that material  is deposited it is also removed by back transport 
mechanisms  (proposed  mechanisms  include  Brownian  motion,  inertial  lift  and 
shear  enhanced  diffusion).  As  TMP  is  increased  the  rate  of solute  convection 
towards the membrane will increase.  Eventually this rate will exceed the rate of 
back transport.  At this point the flux rate will be unchanged by further increases 
in the TMP; the membrane is said to be concentration polarised.  Porter (1972) 
first  noticed  this phenomenon  during  UF  it  has  also  been  observed  during  MF 
(Brown and Kavanagh, 1987; Shimizu, et al.  1994).
Operating at an initial higher TMP may give a higher initial flux rate but it may 
lead to lower flux and transmission performance as polarisation and other fouling 
effects  will  be  increased  (Lee,  et  al.  1995;  Haarstrick,  et  al.  1991;  Field,  et  al. 
1995).  If a lower TMP is used initially it is often possible to operate the process 
for longer periods of time without a significant decline in the flux rate.  The TMP 
can then be gradually increased to maintain the flux as fouling occurs (Maiorella, 
etal.  1991; Van Reis, etal.  1991).
1.3.5.4  Crossflow velocity
The pumping of the feed stream parallel to the surface of the membrane generates 
shear  stress  that  acts  to  sweep  the  membrane,  minimising  the  build  up  of any 
fouling  layer.  Increasing  the  crossflow  velocity  will  increase  the  rate  of back 
transport,  increasing the flux rate achievable for a given TMP.  This removal of
58the fouling layer by crossflow has been demonstrated by a number of researchers 
(Culkin,  1998;  Mikulasek,  1994).  Crossflow  velocity  cannot  however  be 
increased  indefinitely  in  order to  increase  the  flux  rate.  For  one,  the  crossflow 
velocity has no impact on the degree of internal fouling, which occurs within the 
structure  of  the  membrane  and  determines  transmission.  Also  higher  flow 
velocities require bigger pumps and higher energy consumptions, which  impacts 
on the economics of the process.
1.3.5.5  Fouling
The  term  fouling  is  used  to  describe  any  phenomenon  that  is  detrimental  to  a 
membranes performance.  Fouling can take several different forms, the simplest of 
which is pore plugging.
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Figure 1.14 Representation of pore plugging
This results when a particle is sufficiently small to enter a pore but does not pass 
through it (Hermia, 1982).
Pore  narrowing  or  constriction  is  caused  by  the  adsorption  of proteins  to  the 
membrane.
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Figure 1.15 Representation of pore narrowing or constriction
The  pores  become  smaller  and  it  may  result  in  the  smallest  pores  becoming 
blocked. Each particle that is retained within the pore will reduce the pore volume.
59The equation below is used to describe systems where pore plugging is the main 
method of fouling.
(equation 1.11)
Where  Fo  is  the  initial  flux  rate,  K2  is  an  empirical  constant  obtained  from 
experimental data, t is time and V is the volume filtered.  If pore plugging is the 
main mode of fouling then a plot of t/V  versus t should produce a straight  line 
where the gradient is K2/2 and the intercept is 1/Fo (Jomitz and Metzler, 1988).
Gel  or  cake  layer  formation  results  in  a  decrease  in  flux  due  to  irreversible 
accumulation of particles at the membranes surface.  The thickness of the layer 
increases as the volume of filtered fluid increases.
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Figure 1.16 Representation of gel or cake layer formation
Assuming  that  the  cake  is  incompressible  and  that  the  pressure  is  constant  the 
filtration should follow the equation outlined below (Jomitz and Meltzer, 1988).
(equation 1.12)
Where  t is  time,  V  is  the  volume  filtered  and  Ki  is another empirical  constant 
obtained from experimental data.
60If surface retention is the primary method of fouling, then a plot of t/V versus V 
should  result  in  a  straight  line  where  the  gradient  is  Kj  and the  intercept  is  V. 
This  model  is  not  ideal  for  biological  solutions  because  often  the  solids  are 
compressible.
The  hydrophobicity/hydrophilicity  of  the  particle  or  membrane  are  key 
characteristics in determining these interactions.  The type of membrane will also 
affect the type of fouling.  Marshall, et al.  (1993) concluded that proteins reduce 
the performance of UF membranes by surface deposition in the form of a gel layer 
but during MF the main mechanism of fouling was found to be pore plugging.  It 
has  also  been  suggested  that  the  mechanism  of  fouling  is  influenced  by  the 
concentration  of the  feed  stream.  Pore  plugging  is  the  main  factor  at  dilute 
concentrations but surface deposition dominates at high concentrations.
Manufacturers  of  membranes  have  developed  a  wide  range  of products  with 
different properties in order to combat fouling.  There are also several commercial 
systems  available  which  use  mechanical  methods  to  decrease  fouling.  JP. 
Postlethwaite (2004) contains a good review of these systems (Postlewaite, et al. 
2004).
13.5.6  Models of flux prediction
Concentration polarisation model
Porter (1972) proposed that the permeate flux can be predicted from the following 
model.
J = K Incb J
(equation 1.13)
Where J is the flux, K is the mass transfer coefficient, Cw  is the wall concentration 
of protein, Cb is the bulk concentration of protein in the feed stream.
61This model was developed based on the assumption that a boundary layer or gel 
layer of high concentration  solutes builds up on the membrane  surface  and that 
this  layer  forms  the  limiting  resistance  to  flow.  From  this,  it  is  possible  to 
calculate  the  transport  rate  of water through  the  membrane  on  the  basis  of the 
mass transfer of membrane retained  solutes from the  surface back  into the bulk 
stream.  Porter (1972) assumes that the layer has a fixed concentration (Cg) but is 
free to vary in terms of thickness and porosity.
The  mass  transfer  coefficient  (K)  can  be  calculated  using  the  heat  transfer 
correlation described by Dittus and Boelter (1930).
K = k. Q
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(equation 1.14)
Where kp is the proportionality constant,  Q  is the volumetric  flowrate,  D  is the 
diffusion  coefficient,  b  is  the  channel  height,  w  is  the  channel  width,  L  is  the 
channel length and V is the kinematic viscosity of the broth.
The  diffusion  coefficient  is  described  by  the  Stokes-Einstein  relationship  for 
diffusity.
6
(equation 1.15)
Where Kb is the boltzman constant, T is the temperature, p is the viscosity and rp 
is the radius of the diffusing particle.
Assuming that the proteins at the membrane  surface resemble a layer of closely 
packed  spheres  having  65-75%  solids  by  volume,  the  experimental  values  to 
calculate kp can be used to predict the steady state permeate flux.
62This theory has been utilised by many researchers (Wakeman and Williams, 2002; 
Mignard  and  Glass,  2001)  whilst  attempting  to  predict  membrane  flux  and 
fouling.
Membrane fouling model
This theory assumes that the molecules from the feed stream plug the membrane 
pores.  The resulting hydrodynamic resistance can be used to predict flux based on 
the following equation.
j  _ ^TM
MR,
(equation 1.16)
Where Rt is the total hydrodynamic resistance defined for a given membrane and 
a pure solvent (water).
According to Davies, et al.  (2000) Rt can be defined as the sum of the membrane 
resistance  (R m )  the cake resistance  (R c)  and the resistance due to pore blockage 
(R b ).  Davies,  et  al.  (2000)  goes  on  to  state  that  membrane  resistance  can  be 
measured using pure water flux data.
If using pure water as the feed, the flux equation can be rewritten:
j _
(equation 1.17)
The resistance of the membrane can then be calculated from a plot of flux against 
APtm with the gradient equalling  1/Rmp.
631.3.6  Chromatography
Separation by chromatographic means generally exploits a facet of the protein of 
interests  unique physio-chemical  properties.  These  properties  include:  size  (size 
exclusion/gel  filtration),  charge  (ion  exchange),  hydrophobicity  (hydrophobic 
interaction) and bio-specific interactions (affinity).  Ion exchange is used in 75% 
of purification  processes  (Bonneijea,  et  al.  1986).  This  wide  spread  use  was 
attributed  to  the  ease  of scale  up,  the  wide  availability  of cost  efficient,  robust 
matrixes  and  the  acceptance  of  the  technique  by  regulatory  bodies.  Affinity 
chromatography was  found to be used  in  60% of processes and gel  filtration in 
50%  of processes.  Chromatographic  systems  can  achieve  an  excellent  level  of 
purification in a small number of steps. They are also apt for dealing with large 
volumes  of material  containing  only  small  concentrations  of the  target  protein. 
The different types of ligand are described in the following sections.
1.3.6.1  Ion Exchange Chromatography
Ion exchange chromatography has found wide spread use for the purification of 
proteins, both in the lab and in the production plant.  In  1956 it became the first 
type  of interaction  to  be  successfully  employed  for  the  separation  of charged 
macromolecules  onto  oppositely  charged  moieties  (Peterson  and  Sobers,  1956). 
This  technique  has  also  been  employed  for  the  purification  and  separation  of 
proteins, nucleic acids, polypeptides, polynucleotides and other charged molecules 
(Bonneijea, et al. 1986).
Separation  during  ion  exchange  chromatography  is  dependent  on  the  reversible 
binding  of  charged  solute  molecules  to  an  immobilised  matrix  consisting  of 
oppositely charged groups.  There are two types of exchanger:  anion exchangers 
are  positively  charged  and  bind  negatively  charged  molecules  and  cation 
exchangers that are negatively charged and bind positively charged molecules.
64Separation is achieved by giving either the target protein or the main contaminants 
an opposite charge to the matrix. The protein(s) of interest will then be retained by 
the  solid  support  whilst  all  other  proteins  flow  out.  This  selective  charge  is 
obtained by  looking at a proteins iso-electric point.  Above its iso-electric point 
the protein will  have a net negative charge,  below it the protein will  have a net 
positive  charge.  Once  the  protein  of interest  is  bound  to  the  matrix  unbound 
proteins are washed away by applying the starting buffer.  Elution is achieved by 
changing either the pH or the ionic strength. The protein of interest will elute from 
the matrix and can be collected.
There  has been extensive research  into  ion-exchange  chromatography  including 
the  development  of  new  media,  modelling  of  column  dynamics/retention 
characteristics,  process  characteristics  and  process  scale  up  (Lin,  et  al.  1987; 
Regnier,  1984;  Scopes,  1981;  Velayudban  and  Horvath,  1988;  Wankat,  1986; 
Yamamoto,  et  al.  1983).  The  major  disadvantage  of  ion-exchange 
chromatography  is that it  is  not as  specific  as  affinity  chromatography  as more 
than one species of protein may bind to the matrix at the same time.
1.3.6.2  Affinity Chromatography
Affinity  chromatography  is  considered  to  be  the  most  specific  separation 
technology  currently  available.  It  exploits  the  unique  binding  characteristics 
inherent to a ligand-biomacromolecule interaction.  Since the technology relies on 
biological  recognition  rather  than  physio-cheimcal  interactions  affinity 
chromatography preserves the biological activity of the target protein.
Affinity  chromatography  is  a  type  of adsorption  chromatography  in  which  the 
molecule to be purified is specifically and most importantly reversibly adsorbed 
by a complementary binding substance immobilised on an insoluble support, the 
matrix.
65The  technique  was  first  utilised  in  1910  to  selectively  adsorb  Amylase  onto 
insoluble starch.  However the complex organic chemistry required to produce the 
matrix  prevented  widespread  use  of the  technique.  In  1967  Axen,  Porath  and 
Emback  (Axon,  et  al.  1967)  reported  that  molecules  containing  primary  amino 
groups  could  be  coupled  to  polysaccharide  matrices  activated  by  cyanogen 
bromide.  This  method  is  still  commonly  used  today  to  couple  ligands  to  the 
matrix.  Its  development  opened  the  way  for  the  widespread  use  of  affinity 
chromatography.
Advances  in  technology  have  resulted  in  the  development  of new  media,  with 
increased stability in high or low pH and increased binding capacity which lowers 
the  cost.  Verdoliva,  et al.  (2002) reports the  development of an all  D  synthetic 
peptide with higher binding capacities than protein A or G and very high stability 
in  terms  of  ligand  leakage  and  stability.  Gulich,  et  al.  (2002)  reports  the 
development of a genetically engineered version of protein G which has increased 
alkaline  stability.  Therefore  columns  utilising  this  ligand  can  be  cleaned  with 
sodium hydroxide, which standard protein G columns cannot be.
Process scale affinity chromatography
Process scale matrices need to fulfil certain criteria (Cabrera and Wilchek,  1988; 
Janson and Kristiansen, 1990). The perfect resin would be:
Inert,  non-biodegradable,  chemically and physically resistant,  easily derivatized, 
easily  packed  and  macroporous.  However  by  their  very  nature,  most  protein 
affinity  columns  are  biodegradable,  chemically  and  physically  unstable  and 
deform at high flow rates.
The three most important characteristics are high adsorption capacity, high mass 
transfer coefficient and high liquid flow rate through the bed (Katoh, 1987).  From 
a commercial  point  of view cost,  reuse  or  ligand  leakage  and  the  purity  of the 
eluted product are also equally important.
66The optimisation and scale up of chromatographic processes
In  order  to  successfully  scale  up  an  affinity  chromatographic  separation  a 
thorough understanding of the  fundamental  processes  involved  in the  separation 
mechanism are required. Liapis, 1989; Chase, 1988 and McCormick, 1988 contain 
reviews  of  scale  up  methodology.  The  authors  also  address  the  predictions, 
implications and limitations of the affinity chromatography models.
Column and matrix based parameters to consider are: the length and diameter of 
the  column,  the  particle  size  and  pore  size  of the  affinity  support.  Small-scale 
studies  should  be  carried  out  utilising  a  matrix  that  is  suitable  for  large-scale 
separations.  Physical  properties  that  should  be  considered  are:  the  sample 
volume, flow rates, temperature and pH (Liapis,  1989).  Since each separation is 
unique each process must be individually optimised.  However several groups are 
developing  algorithms  to  predict  the  optimum  flow  rates,  gradients,  buffer 
compositions and temperatures (Janson and Hedman, 1987).
Affinity ligands
Any component that may be coupled to a base matrix can be used as a ligand for 
purifying its respective binding substance i.e.
Enzyme: Substrate 
Antibody: Antigen 
Hormone: Receptor
This list contains only three possible ligands.  Narayanan (1994) contains a good 
review of the available ligands and matrices.  Protein G is of specific interest in 
the context of this thesis (as opposed to protein A) because of its affinity for ovine 
antibodies.  It  is  therefore  applicable  to  the  purification  of  the  anti-venom 
antibodies contained with the ovine serum.
67Protein G
Protein  G  (Akerstrom,  et  al.  1985;  Frank,  1997;  McCormick,  1988;  Akerstrom 
and  Bjorck,  1986)  is a bacterial  surface protein  found  in  group G streptococcal 
strains (Forsgen and Sjoquist,  1966; Reis, et al.  1984).  It recognises and binds to 
the Fc part of a wide variety of IgG antibodies:
IgG type Binding Strength IgG type Binding Strength
Human IgGl ++ Rat IgG2c ++
Human IgG2 ++ Rabbit IgG ++
Human IgG3 ++ Bovine IgGl ++
Human IgG4 ++ Bovine IgG2 ++
Mouse IgGl + Sheep IgGl ++
Mouse IgG2a ++ Sheep IgG2 ++
Mouse IgG2b ++ Goat IgGl ++
Mouse IgG3 ++ Goat IgG2 ++
Rat IgGl + Horse IgG(ab) ++
Rat IgG2a ++ Horse IgG(c) ++
Rat IgG2b + Horse IgG(T) (+)
Table 1.2  Summary of different antibody subtype binding patterns to protein G 
(adapted from Bjorrck and Kronvall, 1984)
Protein  G  will  bind  most  strongly  to  the  majority  of different  immunoglobulin 
types, at or near neutral pH, but readily dissociates from these solutes when placed 
in  a  buffer  with  a  lower  pH.  The  native  protein  contains  an  albumin  binding 
region.  This  is  genetically  deleted  in  modem  versions  of protein  G  used  for 
binding immunoglobulins in order to minimise non-specific binding.
681.3.6.3 Gel filtration
Gel filtration has occupied a key position in laboratory scale purification for more 
than 30 years (Porath and Flodin,  1959; Janson,  1987).  Separation of molecules 
during gel filtration is based on molecular size and shape.  The solution containing 
molecules of differing sizes is fed down a column containing a hydrophilic cross- 
linked gel with pores of finite size.  By varying the degree of cross-linking within 
the  gel, different pore  sizes can  be produced  resulting  in media that  covers the 
whole range of molecular sizes.
Molecules which are larger than the pore size of the gel will be excluded from the 
matrix  and  are  therefore  eluted  first  ffom  the  column.  Smaller  molecules  will 
enter  the  pores  within  the  gel  to  various  extents.  This  retards  their  progress 
through the column and they will elute according to their molecular size (largest 
first).
Gel  filtration  is  not  suitable  for  recovery  of  target  proteins  present  in  only 
relatively small concentrations since load volumes should not exceed  10% of the 
column volume.  It is  also  not  suitable  for large-scale  recovery due to the  large 
volumes of gel  required  for large process volumes.  As a result gel  filtration is 
often employed towards the end of a process as a polishing step and within the 
biopharmaceutical industry to remove aggregates.
1.3.6.4  Hydrophobic Interaction Chromatography
The basis of hydrophobic interaction chromatography (HIC) is an entropy driven 
attraction between non-polar groups in an aqueous environment; the specifics are 
summarised in (Eriksson,  1998).  It has been described as “The unusually strong 
attraction  between  non-polar  molecules  and  surfaces  in  water”  (Israelachvili, 
1985).  Chromatographic  separation  of  proteins  by  HIC  were  first  reported 
separately by two groups in 1972 (Er-El, et al. 1972; Yon, 1972).
69The separation is normally run at high salt concentrations.  Hydrophobic pockets 
on  the  surface  of proteins  adsorb  onto  the  support.  The  protein  is  eluted  by 
lowering the  salt concentration.  Proteins with high  surface hydrophobicity will 
elute first (Hammond and Scawen,  1989).  Typically HIC is classified as a mild 
separation  technique,  as  proteins  can  be  eluted  from  the  support  in their native 
state.  However, it has not found wide spread use in industry due to the fact that 
“classical  commercial  hydrophobic  adsorbents  are  inadequate  due  to  their  high 
hydrophobicity” (Oscarsson et al  1995).  As a result proteins readily bind to the 
support but they are difficult to elute in their native state because the binding is 
too strong.  However, it has been successfully employed during the purification of 
periplasmic  human  interferon  a2c  expressed  in  E.coli  (Voss,  et  al.  1994)  and 
human growth hormone (Wu, et al.  1990; Pavlu & Gellerfors, 1993).
1.3.6.5  Adsorption Models
The  simplest  model  used  to  describe  the  adsorption  process  that  occurs  during 
chromatography  assumes  that the  solute  (S)  confined  within the  aqueous phase 
(aq) is adsorbed by the ligand (L) of a solid chromatography matrix.  The equation 
shown below describes this adsorption process:
S(aq)+L{s)(  **  L(s)
(equation 1.18)
The  rate  at  which  the  solute  will  be  adsorbed  by  the  ligand  is  governed  by  an 
association constant KA,  (KA  = K 1/K2) where Kjis the forward rate constant and 
K2 is the backward rate constant.  The disassociation constant Kd= 1/Ka.
70Ka can be calculated from the equation detailed below:
q  _  CMqm   _ CM qm Ka 
s ~ Cm+Kd ~ CuKa+ 1
(equation 1.19)
Where  Cs  is  the  concentration  of  adsorbed  solute  at  equilibrium,  Cm  is  the 
concentration  of solute  in  the  mobile  phase  and  qm   is the  maximum  monolayer 
capacity of the matrix.
Isotherms
Rearranging equation 1.19 forms equation 1.20 shown below:
_[S-L* Q
qk-Q)
(equation 1.20)
It can be concluded from this equation that the concentration of adsorbed solute is 
asymptotically  approaching  the  maximum  capacity  of the  matrix.  This  will  be 
reached  at  lower  mobile  phase  concentrations  for  solutes  that  have  a  higher 
association  constant.  It  can  therefore  be  concluded  that  buffering  conditions 
which increase the association constant will lead to more of the solute that binds 
to the matrix being bound, resulting in a more efficient separation process.  The 
graph resulting from a plot of the concentration of bound solute (Cs) against the 
concentration of solute in the mobile phase (Cm) is called the adsorption isotherm.
71The  relationship  shown  in  figure  1.17  is  called  Langmuir  isotherm  (Langmuir, 
1918).
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Figure 1.17  Hypothetical Langmuirian adsorption isotherm
The Langmuir model was originally developed to portray the chemisorption on a 
set of distinct localised adsorption sites.  As a result it is only valid for monolayer 
adsorption of a single solute species in a one to one binding relationship, which is 
not affected by the presence  of other solutes.  Generally  adsorption of proteins 
onto ion-exchangers or affinity media is of a form similar to the favourable model 
described by Langmuir (Horstmann and Chase, 1989; Skidmore and Chase, 1988). 
Langmuir  isotherms  have  been  successfully  employed  on  several  occasions 
(Weaver  and  Carta,  1996;  Chase,  1984;  Skidmore,  et  al.  1990;  Yoshida,  et  al. 
1993;  Mao,  et  al.  1995).  Deviations  from  the  model  can  be  explained  by 
contaminating  proteins  competing  for  binding  sites  or  proteins  binding  to  the 
matrix by other means. These deviations are discussed by (Gill, et al.  1994).
72A multi-component mixture may be described by the multi-component Langmuir 
isotherm.
Several other isotherms have been developed to account for different conditions. 
For instance, the Freundlich isotherm (Freundlich,  1907) describes adsorption to a 
heterogeneous  surface.  The  flow  rate  through  a  column  and  its  impact  on 
residence time will also affect the isotherm. A good review discussing the various 
merits of the different isotherms can be found in Bellot and Condoret (1993).
1.4  Scale Down Of Industrial Bio-Separation Techniques
Early bioprocess development is often hampered by the availability of material for 
experiments  investigating  different  downstream  processing  options.  The 
production  of  laboratory  scale  devices  that  accurately  mimic  industrial  scale 
purification processes allows options to be considered with out the use of large 
amounts  of valuable  material.  It  also  provides  a  powerful  tool  for  minimising 
bioprocess development times.
Successful  scale  down  requires  a  detailed  understanding  of  the  mechanisms 
involved  in  order  to  identify  the  key  parameters  influencing  a  system.  Once 
identified, these parameters can be mimicked on a small scale thereby ensuring an 
accurate model.
1.4.1  Current approach to the scale down of precipitation
As described in section  1.3.1  the physical properties of a protein precipitate are 
affected  by  several  factors.  Each  of these  have  to  be  maintained  or  taken  into 
account  in  order  to  obtain  a  final  product  with  similar  characteristics  to  that 
produced on an industrial scale.
(equation 1.21)
73Mechanical parameters, which have to be kept constant between the scale down 
mimic and the industrial scale operation, include:
•  Tank geometry (the height to diameter ratio)
•  Impeller type
•  Diameter of the impeller relative to that of the tank
•  Placement of the impeller
•  Baffle geometry (if any)
However, even if all of the above factors are kept constant fluid flow patterns will 
still  alter between  the  small  and  industrial  scale  devices,  which  could  result  in 
differences between the final material.
Process parameters that need to be maintained include:
•  Temperature of operation
•  pH
•  Ionic strength
•  Type of salt
•  Mean velocity gradient, aging parameter (Camp number) and residence time
The mean velocity gradient is a measurement of the power dissipated (P) per unit 
volume  (Smoluchowski, 1917).
—  (   P   ^\2
G =  —
M
(equation 1.22)
Where p equals dynamic viscosity, V is the volume and P is the power input.
74The power input, P, is calculated by:
P = PvpN'D5
(equation 1.23)
Where  Po  is the  power number, p  is  the  density  of the  bulk  suspension, N  the 
impeller speed and D is the impeller diameter (Rushton, et al. 1950).
The controlling parameter of a precipitation operation is the Camp number; this is 
a measurement of the amount of energy inputted into a system over time and is 
defined by the equation below.
Ca = Gt
(equation 1.24)
Where G is the mean velocity gradient and t is time.
By maintaining the  Camp  number between  scales  of operation  it  is possible to 
mimic a precipitation operation.  This has been successfully achieved for protein 
precipitant formation (Boychyn, et al. 2000; Maybury, 1999; Neal, et al. 2003).
1.4.2  Scale down of centrifugation
The  scale  down  of  centrifugation  has  been  achieved  through  two  different 
methods (Mannweiler and Hoare,  1992; Boychyn, et al. 2000).  The first involves 
the insertion of blank discs into a disc stack centrifuge in order to reduce the feed 
flow  requirement.  The  second  involves  the  utilisation  of an  in  house  shearing 
device.  Each method will be discussed separately.
1.4.2.1  Scaling down by reducing the number of active discs
The smallest disc stack centrifuge is a pilot scale model that operates with a bowl 
capacity of 0.69 litres. This means that in order to run the centrifuge more than 10 
litres  of  feed  material  are  required.  During  the  early  stages  of  process 
development the amount of material available for study is small. By scaling down
75the  amounts  required  for  centrifugation  studies  the  purification  process  can  be 
more extensively studied and alterations made without the need for large amounts 
of valuable material.
Work  by  Mannweiler  and  Hoare  (1992),  Rumpus  (1997)  and  Maybury  (1999) 
concentrated on scaling down a disc stack centrifuge by reducing the number of 
active discs.  Maybury,  et al.  (1998) achieved a 76% scale down of the  settling 
area in conjunction with a 70% reduction in bowl volume whilst still maintaining 
a  separation  performance  that  matched  that  of  the  full-scale  machine.  The 
reduction in feed requirements was achieved by blanking off the stack; this was 
done  by  utilising  stainless  steel  inserts  specially  made  by  Westfalia  separators. 
These  inserts  reduced  the  number  of  active  discs,  therefore  reducing  the 
separation area, bowl volume and solids holding capacity.  There are two different 
types of insert.  The top inserts reduce the bowl volume and solids holding space, 
whilst a bottom insert reduces the bowl volume and lifts the stack off the bottom 
of the centrifuge.
a  b  c
Active discs
Figure  1.18  Diagrammatic  representation  of a  disc  stack  centrifuge  showing 
different  regions  blanked  out.  a)  Top  position  b)  Bottom position  c)  On  top  of 
insert equivalent to 7 discs (Maybury, et al.  1998)
76Work by Maybury, et al.  (1998) highlighted the importance of the positioning of 
the active discs within the stack.  If the active discs are positioned at the bottom, 
the recovery performance was found to be inferior to the full-scale machine.  This 
was attributed to turbulence associated with the region of the centrifuge where the 
feed  stream  enters  the  settling  region  resulting  in  re-entrapment  of sedimented 
solids.  Positioning of the active discs at the top of the stack was found to give a 
superior performance; this was attributed to solid particles settling out as the feed 
stream passed through the  solids holding space before reaching the active discs. 
When  the  discs  were  positioned  a  small  distance  from  the  bottom  above  the 
turbulent region,  the  recovery performance  was  found to  be  similar to  the  full- 
scale machine.
Scaling down by this method changes the bowl geometry, since the bowl height is 
reduced  whilst  the  diameter  remains  the  same.  Although  this  change  may  be 
expected to alter the recovery performance, Maybury, et al.  (1998) concluded that 
it  does  not.  This  method  has  advantages  in  the  fact  that  the  bowl  speed  and 
diameter  remain  unchanged  and  hence  dewatering  of  collected  solid  should 
remain the same.  However this method still requires several litres of material. A 
more useful mimic would require only millilitres of material per run.
1.4.2.2  Scaling down using the shearing device
There  are  several  methods  for  comparing the  performance  of centrifuges.  One 
popular method is the Sigma or settling area based on Stokes law which describes 
the sedimentation of a particle in a centrifugal field (Ambler 1959).  In theory, by 
maintaining  the  same  flow  rate  (Q)  to  settling  area (£)  the  end product  should 
have the same clarification for all  centrifuges.  However correction factors must 
be introduced to account for non-ideal flow conditions.
Mannweiler, et al.  (1989) demonstrated that the entrance zone of a centrifuge is 
the area where the highest flow stresses prevail. Therefore when a shear sensitive 
material  enters  the  feed  zone  of a  centrifuge,  breakage  of the  particles  occurs. 
This increases the proportion of fines resulting in a reduction in the clarification of 
the material.  Within a laboratory scale batch centrifuge, this break up of process
77material does not occur since the process material is still relative to the wall of the 
tube.  This means that the  laboratory centrifuge will  achieve a higher degree  of 
clarification  than  an  industrial  device,  even  if the  flow  rate  to  settling  area  is 
maintained between different centrifuges.
The rotating disc device works on the principle that by mimicking the feed zone 
of an  industrial  centrifuge,  the  sample  can  be  sheared thus  producing the  same 
fine  particles  and  decrease  in  particle  size  distribution  as  found  at  an  industrial 
scale.  Once sheared samples are centrifuged whilst maintaining the same relative 
settling  area  between  industrial  and  laboratory  scale  centrifuge,  as  a  result  the 
same degree of clarification should then be observed.
The rotating disc device consists of a Perspex chamber of diameter 40mm.  The 
rotating elements are fabricated from smooth aluminium alloy coated with a thin 
layer  of  PTFE  mounted  on  a  stainless  steal  shaft.  The  Perspex  chamber  is 
constructed of four interchangeable sections that can be arranged to give different 
heights  from  10mm  to  40mm.  The  shaft  of the  rotating  elements  is  extended 
through a top cover via a relatively airtight PTFE bearing and connected to a high 
speed DC motor.  The motor is powered by a set of trickle batteries which via a 
transformer, are capable of delivering a series of fixed voltages between 2 and 12 
volts, thus providing six fixed speeds of rotation.  The whole assembly is mounted 
on  a  heavy  metal  base  to  stop  vibration  whilst  it  is  being  operated.  A  full 
description can be found elsewhere (Levy, et al.  1998).
The first step in designing a device that could mimic the shear fields within the 
feed  zone  of an  industrial  scale  centrifuge  was  to  accurately  map  the  complex 
flow  fields  found  within  an  industrial  scale  centrifuge.  Boychyn,  et  al.  (2001) 
used  computational  fluid  dynamics  (CFD)  coupled  with  a  modem  computer to 
solve  the  necessary  equations.  Therefore  they  provided  a method  where-by  the 
complex  flow  field  in  an  industrial  centrifuge  could  be  quantified.  Once 
quantified the CFD analysis can be used to predict the speed of disc rotation that 
would  be  required  to  mimic  the  feed  zone.  When  used  in  combination with  a 
laboratory scale centrifuge, accurate predictions of the behaviour of an industrial
78device can be made.  This method has been validated by correlation to boundary 
layer theory (Schlichting,  1979, Boychyn, et al. 2001). It is however laborious and 
time consuming.
A less laborious method is based on maintaining a constant tip velocity between 
the rotating disc device and the critical structure in the feed zone of the centrifuge. 
The critical structure is identified as the area where initial contact and acceleration 
of the process stream occurs.  In a disc stack machine the lock nut represents the 
initial  point  of contact  for  the  feed  suspension.  Once  the  structure  has  been 
identified the critical radius must be selected.  For the lock nut this is the radius at 
its top.  The tip velocity can be converted into a maximum power dissipation as 
discussed below and this can be used to predict the performance.
The  flow  over  a  disc  of radius  R,  rotating  at  an  angular  velocity  co,  has  been 
theoretically described by Schlichting (1979) and verified by CFD analysis (Levy, 
et al. 1999).  The maximum power dissipation is given by:
P  c d T 
£ ~ p V ~  pV
(equation 1.25)
Where  P  is  the  power  dissipation,  p  is  the  density  of the  bulk  fluid,  V  is  the 
volume of the boundary layer, co is the angular velocity and T is the torque.
The  magnitude  of forces  occurring  in  the  feed  zone  of a continuous  centrifuge 
may be estimated by determining the tip-velocity (Vcrit) of the critical structure:
Vcrit —  rcritCO C rit —  27lNcritrcrit
(equation 1.26)
79Where  rcrit  is the critical  radius of the structure  and N crit  is the rotational  speed. 
The critical velocity is then maintained in the laboratory rotating disc device,  its 
rotational speed is determined by:
r N \ j   _   crit  crit 
iV rd  ~
rrd
(equation 1.27)
From this an associated maximum energy dissipation rate can be calculated.
Thus the rotating disc device can be used to mimic the feed zone of an industrial 
centrifuge  and  a  batch  laboratory  scale  centrifuge  can  be  used  to  mimic  the 
settling  conditions.  This  provides  an  effective  method  of  scaling  down 
centrifugation  so  that  process  options  can  be  studied  using  only  millilitres  of 
material.
1.5  Aims
Downstream purification process development and optimisation currently requires 
large quantities of material and time, commodities that are in short supply during 
the  initial  stages  of drug  development.  Research  into  methods  of accurately 
scaling down purification operations has been on going for a number of years.
The  aims  of this  project  are  to  develop  novel  or  utilise  current  scale  down 
methodologies in order to  mimic  the primary industrial  scale purification stages 
used during the production of polyclonal Fab fragments.  These mimics are to be 
tested by comparison to the feed stream produced at an industrial scale and used 
to study the effects of changes to the purification process.  Alternative purification 
options  for  the  removal  of  the  precipitated  antibodies  such  as  the  use  of 
microfiltration will be investigated.  Chromatographic methods for purification of 
the  antibodies  directly  from  the  serum,  without  the  need  for  precipitation  or 
centrifugation  will  also  be  investigated.  These  investigations  may  lead  to 
improvements in the yield or in the ease of operation of the process.
802 Materials And Methods
2.1  Introduction
Unless  otherwise  stated  all  chemicals  and  materials were  obtained  from  Sigma, 
Poole  UK.  This  chapter  details  the  methods,  analytical  techniques  and 
experiments that were conducted during the preparation of this thesis.
All  assay  variances  quoted  within  the  results  sections  of this  thesis  (standard 
deviations and standard errors) were calculated from the actual results.
Section 2.2 describes the design of the scale down mimics, section 2.3 describes 
the analytical techniques and section 2.4 describes the running of the scale down 
mimics and other small-scale experiments.
2.2  Application Of Existing Scale Down Theory
2.2.1  Scaled down precipitation
The application of the theories and experimental conclusions outlined in section
1.4.1  allows  a  large-scale  precipitation  reaction  to  be  mimicked  and  accurately 
reproduced at a laboratory scale.
The  first  step  in  any  scale  down  work  is  to  investigate  the  equipment  and  the 
process used at the large scale.
2.2.1.1  Industrial scale vessel parameters and operating conditions
Table 2.1  shown below details the dimensions of the precipitation vessel used 
during the industrial scale precipitation operation.
81Vessel height 0.6m
Vessel diameter 0.686m
Volume of liquid 200L
Construction material Stainless steel
Impeller type 3-bladed marine propeller
Impeller diameter 0.175m
Impeller placement Bottom comer
Height of impeller 0.20m
Table 2.1  Dimensions of the industrial scale precipitation vessel
The precipitation reaction is operated under the conditions outlined in table 2.2
Speed of impeller rotation during addition phase 125rpm
Speed of impeller rotation during conditioning phase 500rpm
Conditioning time 15 hours
Rate of addition of precipitant 4L/minute
Table 2.2  Operating parameters for the industrial scale precipitation reaction 
2.2.1.2  1000 fold scale down mimic
In order to produce an accurate scale down mimic the vessel geometry and power 
input into the precipitation system needs to be maintained between scales.
Scale down of  precipitation vessel
By maintaining vessel geometry between scales a 1000 fold scale down version of 
the industrial scale vessel described in the previous section was produced.  It has 
the following dimensions, shown in table 2.3.
82Vessel height 0.06m
Vessel diameter 0.0686m
Volume of liquid 0.2L
Construction material Perspex
Impeller type 3 bladed marine propeller
Impeller diameter 0.02m
Impeller placement Bottom middle
Height of impeller 0.02m
Table 2.3  Dimensions of the 1000 fold scaled down precipitation vessel
As can be seen there are some differences between this vessel and the industrial 
one,  such as the material of construction.  The industrial  scale vessel also has a 
curved  bottom  where  as  the  scale  down  vessel  has  a  flat  bottom.  The  main 
difference  is  in  the  placement  of the  impeller:  in  the  scale  down  version  the 
impeller is in the middle.  These differences will affect the flow conditions within 
the  reactor.  However  the  controlling  factor,  which  is  the  power  input  into  the 
system, remains unchanged, which should result in an accurate mimic.
Scale down of operating conditions
In order to recreate the mixing conditions experienced by the precipitate particles 
during the precipitation process, the total power input into the system needs to be 
calculated.  This is expressed as the Camp number.  The first step is to calculate 
the power inputted into the industrial scale system.  Solving equation 1.23 (shown 
below  for  reference)  using  the  parameters  from  tables  2.1,  2.2  and  the  density 
experiments (described later), allows the power input into the precipitation system 
during the conditioning phase to be calculated.
P = P0pN3D5
(equation 2.1)
83If Po  =  0.8  (standard  power  number  for  a  three  bladed  marine  impeller  from 
Rushton,  et  al.  1950), p =  130Kgm'3 N =  8.3rps  and  D =  0.175m the  resulting 
power input equals 9.7W.
Using  equation  1.22  (shown  below  for  reference),  the  power  input  calculated 
above, the volume shown in table 2.1 and the value for the viscosity deduced from 
experiments  described  later,  the  mean  velocity  gradient  for  the  precipitation 
reaction can be calculated.
i
-   (  p ^
G =
\Vpj
(equation 2.2)
If P = 9.7W, V= 0.2m3 and p = 0.0024Pa.s then the mean velocity gradient is 142. 
From this the Camp number can be calculated where:
Ca = Gt
(equation 2.3)
The conditioning time is 15 hours, therefore the Camp number is 7668000s’1.
The mean velocity gradient can be mimicked at the laboratory scale by calculating 
the power input required to achieve the level found at the industrial scale and then 
calculating the impeller speed required to give that power input.
Rearranging equation 2.2 to make the power input the subject gives
P = G2Vp
(equation 2.4)
Solving  this  equation  where  G  =  142  (calculated  above),  V =  0.0002m3  (from 
table 2.3) and p = 0.0024Pa.s gives a power input of 0.0097W.  The recalculated
84power input is then inserted into equation 2.1  which has been rearranged to make 
the impeller speed the subject.
(equation 2.5)
Solving this equation where P = 0.0097W, P0 -  0.8,/?= 130Kgm'3 and dj = 0.02m 
(from  table  2.3)  yields  an  impeller  speed  of  1840  rpm  to  be  used  during  the 
conditioning phase.  This speed needs to be divided by 3.33 to give the impeller 
speed used during the addition phase of the precipitation reaction.
Table 2.4 (shown below) summarises the operating conditions of the scaled down 
precipitation reaction that should mimic the industrial scale operation.
Speed of rotation during addition phase 555rpm
Speed of rotation during conditioning phase 1840rpm
Conditioning time 15 hours
Rate of addition of precipitant 4ml/minute
Table 2.4  Operating parameters of the scaled down precipitation reaction
2.2.2  Mimicking centrifugation
It was decided to use the method described  in section  1.4.2.2 to  scale down the 
centrifugation stage;  since this offered the possibility of producing a mimic that 
would require only millilitres of material.  The disc stack centrifuge mimicked has 
the following dimensions and operating conditions:
85Number of discs 95
Outer disc radius 0.1m
Inner disc radius 0.045m
Half disc single 55°
Diameter of lock nut 0.08m
Rotational speed 125rps
Feed flow rate 120L/hr
Sigma Value 8400m2
Correction factor 0.25
Table 2.5  Dimensions and operating conditions of the industrial scale disc stack 
centrifuge
Calculating the tip velocity of the critical structure and then mimicking this with 
the  in  house  shear  device,  mimicked  the  shear  conditions  in  the  centrifuge. 
Equation  1.27 (shown below) was solved in order to determine the speed that the 
in house shear device would be run at, in order to mimic the industrial centrifuge.
r  N  . \ t      cnl  crit
iV rd  ~
rrd
(equation 2.6)
Where N crit =  125rps and rcrit = 0.04m and rr< j = 0.015m a rotational speed within 
the shear device of 20000rpm  should recreate the shear conditions found within 
the industrial scale machine.
Once sheared the settling conditions were modelled by maintaining the same Q /Z  
between  scales.  The  sigma value for the  industrial  disc  stack centrifuge can be 
calculated from the equation below (Axelsson, 1985):
Z   =  — ttz c o 2q o \Q ( R q   - R ? ) F X
(equation 2.7)
86Where z is the number of discs in the stack, co = 27m (n is the rotational speed), 0 
is the half disc angle, Ro is the outer disc radius, R\ is the inner disc radius and ¥\ 
is the correction  factor applied to account for the presence of the  spacer chalks. 
Solving  this  equation  using  the  parameters  in  table  1.6  gives  a  sigma value  of 
8400m2.
The  sigma  value  of the  Beckman  J2.M1  lab  centrifuge  fitted  with  a  swing  out 
bucket  rotor  (JA  13.1)  with  the  following  dimensions  and  operated  under  the 
following conditions can be calculated by utilising equation 2.8.
Maximum radius 0.14m
Minimum radius 0.041m
Volume 3x10 V
Rotational speed 100rps
Sigma 2.76m2
Table 2.6  Dimensions and operating parameters of the in-house shear device and 
lab centrifuge
Vco2
g In
2 R
in  J
(equation 2.8)
Where  R max  is  the  maximum  radius,  R mi„  is  the  minimum  radius.  Altering  the 
volume of material to be separated and the  length of centrifugation can account 
for the difference between the Sigma values. The flow rate to Sigma ratio  (Q /Z ) 
can be maintained by utilising the following equation:
87Q, ind  ^lab
£  md ^1  ^la b
(equation 2.9)
Rearranging equation 2.9  in order to  make time the  subject gives the  following 
equation:
t =
lab
Xm F ,
\  'E'md  J
(equation 2.10)
Where  Qind  is  the  volumetric  flow  rate  at  the  industrial  scale  and  Fi  is  the 
correction  factor applied  to  account  for  irregularities  in the  flow.  Solving this 
equation shows that the lab scale centrifuge should be run at 6000rpm, with 25ml 
of  sample  for  9.6minutes  in  order  to  recreate  the  settling  conditions.  The 
methodology based on these calculations can be found in section 2.4.2.
2.2.3  Conclusion
This section describes how the operating conditions detailed in section 2.4 were 
determined.  Operating  the  scale  down  mimics  under  these  conditions  should 
accurately mimic the industrial scale operations.
2.3  Analytical Techniques
2.3.1  Biological assays
2.3.1.1  T  otal protein
Total protein concentration was determined by the method of coomassie (Pierce, 
Rockford, USA).  The method is a modification of the work of Bradford (1976). 
The  binding  of protein  to  the  reagent  suppresses  protonation  and  results  in  a 
colour change from brown to blue.  Samples to be assayed were diluted to within
88the  working  range  of the  reagent  (200-1000pg/ml  of protein),  using  phosphate 
buffered saline.  This also ensured that the levels of possible interfering buffers, 
such sodium  sulphate,  were below the  level where they could  interfere with the 
assay.  50pl of sample were mixed with 950pl of commassie reagent in a cuvette. 
The  change  in  absorbance  at  595nm  was  measured  using  a  spectrophotometer 
(Kontron  instruments  model  922)  after  10 minutes.  Comparison of the  reading 
with  a  standard  curve  produced,  using  bovine  serum  albumin  or  ovine  IgG 
depending  on  the  nature  of  the  sample  being  tested,  enabled  the  protein 
concentration to be determined.  Each sample was measured in triplicate to give a 
mean value.
2.3.1.2  ELISA (Enzyme Linked Immuno Sorbant Assay)
The  percentage  of  active  anti-snake  venom  antibodies  was  determined  using 
enzyme-linked  immuno  sorbant  assay,  which  allows  the  identification  and 
quantification of an antigen from within a mixed solution.  The assay was carried 
out according to the following protocol.  A series of wells were coated with lOOpl 
each of snake venom (Protherics, Wales, UK) diluted (1:2000) with PBS pH 7.4 
and incubated for two hours at room temperature.  Each well was washed three 
times with a PBS/Tween 20 buffer, pH 7.4 and blocked by the addition of 100pi 
of 1% skimmed milk diluted in PBS, pH  7.4.  After 30 minutes the wells were 
then washed three times with the PBS/Tween 20 buffer.  Serial dilutions, using 
PBS, pH 7.4, of each sample were prepared in the range of 1:2000 to 1:320000 for 
samples  where the  levels  of antibody  present were  expected to  be  low e.g.  the 
supernatant and  1:40000  to  1:1280000  for  sample  where the  levels  of antibody 
were expected to be high e.g. ovine serum and precipitated solids.  lOOpl of each 
sample  was  pipetted  in  duplicate  into  the  coated  wells  and  incubated  at  room 
temperature  for  2hr.  The  wells  were  washed  three  times  with  PBS/Tween  20 
buffer,  pH  7.4.  lOOpl  of anti  sheep  alkaline  phosphatase  diluted  1:5000  with 
PBS/Tween 20,  pH  7.4  were  added to  each well.  The wells were  incubated  at 
room temperature for  lhr, after which they were washed again with PBS/Tween 
20, pH  7.4.  Finally,  lOOpl of alkaline phosphate yellow substrate was added to 
each well.  When the yellow colour developed,  after approximately 30 minutes,
89the reaction was stopped by the addition of 25pi of 3M sodium hydroxide.  The 
absorbance of the contents of each well was measured at 405nm by using a plate 
reader (Dynatech MR7000, Guernsey, Channel islands).
The total concentration of ovine IgG was also measured using an ELISA assay.  A 
series of wells were coated with  lOOpl of ovine IgG diluted using PBS, pH 7.4 to 
concentrations  between  lOOOng/ml  and  25ng/ml  in  order to  produce  a  standard 
curve.  Each  sample  to  be  assayed  was  serially  diluted  using  PBS,  pH  7.4  to 
within the working range of the assay and then  lOOul  were added to each well. 
The plates were incubated for either two hours at room temperature or over night 
at 4°C.  Each well  was washed three times with a PBS/Tween 20 buffer, pH 7.4 
and blocked by the addition of lOOpl of 1% skimmed milk diluted in PBS, pH 7.4. 
After 30 minutes the wells were then washed three times with the PBS/Tween 20 
buffer.  lOOpl of anti-ovine IgG diluted  1:2000 with PBS/Tween 20, pH 7.4 was 
added to each well and allowed to incubate for lhr.  The wells were washed three 
times  with  PBS/Tween  20  buffer,  pH  7.4.  lOOpl  of  anti  sheep  alkaline 
phosphatase conjugate diluted  1:5000 with PBS/Tween 20, pH 7.4 were added to 
each well.  The  wells were  incubated  at room temperature  for  lhr,  after which 
they were washed again with PBS/Tween 20, pH 7.4.  Finally,  lOOpl of alkaline 
phosphate yellow substrate  solution was added to  each well.  When the yellow 
colour developed, after approximately 30 minutes, the reaction was stopped by the 
addition of 25 pi of 3M sodium hydroxide.  The absorbance of the contents of each 
well  was  measured  at  405nm  by  using  a  plate  reader  (Dynatech  MR7000, 
Guernsey, Channel islands).
2.3.1.3  Albumin concentration
The concentration of the contaminating albumin in each sample was determined 
by  using  albumin  reagent,  bromocresol  green  BCG.  Albumin  binds  to  BCG  to 
produce a blue/green colour with an absorbance maximum at 628nm (Corcoran, 
1977).  50pl of each sample was mixed with  1ml  of BCG in a cuvette.  After 5 
minutes  the  colour  change  was  measured  using  a  spectrophotometer  (Kontron
90instruments  model  922).  The  concentration  of  albumin  was  determined  by 
comparing  the  result  with  the  standard  curve  produced  using  bovine  serum 
albumin.  Each sample was measured in triplicate in order to obtain a mean value.
2.3.2  Physical properties
2.3.2.1  Solid/Aqueous fraction  determination
The percentage solid content of each sample was determined by pipetting  1ml of 
precipitated  material  into  an  eppendorf and  spinning  it  at  13000  rpm  for  10 
minutes.  The  volume  of the  sample  occupied  by  solid  material  could  then  be 
measured by comparison to a graduated eppendorf.  The percentage of solid was 
then calculated by dividing by the total  volume.  Each  sample  was  analysed  in 
triplicate in order to calculate the mean value.
2.3.2.2  Liquid density
The density of the suspending solution containing the antibodies of interest was 
measured  using a  specific  gravity  bottle.  70ml  of sample  was  spun  at  12100g 
using a Beckman J2 Ml  centrifuge with a JA 20 rotor for 30 minutes in order to 
remove all  solid material.  10ml of the supernatant was decanted into a specific 
gravity bottle and weighed.  This was repeated three times  in order to  obtain an 
average reading.
2.3.23  Precipitate density
The  density  of the  antibody  solid  fraction  was  determined  by  measuring  the 
gravity settling velocity i.e. the time taken for the precipitate particles to settle out. 
Then using Stokes law of free settling and assuming laminar flow the density of 
the particles could be calculated, given that both the viscosity and the density of 
the liquid through which the particles were settling had been determined. This was 
considered reasonable considering the relatively small size of the particles.
2.3.2.4  Viscosity
Sample  viscosity  was  determined  using  the  Contraves  Rheomat  115  rheometer 
(Contraves  AG,  Zurich,  Switzerland).  The  Rheomat  115  is  a  rotational
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principle.  A coaxial  cylinder arrangement, which rotates  in the  substance to be 
measured was used to  measure the viscosity of the  sample at  15  different shear 
rates.  The shearing speed prevailing in the sample is a function of the cylinders 
rotational  speed  and  the  shear  stress  is  a  function  of the  braking  torque.  The 
samples viscosity, or its flow behaviour respectively can be deduced from these 
values.
20ml of sample at a temperature of 20 to 25°C were used for each run and each 
was repeated in triplicate in order to determine a mean value.
2.33  Gel Electrophoresis
2.3.3.1  Reducing SDS-Page gel  electrophoresis
The  proteins  contained  within  each sample  were  separated  and  visualised
according to size under denaturing conditions by using SDS polyacrylamide gel 
electrophoresis  (SDS-PAGE).  A  12% resolving,  4%  stacking  gel  was prepared 
using  the  method  of  Laemmli  (1970).  The  separated  protein  bands  were 
visualised by staining with Coomassie brilliant blue R250 protein dye for 30 to 60 
minutes.  Once stained, the gels were destained by shaking in 45% (v/v) methanol, 
10% (v/v) acetic acid in deionised water.
Each sample was diluted to  1  mg/ml.  They were then diluted  1   in 2 with sample 
buffer containing  10% (v/v) glycerol, 20% (v/v) of 10% (w/v) SDS,  12.5% (v/v) 
0.5  M  Tris-HCl  pH  6.8,  5%  (v/v)  p-mercaptoethanol,  5%  (v/v)  of  0.5% 
bromophenol blue and 47.5% (v/v) deionised water to give a final concentration 
of 0.5mg/ml.  Each sample was boiled  for one minute to  ensure that the  proteins
were fully denatured.  15pl of each sample were loaded into each well.  The gel 
was run at 80V for 30 minutes and then at 150V until the tracking dye reached the 
bottom.
922.3.3.2  Non-reducing SDS page gel electrophoresis
The  proteins  within  certain  samples  were  separated  under  non-denaturing 
condition.  Each  sample  was  diluted  to  5mg/ml  and  then  diluted  1:8  in  native 
sample  buffer  (Invitrogen  Ltd,  Paisley,  UK)  to  give  a  final  concentration  of 
0.6mg/ml.  Each  sample was then placed  in boiling water for  1   minute.  15ul  of 
sample  were  loaded  into  a  pre-cast  4-20%  Tris-Glycine  gel  (Invitrogen  Ltd, 
Paisley,  UK).  The gels were run at  150 volts for  roughly  1.5  hours or until the
tracking dye reached the  bottom.  The proteins were visualised by staining with 
Coomassie Brilliant blue R250 (Biorad, Hertfordshire, UK) for 30 to 60 minutes. 
Destaining was achieved by shaking in 45% (v/v) methanol, 10% (v/v) acetic acid 
in deionised water.
2.3.4  Particle size analysis
2.3.4.1  Laser particle sizing
Particle  size  analysis  was  carried out using the  Malvern  Mastersizer 2000  laser 
sizer (Malvern,  Worcestershire,  UK).  Laser diffraction,  more  accurately  called 
Forward Light Scattering measures particles in the range of 0.1  to 2000 microns. 
The instrument consists of three major parts; a schematic is shown in figure 2.1.
Recirculating cell
Laser
Detector
Computer
Pump
Figure 2.1  Schematic of the Malvern Mastersizer 2000
93•  The  laser,  which  acts  as  a  source  of coherent  intense  light  of a  fixed
wavelength.  The  lower the  wavelength  of the  light the  more  stable  the
system  is and the better the signal to noise ratio becomes.  The standard 
He-Ne  gas  lasers  operate  at  a  wavelength  of  0.633pm.  It  is  expected 
however that the smaller laser diodes, with wavelengths as low as 600nm, 
will  begin  to  replace  the  bulkier  gas  lasers  once  they  become  more 
reliable.
•  A detector:  this consists of a slice of photosensitive silicon with a number 
of discrete  detectors.  It  has  been  shown  that  the  optimum  number  of 
detectors is between  16 and 32.  Increasing the number of detectors does 
not necessarily result in an increase in the resolution.
•  A means of passing the sample through the laser beam.  Aerosols can be
sprayed  directly  through  the  beam.  Dry  powders  can be  measured  by
being  blown  through  the  beam  and  collected  by  a  vacuum  cleaner  to 
prevent  dust  being released to  the  environment.  Particles  in  suspension 
can be measured by recirculating the sample in front of the laser beam.
The  Malvern  Mastersizer  uses  the  Mie  theory  to  “assume”  the  volume  of the 
particle  and  then  convert  this  into  the  diameter  of an  equivalent  sphere.  This 
theory completely solves the equations for the interaction of light with matter.
In  order to  measure  a  sample  the  refractive  indices  for the  material  and  media 
need  to  be  known.  The  refractive  index  of the  median  was  estimated  from 
literature (Weast 1978) and that of the particles was assumed to be the roughly the 
same as biological particles (1.33).  Once the  samples were measured, the fit of 
the refractive index could be checked by utilising the Malvern software.
4 drops of each sample to be tested were added into the recirculating cell, which 
contained  18%  (w/v)  sodium  sulphate.  This  was  to  ensure  that  the  conditions 
within  the  instrument  matched  that  of the  sample.  Each  sample  was  analysed 
three times in order to obtain a mean value.
942.4 Ultra Scale Down Techniques
2.4.1  Ultra scale down precipitation
The precipitation reaction is the first stage in Protherics PLC purification process; 
by  mimicking  this  stage  it  becomes  possible  to  predict  the  effect  changes  will 
have  on  the  large-scale  operation  and  also  study  the  existing  process.  The 
operating parameters and vessel dimensions were determined in section 2.2
100ml of serum (Protherics, Llandusul, U.K.) were thawed overnight.  The serum 
was  then  filtered  through  a  0.2pm  filter  (Millipore,  Watford  UK)  in  order  to 
remove any cryoprecipitates.  The amount of filtrate was measured and this was 
then poured into the scaled down reaction vessel.  The vessel was placed into a 
water  bath  set  to  30°C  and  the  serum  allowed  to  equilibrate  with  the  water 
temperature.  Once  the  temperature  of the  serum  had  reached  30°C,  an  equal 
amount of 36% (w/v) sodium sulphate (Protherics, Llandusul, U.K.) temperature 
30°C was added at a rate of 4ml/minute by using a Watson Marlow pump model 
101U/R  (Watson  Marlow,  Falmouth,  U.K.).  Whilst  adding  the  precipitate  the 
impeller  was  set  to  555rpm  (as  determined  in  section  2.2.1.2).  The  speed  was 
controlled by using a variable speed stirrer (Eurostar Digital, IKA, Lobotechnik). 
Once  all  the  sodium  sulphate  had  been  added  (approximately  30  minutes),  the 
impeller was turned up to 1840rpm and the water bath was switched off.  After 15 
hours, the  final  solution was  characterised according to the methods  detailed  in 
section 2.3.
2.4.2  Ultra scale down centrifugation
Following precipitation at an industrial scale the solid fraction is removed by disc 
stack centrifugation. This operation was mimicked through the use of the in house 
shear  device  and  a  standard  swing  out  bucket  lab  centrifuge.  The  operating 
conditions were determined in section 2.2.2.
30ml of the precipitated antibody solution, prepared as per the method detailed in 
section 2.4.1, was sheared in the in-house shear device at 20000rpm for 1  minute.
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bucket  rotor  for  9.6minutes  at  6000rpm.  The  solids  fraction  was  then  re­
suspended in  18% (w/v) sodium sulphate.  Once re-suspended this solution was 
then sheared again at 20000rpm for  1   minute before being spun down under the 
same  conditions  as  before  (at  this  point  samples  were  taken  for  particle  size 
analysis).  Finally, the resulting solids fraction was re-suspended in PBS pH 7.4.
2.4.3  Scaled down filtration
Previously,  precipitated  immunoglobulins  were  recovered  from  the  liquor 
containing  contaminating  proteins  by  disc  stack  centrifugation.  This  process  is 
time consuming and  requires very  strict monitoring  for validation purposes.  A 
small-scale stirred cell filtration device (Millipore, Watford, UK) has been used to 
study the effects of replacing the centrifuge with a filter. The precipitated antibody 
feed used in these experiments was produced as per the method in section 2.4.1.
2.4.4  Stirred cell methodology
The stirred cell device was operated in two different modes: batch and continuous. 
It has a diameter of 0.063m with a total volume of 200ml and was modified for 
use  as  a small-scale microfiltration device.  A  3 pm  (pore  size)  cellulose  acetate 
membrane  90mm  in  diameter  (Millipore,  Watford,  UK)  was  cut  to  the  correct 
diameter, as 3 pm pore size membranes were not available in the correct diameter. 
These were then placed at the bottom of the cell.  The cell was equipped with a 
single  paddle  impeller  (width  =  4.3mm,  height  =  8.4mm,  length  =  49.6mm) 
positioned  centrally  in  the  cell  in  close  proximity  to  the  surface  of the  filter 
membrane.  The shaft was driven from the top by a variable speed motor having a 
maximum speed of 242rpm. The rotational speed of the shaft was measured using 
a digital tachometer. The cell was hermetically sealed, once the lid was screwed in 
place,  and  was  supplied  with  an  air  inlet  and  pressure  control  system  allowing 
precise setting of the air pressure above the solution in the cell during operation.
During continuous (diafiltration) operation the working liquid volume in the cell 
was  maintained  at  a  constant  level  by  continuously  feeding  a  wash/diafiltrate 
buffer (18% Na2SC>4 w/v) to the vessel at a rate equal to the permeate rate.
962.4.4.1  Batch filtration
Standard  batch  filtration  tests  were  carried  out  as  follows:  75ml  of suspension 
containing the precipitated antibody was placed in the stirred cell.  The rotational 
speed of the paddle was set at a pre-determined value and an air pressure applied. 
The  permeate  was  collected  (sample  2a,  Figure  5.1b)  until  the  permeate  flow 
stopped and a filter cake formed on the membrane. In the second part of the test, 
the cake  was washed,  as  described next.  The operation was  stopped,  150ml  of 
18% sodium sulphate (w/v) was added to the vessel and the paddle speed was set 
to the same speed as before. The mixture was stirred for ten minutes to break and 
resuspend the cake of precipitated antibody. The air pressure was re-applied and 
the  filtrate  was  collected  and  measured  every  minute  until  the  permeate  flow 
stopped.
2.4.4.2  Continuous filtration
In diafiltration mode, 75ml of precipitated antibody was placed in the cell.  The 
speed of the paddle was set at the pre-determined value and air pressure applied. 
A buffer solution of 18% sodium sulphate (w/v) was drawn in at the same rate that 
the  permeate  was  collected,  thus  maintaining  a  constant  level  of liquid  in  the 
vessel.  The flow of buffer was stopped after  150ml of buffer solution had been 
added and the operation switched to cake-filtration mode until the permeate flow 
stopped  and  a  filter  cake  of the  antibody  precipitate  formed.  The  225ml  of 
permeate was collected in three separate 75ml fractions for analysis.
The  final  step  for both  modes  of operation  consisted  of adding  75ml  of warm 
(37°C) phosphate buffered saline (PBS) pH 7.4 to the solid cake in the cell. The 
antibody rich filter cake was allowed to dissolve over approximately ten minutes. 
The air pressure was applied as before and the antibody rich permeate collected 
for analysis.
2.4.4.3  Loading and wash volume determination
75ml  and  100ml  respectively  of precipitated  serum  were placed  into  the  stirred
cell. The rotational speed was set to  121rpm and an air pressure of lbar applied. 
The  permeate  was  collected  until  the  permeate  flow  stopped.  The  layer  of
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then washed as described below.  The operation was stopped and an equal volume 
in the first set of experiments and twice the initial load volume in the second set of 
experiments of 18% sodium sulphate (w/v) was added to the vessel.  The paddle 
speed  was  set  to  the  same  speed  as  before  and  the  mixture  was  stirred  for ten 
minutes  to  break  and  re-suspend  the  cake  of  precipitated  antibody.  The  air 
pressure was re-applied and the filtrate was collected.
2.5  Chromatography
Precipitation  followed  by  centrifugation  is  an  unwieldy  and  time  consuming 
method of achieving the initial separation.  Affinity chromatography utilising the 
unique properties of protein G (as detailed in section  1.3.6.2) offers a simple one 
step procedure for isolating and concentrating the ovine immunoglobulins from all 
the other contaminating proteins.
A  preliminary  investigation  into  the  feasibility  of this  process  option  has  been 
carried out. Computer modelling has been utilised to predict breakthrough curves 
of column separations based on equilibrium data obtained at the laboratory scale.
2.5.1  24 hour equilibrium
Equilibrium binding experiments were used to determine experimental values of 
the  amount  of IgG  bound  to  the  matrix  and  the  amount  remaining  soluble  in 
solutions of different concentrations after 24 hours.  This data can then be fitted to 
model isotherm equations such as the Langmuir curve.
lOOpl  of  Protein  G  sepharose  4  fast  flow  matrix  (Amersham  Biosciences, 
Buckinghamshire,  UK)  equilibrated  in  0.2M  sodium  phosphate  buffer  pH  7.4 
(binding buffer)  was  pipetted  into  a  series  of eppendorfs.  Samples  of purified 
ovine  IgG  (prepared  according to  section  2.5.3)  and  Albumin  were  prepared  at 
concentrations of 40, 35, 30, 25, 20, 15, 10, 8, 6, 4, 2, 1, and 0.5mg/ml by dilution 
with binding buffer. The protein solutions remained clear and there was no visible 
precipitation.
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closed and placed on an end over end stirrer.  After 24 hours, the eppendorfs were 
spun  in a microfuge (Biofuge  13, Heraeus sepatech,  Germany) at  13000rpm for 
two minutes in order to pack the matrix to the bottom of the tube. (Measuring the 
concentration of a control  sample that had been left at room temperature  for 24 
hours checked the stability of the protein. This showed that no degradation of the 
protein was occurring).  80pl of the mobile phase was then removed and analysed 
by Bradford assay for total protein content and ELISA for total IgG content as per 
sections  2.3.1.1  and  2.3.1.2.  Each  run  was  repeated  three  times  in  order  to 
determine a mean value.
2.5.2  Dynamic equilibrium determination
2ml  of  protein  G  sepharose  4  fast  flow  matrix  (Amersham  Biosciences, 
Buckinghamshire,  UK),  equilibrated  by  washing  in  10ml  of  0.2M  sodium 
phosphate buffer pH 7.4, was pippetted into a stirred cell (Millipore, Watford UK) 
(model 8010). The mixer was turned on at a slow speed in order to ensure good 
mixing.  2ml  of each  sample  (IgG  30mg/ml  and  Albumin  30mg/ml)  was  then 
added to the stirred cell.  30ul samples were removed at  15, 30, 45, 60, 90,  120, 
300,  600,  900,  1200,  1500  and  1800  seconds.  Any  matrix  contained  with  the 
sample  was  immediately  removed  by  centrifugation  through  a  centrifugal  filter 
fitted with a 1  pm pore diameter filter (Millipore, Watford UK). This ensured that 
no further adsorption of protein to the matrix would occur.  The collected samples 
were assayed for total protein content and total IgG content as per sections 2.3.1.1 
and 2.3.1.2.
2.5.3  Purification of ovine IgG by adsorption to Protein G
A  2.5cm  high  by  0.7cm  diameter  protein  G  column  (Amersham  Biosciences, 
Buckinghamshire, UK) was used to purify the ovine IgG from the serum, forming 
a source of pure IgG for further experiments.  1ml of 0.2pm depth filtered serum 
was  mixed  with  1ml  of binding buffer,  in  order to  ensure  buffering  conditions 
suitable for the binding of IgG to protein G.  This was loaded onto the column at a
99flow  rate  of  157cm/hr.  Any  unbound  proteins  were  then  washed  away  by  the 
addition of 6 column volumes (CVs) of binding buffer.  The bound IgG was then 
eluted  by  the  addition  of 8  CVs  of 0.1M  glycine-HCl  buffer pH  2.7.  Samples 
were collected in one millilitre fractions and the elutant samples were immediately 
quenched  to  pH  7.0  by  the  addition  of 46pl  of  1.0M  Tris-HCL  pH  9.0  buffer. 
This  ensured  that  the  acid  labile  immunoglobulins  were  not  denatured  by  the 
harsh  elution  conditions.  Following  elution,  the  column  was  immediately  re­
equilibrated with 8 CVs of binding buffer.  After every five runs, the column was 
cleaned by running a solution of 0.1% Triton  100 detergent through the column 
for one minute (as recommended by the manufacturer).  This should remove any 
proteins or lipids that remained bound to the column.
The  eluted  fractions  were  pooled,  concentrated  and  a buffer exchange  affected. 
This  was  achieved  by  centrifugal  filtration  through  a  lOOKDa  membrane 
(Millipore, Watford, UK) until a final concentration of IgG in excess of 40mg/ml 
(determined  by  measurement  of the  absorbance  at  280nm)  was  reached.  This 
product  could  then  be  diluted  as  necessary  (6  runs  were  generally  required  to 
produce 3ml of final product).  The flow through, wash and elution fractions were 
assayed for total protein content and the proteins contained in the samples were 
visualised by non denaturing SDS page as per section 2.3.1.1 and 2.3.3.2.
2.5.4  Breakthrough curves
Purified and concentrated IgG was produced as per the method in section 2.5.3. 
This was diluted with binding buffer to 30mg/ml and  15mg/ml as determined by 
absorbance  at  280nm.  Columns  with  the  dimensions  and  bed  heights  shown 
below in table 2.7 were poured:
100Bed Height  Bed Diameter  Column Volume 
(cm)  (cm)  (ml)
2.5  0.7  0.96
5  1   3.95
10  1   7.9
15  0.8  7.5
Table 2.7  Chromatography bed dimensions for breakthrough curve experiments
The  purified  IgG  was  then  pumped  onto  the  column  at  the  flow  rates  and 
concentrations  shown  below  in  table  2.8.  A  range  of  flow  rates,  feed 
concentrations  and  bed  heights  were  chosen  in  order  to  generate  differing 
breakthrough curves and test the ability of the mathematical model to accurately 
predict the shape of the breakthrough curves.
Bed Height (cm) Feed Concentration (mg/ml) Flow rate (cm/h)
2.5 30 157
2.5 30 316
2.5 15 157
2.5 15 316
5 30 76
5 15 76
10 30 76
10 30 38
15 30 120
15 30 60
Table 2.8  Feed concentrations and flow rates used during the breakthrough curve 
experiments
Each column was run until the absorbance reading of the effluent levelled out and 
was within 0.1 AU of the feedstock.
1013  An  Ultra  Scale Down Approach  For The Predication
Of  Full  Scale  Recovery  Of  Ovine  Polyclonal 
Immunoglobulins Used In The Manufacture Of Snake 
Venom Specific Fab Fragment
3.1  Introduction
The results presented in this chapter have been published (Neal, et al. 2003). This 
chapter describes a new approach that allows the prediction of the performance of 
a large-scale integrated process for the primary recovery of a therapeutic antibody 
from an analysis of the individual unit operations and their interactions in an ultra 
scale-down mimic of the process. The recovery process consisted of four distinct 
unit operations (figure 3.1a).  Using the new approach the important engineering 
parameters  in  each  operation  that  impacted  the  overall  recovery  process  were 
defined and in each case its effect was verified by a combination of modelling and 
experimentation.
Immunoglobulins  were  precipitated  from  large  volumes  of dilute  blood plasma 
and  the  precipitate  particles  were  recovered  by  centrifugal  separation  from  the 
liquor  containing  contaminating  proteins  including  albumin.  The  fluid 
mechanical forces acting on the particles and the time of exposure to these forces 
were used to define a time-integrated fluid stress. This was used as a scaling factor 
to predict the properties of the precipitate particles at large scale.  In the case of 
centrifugation, the performance of a full-scale disc stack centrifuge was predicted. 
This was achieved from a CFD analysis of the flow field in the centrifuge coupled 
with experimental  data obtained  from the precipitated immunoglobulin particles 
using the  scale  down precipitation tank,  a rotating  shear device,  and  a standard 
swing-out rotor centrifuge  operating under defined conditions.  In this way, the 
performance of the individual unit operations, and their linkage, was successfully 
analysed from a combination of modelling and  experiments.  These  experiments 
required only millilitre quantities of the process material. The overall performance 
of the large-scale process was predicted by tracking the changes in physical and
102biological  properties  of the  key  components  in  the  system  including  the  size 
distribution of the antibody particles and antibody activity through the individual 
unit operations in the ultra scale-down process flowsheet.
This  chapter  is  concerned  with  the  initial  downstream  recovery  of  ovine
polyclonal  immunoglobulins  as  part  of a  process  for  the  preparation  of
monovalent  Fab  fragments  developed  as  an  antidote  to  rattlesnake  bites.  The 
preparation of the anti-venom is detailed in chapter 1.
From  a process  engineering  perspective,  there  is  now  very  intense  pressure  on 
companies to establish techniques that can rapidly assess new process options to 
produce a potential  new drug candidate  in  sufficient quantities for its perceived 
demand.  This  pressure  is  compounded  further  by  the  fact  that  such  process 
information is needed often early in the life cycle of the new drug candidate when 
pilot  plant trials  are  either not  feasible,  because  the  company has  no  access  to 
suitable facilities, or not practical because only very small quantities of relevant 
materials are available for tests.  Recently an engineering approach that allowed 
key process information to be generated from small mimics of large industrial unit 
operations  was  developed.  This  provided  experimental  evidence  that 
demonstrated the  applicability  of the  technique  in two  separate  operations,  one 
involving the  recovery  of a protein precipitate  using  a multichamber centrifuge 
(Boychyn,  et  al.  2001)  and  the  other  the recovery  of a  monoclonal  antibody
fragment  in  solution  from  fermentation  broth  using  a  filtering  centrifuge
(Boulding,  et  al.  2002).  This  chapter  provides  experimental  evidence  to 
demonstrate the capacity of the approach to link two neighbouring operations of 
precipitation and centrifugation used in sequence in the primary recovery of the 
immunoglobulins.
3.2  Methodology
All  experiments  were  carried  out  with  the  same  stock  of  anti-venom  serum 
supplied by, Protherics PLC (Llandusul, Wales, UK).
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for  the  primary  recovery  of  the  immunoglobulins.  The  process  starts  with  a 
precipitation  step  during  which  the  immunoglobulins,  primarily  IgG,  are 
precipitated from the serum solution by the addition of an equal volume of 36% 
(w/v) solution of sodium sulphate (final concentration 18% w/v). This is followed 
by  a  solid-liquid  separation  step  in  a  disc  stack  centrifuge  to  remove  the 
precipitated  antibodies  from  the  liquor  containing  the  contaminating  proteins 
including albumin.  The  solid fraction containing the  immunoglobulins are then 
resuspended  in  a  fresh  solution  of 18%  (w/v)  sodium  sulphate  and  centrifuged 
again to remove the residual contaminating proteins.
In  the  large-scale  process,  the  precipitation  step  was  carried  out  in  a  0.68m 
diameter cylindrical  stainless steel, dished-bottom tank having a height of 0.6m. 
The liquid height in the vessel was maintained at 0.5m giving a working volume 
of 200L. The vessel was equipped with a 3-bladed stainless steel marine propeller, 
positioned off-centre in the tank.  The impeller shaft entered the vessel through 
the side-bottom of the tank,  1/5 of the liquid height from the base of the vessel, at 
an angle of approximately 45°. The impeller was driven by an electric motor with 
the speed of agitation set at 150rpm. Agitation was maintained at this speed for 30 
min to complete the precipitation process, following which the impeller speed was 
increased to 500rpm and maintained at this speed for  15hr to condition (age) the 
precipitate.  The  whole  operation  (precipitation  and  aging)  was  carried  out  at 
30°C.  The  precipitated  antibody  was  separated  from  the  liquor  containing  the 
other  biomolecules  by  using  a  continuous  flow  disc  stack  centrifuge  (Model 
SAMR 3036, Westfalia, UK) with a bowl volume of 6.9L operating at a speed of 
7500rpm  and  a  flow  rate  of 120Lhr"'.  The  solids  were  collected  intermittently, 
pooled and resuspended  in an equal  volume of 18% (w/v)  sodium sulphate  in a 
tank with identical  configuration to the precipitating vessel  and operating under 
the  same  speed.  The  resuspended  antibody  particle  was  then  centrifuged  under 
operating conditions similar to those used in the first centrifuge. The solids from 
the second centrifuge were pooled and resuspended in phosphate buffered saline 
(PBS)  solution before being transferred to the fractionation vessel  for treatment 
with papain.
104Figure 3.1b shows the ultra scale-down flowsheet used to mimic the operations in 
the  full-scale  process  (Figure  3.1a).  The precipitation tank  was  scaled-down  by 
factor of 1000, based on the working volume of the liquid. The main dimensions 
of the scale-down precipitation vessel were as follows:  tank diameter = 0.068m; 
tank height = 0.06m; liquid height = 0.05m; and impeller diameter = 0.02m. There 
were major geometrical  differences between the full-scale precipitation tank and 
its mimic. For example, in the scale-down configuration, both the vessel and the 
three bladed marine propeller were constructed from plastic, the vessel had a flat 
bottom and the impeller was positioned in the centre of the tank and driven via a 
shaft from the top of the vessel  by a small  electric motor with a variable speed 
control.  The impeller was placed approximately  1/3  of the vessel diameter from 
the base of the vessel and the ratio of impeller to tank diameter was different to 
that used in the full-scale unit.
3.2.1  Computational Fluid Dynamics simulation
The  velocity  profile  and  the  associated  local  energy  dissipation  rates  in  the 
entrance region of the disc stack centrifuge were simulated using a commercially 
available  package  (CFX  4.1,  AEA  Technology,  Oxfordshire,  UK).  A  finite 
volume code was used to solve the integrated form of the governing flow equation 
(Versteeg and Malalasekera, 1955). The flow of the fluid in the entrance is highly 
turbulent, and the high Reynolds number form of the k-e turbulence model (RNG 
k-s turbulence model) was built into the CFX-4.1  code and used for calculation 
purposes. Previously described experimental results validate simulations made by 
CFX  (Soon et al, 2001).  This package is now used routinely to assess the flow in 
complex process geometry (Boychyn, et al. 2001; Boulding, et al. 2002).
For the purpose of flow analysis, the two-liquid phase mixture was treated as a 
continuum having the physical properties of the continuous aqueous phase. This is 
a reasonable assumption given the relatively low solid concentration in the feed 
(12% v/v).  The  antibody  suspension flows into the empty space of the entrance 
chamber,  and in  its normal  mode of operation the  flow is considered  as  a two- 
phase,  gas-liquid  system with the  liquid  expanding through the  air space  of the
105chamber.  The homogeneous two-phase flow model was used to describe the gas- 
liquid  interaction.  It  was  assumed  that  the  solution  fields  for  each  phase  were 
identical except for the volume fractions, which were found by solving separate 
continuity  equations  for  each  phase.  This  approximation  was  considered  to  be 
reasonable because the majority of the volume fractions are close to zero or unity, 
with  the  exception  of  those  at  the  interface.  The  two-phase  fluid  flow  was 
assumed to be transient, weakly compressible for the gas phase and Newtonian, 
non-isothermal  and  homogeneous  with  constant  density  and  viscosity 
(incompressible)  for  the  liquid  phase.  Gravity  effects  were  assumed  to  be 
negligible and were not included in the calculations.
Because  of the  symmetry  of flow  the  simulations  were  carried  out  only  for  a 
quarter  of the  centrifuge  volume.  In  terms  of  CFD  analysis  of flow  in  the 
centrifuge, an important consideration is the treatment of boundary conditions at 
moving  surfaces.  The  simulation programme used  in the present study  is  a cell 
centred  code  in  which  the  variables  are  calculated  and  stored  at  a node  in  the 
centre of the cell.  Therefore, unlike other codes that have active vertices on the 
wall, for example a finite element code, CFX4 does not require the specification 
of turbulence values on the wall.
The  entrance  region  of the  centrifuge  forming  the  computational  domain  was 
“body  fitted”  for  grid  generation  and  the  governing  equation  solved  using  a 
personal  computer  (Hewlett  Packard,  Vectra,  Pentium  II  400  MHz).  Grid 
independent solutions were obtained by using a mesh design consisting of 90,000 
grids.  The  grids  were  refined  to  allow  the  details  of flow  to  be  examined  in 
regions where rapid changes in flow occurred.
3.2.2  Analytical techniques
Biological assays
The activity of antibodies, the total protein concentration and the concentration of 
albumin within the samples were determined as per the methods in section 2.2.1.
106The proteins contained within each sample were separated according to size under 
denaturing  conditions  by  sodium  dodecyl  sulphate  polyacrylamide  gel 
electrophoresis (SDS-PAGE). The methodology is described in section 2.2.3
Physical properties
To  assess  the  physical  state  of the  precipitated  antibody  particles,  particle  size 
measurements were performed on samples removed from the full-scale process as 
well as the scale-down mimic. The sampling locations are shown in Figures 3.1a 
and 3.1b. Particle size measurements were obtained as per section 2.2.4.
Density  measurement  of the  liquid  and  solid  fractions,  viscosity  measurements 
and percent solids content were determined as per the methods in section 2.2.2.
1073.3  Results
Figures  3.1a  and  3.1b  are  process  flow  sheets  detailing  the  initial  purification 
steps used during the production of rattlesnake anti-venom. Figure 3.1a shows the 
industrial  scale  process  which  consists  of  precipitation,  centrifugation,  re­
suspension and a second centrifugation step.  Figure 3.1b shows the scaled down 
mimic  process  which  consists  of  precipitation,  shearing,  centrifugation,  re­
suspension, a second shearing step and a second centrifugation.
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Figure 3.1a  &  b  Process  flow  sheet  detailing the  initial  stages  of the process 
scale  purification  process,  the  ultra  scale  down  mimic  of the  process  and  the 
sampling points
108Table  3.1  is  a  comparison  of the  physical  properties  of the  antibody  particles 
produced at the industrial  scale and by the ultra scale down mimic.  The mimic 
produces a feed stream which closely matches the physical properties of the feed 
stream  produced  at  the  industrial  scale  (standard  error:  Viscosity  +/-  O.lmPa.s 
(n=5), Solids content +/-  1.3% (n=5), Density solid +/- 0.16g.cm'3 (n=5), Density 
liquid +/- 0.02g.cm*3 (n=5)
Viscosity (mPa.s) Solids content (%) Density solid (g.cm'3) Density liquid (g.cm'3)
Scale down 2.5 12.0 1.3 1.17
Industrial scale 2.4 12.0 1.3 1.17
Table  3.1  Comparison  of the  precipitated  antibodies  (sample  number  two  in 
figure 3.1a & b) physical properties produced on an industrial  scale and by the 
scale down mimic
109The  particle  size  distribution  of  the  antibody  particles  produced  at  the  two 
different operating scales should match,  if they do it indicates that the mimic  is 
effective.  Figure  3.2  shows the particle  size distribution of the  industrial  scale 
particles and the ultra scale down particles.  The particle size distributions match 
closely between the two  scales indicating a good mimic  (standard deviation +/- 
3 pm at d0.9, n=5).
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Figure  3.2  Comparison  of the  particle  size  distribution  produced  during  the 
precipitation of antibodies with sodium sulphate on an industrial scale, •  and by a 
1000 fold scale down model,  A  with the same time integrated shear stress value 
(Ef) (sample point 2 fig 3.1a & b)
110Disc  stack  centrifugation  is  expected  to  have  some  degree  of impact  upon  the 
particle size distribution of the antibody particles.  Figure 3.3 depicts the particle 
size  distribution  of  the  particles  before  and  after  their  passage  through  the 
centrifuge.  Disc stack centrifugation results in a 50% decrease in the particle size, 
it is interesting to note however that no further reduction size occurs during the 
second passage (standard deviation +/- 3pm at d0.9, n=3).
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Figure 3.3  Comparison  of the  precipitated  antibodies  particle  size  distribution 
before,  ▲  after,  •   1st  industrial  scale  disc  stack  centrifugation  and  after  2nd 
industrial scale disc stack centrifugation ■ (sample points 2,4 & 6 fig 3.1a)
111SDS  page  gel  electrophoresis  provides  a  means  of  visualising  the  proteins 
contained within a sample.  Figure 3.4a is a SDS page reducing gel of the proteins 
contained within the feed and waste streams at various points during the industrial 
scale purification process.  It can be seen that the albumin, which forms the main 
contaminant, is removed during purification.
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Figure3.4a  SDS-page  reducing  gel  showing  the  contaminants  of  each  feed 
stream  at  the  industrial  scale,  lane  one  contains  Serum,  three  contains  1st 
supernatant, four contains  1st solid, five contains 2nd supernatant and six contains 
2nd solid.  Sample numbers refer to figure 3.1a
112Figure 3.4b is a SDS page reducing gel of showing the proteins contained in the 
feed and waste streams of the ultra scale down mimic purification process.  The 
gel shows that the same contaminants are present at both scales.
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Figure  3.4b  SDS-page  reducing  gel  showing  the  contaminants  of each  feed 
stream  at  the  laboratory  scale,  lane  one  contains  Serum,  three  contains  1st 
supernatant, four contains  1st solid, five contains 2nd supernatant and six contains 
2nd solid.  Sample numbers refer to figure 3.1b
113CFD  simulations allow predictions of the magnitude of forces acting within the 
disc  stack  centrifuge.  Figure  3.5  is the  CFD  simulation  of the  flow  conditions 
within a disc stack centrifuge.  The shear rate is highest within the region of the 
lock nut.
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Figure 3.5  CFD simulations of flow and associated hydrodynamic parameters in 
the entrance region of the disc stack centrifuge
114Particle size distribution measurements of the antibody particles at various stages 
during the ultra scale down purification process are shown in figure 3.6.  As can 
be seen without shearing little degradation of particle size occurs.  However the 
introduction of shear stress results in degradation of the particle size distribution 
to a size which closely matches the particle size produced during industrial scale 
centrifugation (standard deviation +/- 3 pm at d0.9, n=5).
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Figure 3.6  Comparison  of the  precipitated  antibodies particle  size  distribution 
before,  ■  and after,  ♦   (sample points 2 & 6 fig 3.1b) centrifugation in a swing 
out  bucket  centrifuge  at  the  same  flow  rate/sigma  as  the  industrial  disc  stack 
centrifuge  (no  shear).  After  shearing  with  an  air  liquid  interface  followed  by 
centrifugation in a swing out bucket centrifuge, X (sample point 4 fig 3.1b). After 
shearing twice with an air liquid interface followed by centrifugation twice in a 
swing out bucket centrifuge, A  (sample point 6 fig 3.1b) and after industrial disc 
stack centrifugation, •  (sample point 6 fig 3.1a)
115The levels of total protein, albumin and active antibody were measured in order to 
produce a mass balance.  Figure 3.7a is the mass balance for the industrial scale 
operation.  The balance correlates with the visual  information given by the  SDS 
page  gels  shown  in  figure  3.5  (standard  error:  Total  protein  +/-  3%  (n=5), 
Albumin +/- 5% (n=5), Active antibody +/- 8% (n=3)).
B  Average Total protein (%)
□  Average Albumin (%)
B  Average Active Antibody (%)
Figure 3.7a  Mass balance  for industrial  scale purification process  showing the 
levels  of total  protein,  the  main  contaminant  and the  product  (sample  numbers 
correspond to those in fig 3.1a)
116A mass balance was also carried out for the ultra scale down purification process. 
Figure  3.7b  depicts  the  levels  of total  protein,  albumin  and  active  antibodies 
within  the  various  samples.  It  can  be  seen  that  they  closely  match  the  levels 
produced  at  an  industrial  scale  (standard  error:  Total  protein  +/-  3%  (n=5), 
Albumin +/- 4% (n=5), Active antibody +/- 9% (n=3)).
Average Total protein (% )
Average Albumin (% )
□  Average Active Antibody (% )
I Average Active Antibody 
without shear (% )
Figure 3.7b  Mass balance for the ultra scale down purification process showing 
the levels of total protein, the main contaminant and the product (sample numbers 
correspond to those in fig 3.1b)
117A comparison of the levels of total protein, albumin and active antibodies found 
with the first solid of the industrial scale process and ultra scale down process is 
presented  in  Figure  3.8a.  The  levels  of protein closely match  between the  two 
differing  scales  of operation  (standard  error  Scale  down:  Total  protein  +/-3% 
(n=5), Albumin +/- 4% (n=5), Active antibodies = +/- 9% (n=3). Industrial scale: 
Total  protein +/-3%  (n=5),  Albumin  +/-  5%  (n=5),  Active  antibodies = +/-  8% 
(n=3)).
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Figure 3.8a  Mass balance showing a the quantities of total protein (%), albumin 
(%) and active antibody (%) present in the 1st solid (sample point 4)
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118A  mass  balance of the total  protein content,  albumin  levels and active antibody 
concentration contained in the final product reveals that the levels match closely 
between the two scales of operation and that the amount of albumin present has 
been  reduced  to  almost  zero  (standard  error  Scale  down:  Total  protein  +/-3% 
(n=5), Albumin +/- 4% (n=5), Active antibodies = +/- 9% (n=3). Industrial scale: 
Total  protein  +/-3%  (n=5),  Albumin +/-  5% (n=5),  Active  antibodies =  +/-  8% 
(n=3)).
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Figure 3.8b  Mass balance  showing the quantities of total protein (%),  albumin 
(%) and active antibody (%) in the final product (sample point 6)
1193.4 Discussion
3.4.1  Precipitation
The recovery of the immunoglobulin fraction from the serum solution containing 
other biomolecules  must  ensure  conditions,  which  avoid  damage  to  the  protein 
product. Precipitation is an attractive option that is capable of rapidly isolating the 
desired  product  and  bringing  about  product  concentration  and  fractionation 
simultaneously.  The  precipitation  step  also  impacts  on  the  efficiency  of any 
subsequent recovery and purification stages in the process flow sheet through the 
size  and  strength  of the protein precipitated particles.  In this  investigation,  we 
defined the process conditions that allowed the properties of the immunoglobulins 
precipitated  particles  in  a  large-scale  precipitation  reactor to  be  predicted  from 
small-scale  studies  (figures 3.1a and  3.1b).  The methodology is not intended to 
greatly change the concepts and theories of protein precipitation (Przybycien and 
Bailey, 1989) but to lead to more effective means for its control particularly when 
shear sensitive biological products are processed.
Based on previous work  on the  impact of turbulence on biomaterials  (Yim  and 
Ayazi  Shamlou,  2000;  Henzler,  2000;  Kieran,  et al.  2000),  it was hypothesized 
that the physical  properties  of the  precipitated particles  at the  end of the  aging 
process  were  determined  primarily  by  the  total  fluid  stress,  Ef,  acting  on  the 
particles  during  the  conditioning  stage.  Assuming  that  fluid  stress  is  equal,  or 
directly proportional to the fluid energy dissipated in the liquid by the  impeller, 
then Ef was defined as the product of the power input by the impeller, P, per unit 
volume of suspension,  V, and the  aging (conditioning) time, t.  Thus,  Ef = evt = 
[(P/V)t].  The group  (svt)  with the units of N m ', may be thought of as a "time- 
integrated  fluid  stress"  acting  on the  particles  in  the  aging process  and  gives  a 
measure of the total work done on the particles during this period.  Previous work 
in our  laboratories  (Bell,  et al.  1982a and  1982b)  and  elsewhere  have  used  the 
concept of Camp number, defined as the product of the average shear rate, G, in 
the precipitating vessel  and aging time, t, to  correlate experimental  data.  For a 
Newtonian  system  the  dimensionless  Gt  is  related to  svt through the  kinematic
120viscosity. It is proposed that the physical basis of the time-integrated fluid stress, 
(svt), provides a more rational  basis for comparing and correlating experimental 
results and here we used this approach to  compare  data from the two  scales  of 
precipitation.  In  both  scales  the  calculation  of the  operating  Reynolds  number 
showed  that  flow  was  fully  turbulent  and  power  input  was  obtained  from  a 
standard power-curve for each impeller.  Suspension viscosity, density and solids 
contents were measured as described in section 2.2.2 and particles  size  analysis 
was performed on samples removed from different points in the process (figures 
3.1a and 3.1b). In table 3.1  physical properties are presented for the two scales of 
precipitation vessel operating at an equal time-integrated shear stress. The data in 
table 3.1  refers to samples taken at the end of the aging period and prior to the 
first step centrifugation (sampling point 2 figures 3.1a and 3.1b). Figure 3.2 shows 
the corresponding size distribution of the immunoglobulins precipitated particles 
for the two  scales.  Excellent agreement is observed between the two  scales of 
precipitation.  These  experiments  were  carried  out  at  a  constant  time-integrated 
fluid stress of 2.6x1 O ^m '2, which was calculated based on an aging time of 15h 
and  an  operating  power  input  per  unit  volume  of 48.5Wm' ,  representing  the 
conditions  in  the  large  scale  precipitation  tank.  Using  the  ultra  scale-down 
process,  we  carried  out  additional  experiments  in  which  Ef  was  maintained 
constant  for  different  combinations  of P/V  and  aging  times,  t.  Particle  size 
distributions  thus  obtained  for  constant  Ef were  comparable  demonstrating  the 
general applicability of the concept of time-integrated shear stress.
3.4.2  Centrifugation
The plots in figure  3.3  represent the size distribution of samples before (sample 
point  2,  figure  3.1a)  and  after  (sample  points  4  and  6,  figure  3.1a)  the  two 
centrifugation  steps.  The  data  refer  to  samples  obtained  from  the  full-scale 
operation  and  demonstrate  a  significant  shift  in  the  size  distribution  towards 
smaller  sizes  occurring  as the  material  passes through the  first  centrifuge.  It  is 
notable that the  second centrifuge has negligible  impact on the  size distribution 
confirming that particle size is determined mainly by the aging conditions and the 
first stage centrifuge. The SDS-PAGE gel analysis of samples (figure 3.4) allowed 
the  contents of the  solids  and  supernatant  streams to be visualised  and tracked.
121Comparison of samples  1   and 3  shows that a large fraction of the contaminating 
albumin  protein  is  removed  from  the  immunoglobulin  product  during  the 
precipitation  and  first  stage  centrifugation  and  according  to  samples  3  and  6 
further  albumin  is  removed  during  the  resuspension  and  second  step 
centrifugation steps.  The remaining contaminating components seen in sample 6 
are removed by further downstream processing following treatment with papain. 
Additionally, these gels indicate that there is no detectable antibody present in the 
supernatant (Lane 3) of the first centrifuge and mass balances by ELISA carried 
out on immunoglobulins showed only a small amount of loss of binding (see later 
discussion).
As described below, we used the ultra-scale down process flowsheet (figure 3.1b) 
to  mimic  the  large-scale  process.  Previous  work  on  protein  precipitates 
(Mannweiler  and  Hoare,  1992)  using  a  disc  stack  centrifuge  concluded  that 
breakage of precipitates occurred in the entrance zone of the centrifuge.  This has 
also been confirmed recently for a multichamber-bowl centrifuge (Boychyn, et al. 
2000).  The breakage of the feed material increases the proportion of fine particles 
causing a reduction in the separation performance of the centrifuge (Maybury, et 
al.  1998). The difficulty in using a conventional laboratory centrifuge to predict 
the consequences of such breakage on the performance of an industrial centrifuge 
is that unlike the former, shear damage in the latter is practically negligible since 
the fluid in the laboratory centrifuge is at rest relative to the centrifuge tube.  An 
approach, which overcomes this difficulty, has been recently reported (Boychyn, 
et al. 2001; Boulding, et al. 2002).  The methodology used to obtain the necessary 
information  is  briefly  as  follows.  For  a  given  set  of operating  conditions,  the 
velocity  field  and  the  associated  hydrodynamic  parameters  such  as  shear rates, 
energy dissipation rates and shear stresses in the full-scale centrifuge are mapped 
out by using computational fluid dynamics (CFD) analysis of the prevailing flow. 
Using  CFD  simulations  the  regions  of highest  energy  dissipation  rates  in  the 
centrifuge are identified. A small laboratory device consisting of a 30mm rotating 
disc  housed  in  a  40mm  diameter,  20mm  height,  cylindrical  chamber  described 
previously (Levy, et al.  1999) is used to create flow conditions inside the chamber 
that accurately produce the highest predicted energy dissipation rates in the full- 
scale  centrifuge.  A  small  quantity,  typically  30ml,  of the  process  material  is
122subjected to the predetermined flow environment in the chamber of the rotating 
disc  device  and  the  resulting  suspension  is  treated  in  a  standard  laboratory 
centrifuge.  In  the  present  study,  we  used  the  above  protocol  with  a  standard 
laboratory centrifuge (Beckman J2, UK) equipped with a set of swing out bucket 
rotors  (type  J13.1).  The  Beckman  centrifuge  was  operated  at  a  ratio 
(Boychyn, et al. 2001) equal to that used in the full-scale centrifuge. Each run was 
repeated  twice  and  the  material  pooled  and  suspended  in  18%  (w/v)  sodium 
sulphate solution for analysis.
CFD simulations of the entrance region of the disc stack centrifuge are shown in 
figure 3.5. These simulations indicated that the maximum energy dissipation rate 
in the centrifuge was  in the order of 5xl04 WKg'1.  We carried out ultra scale- 
down  experiments  using  the  swing  out  bucket  laboratory  centrifuge  and  the 
rotating disc shear device operating under conditions that matched the maximum 
energy  dissipation  rate  in  the  disc  stack  centrifuge.  The  results  are  shown  in 
Figure 3.7 and demonstrate that the laboratory centrifugation on its own fails to 
mimic the performance  of the  disc  stack centrifuge.  However,  by  shearing the 
sample in the  small  scale rotating disc  device  followed by centrifugation in the 
swing out centrifuge operating at an equal  ratio to that used in the full scale 
centrifuge it was possible to achieve results that were in excellent agreement with 
the full-scale unit.
Examination of the size distribution plots in figure 3.6 also shows no significant 
differences in the size distribution of precipitated particles for solid samples taken 
at points 4 and 6  (figure 3.1b).  This agrees very well with the results shown in 
figure  3.3  (for  samples  points  4  and  6,  figure  3.1a)  and  confirms  the  general 
applicability of the proposed ultra scale-down approach.
These  results  are  also  consistent  with  previous  observations  on  breakage  of 
precipitates  and  particles  in  turbulent  flow  fields,  which  suggest  that,  in  these 
cases the size of the particle that survives an imposed turbulent flow environment 
is uniquely determined by the intensity of the prevailing fluid stresses. Significant 
structural changes occurring during the conditioning stage cause the compaction
123of the particle and,  in the case of precipitate particles, previous work has shown 
that the degree of compaction is not uniform within the structure.  Most particles 
tend to posses a hard core and a relatively loose structure on the outer region. In a 
high  intensity  flow  environment,  such  as  that  of the  centrifuge,  the  size  the 
particle  reduces  rapidly  as  the  outer  loose  structure  is  removed  rapidly  by  the 
prevailing  fluid  stresses.  As the outer mechanically weak  layers of the particles 
are  removed  a  point  is  reached  at  which  mechanical  strength  of the  surface 
exceeds  the  magnitude  of the  imposed  fluid  mechanical  stress.  The  result  is  a 
pseudo-equilibrium size which is determined by the balance of these two forces. 
Based  on the  results  shown  in  figures  3.3  and  3.6  it can be  concluded that the 
physical  properties  of the  precipitated  antibodies  are  determined  wholly  by  the 
aging  (conditioning)  process  in  the  precipitation  step  and  the  first  step 
centrifugation,  the  re-suspension  and  the  second  centrifuge  steps  have  no 
detrimental impact on the size of the precipitate. The latter stages however have 
an important role in removing some of the residual contaminating proteins from 
the precipitate.
Component and total  mass  balances  for the full-scale process  flowsheet and its 
scale-down mimic were also carried out. The results are shown in figure 3.7 and 
3.8.  The differences observed between the two systems are within the measured 
level  of error  of the  biological  assays  used.  Comparing  the  data  for  the  two 
flowsheets  (figures  3.1a  and  3.1b)  it  is  notable  that  shearing  of the  antibody 
precipitate in suspension in the chamber of the rotating disc device causes some 
loss  of activity.  The  differences  between  the  two  scales  however  is  within  the 
margin  of error  and  taken  together  the  results  support  the  applicability  of the 
proposed  approach  to  scale-down  of both  the  precipitation  and  centrifugation 
stages.
3.5  Conclusion
This chapter describes a new scale-down approach for the primary recovery of a 
therapeutic  protein  precipitate  based  on  a  full-scale  process  flowsheet.  The 
process consisted of a sequence of four unit operations including a precipitation 
followed by  a centrifugation,  resupension  and a final  centrifugation  step.  Using 
millilitre  quantities  of process  material  a new approach was  used to  define  the
124important physical properties of the precipitate which impacted upon the recovery 
process.  The results show that protein precipitate size distribution was critically 
influenced by the precipitation and first stage centrifugation step, the resuspension 
and second stage centrifugation had no effect on the size of the particles but were 
significant in removing more of the residual contaminating proteins.
In the case of (first stage) centrifugation, prediction of the performance of a disc 
stack centrifuge was achieved from the CFD analysis of flow in the full-scale unit 
combined with shear sensitivity data obtained from a small rotating shear device 
together with  clarification  data  obtained  from  a  standard  laboratory  centrifuge. 
The  large  scale  precipitation  step  was  successfully  mimicked  at  small  scale  by 
using the concept of time-integrated fluid stress which was defined as the product 
of  the  power  input  per  unit  volume  of  suspension  and  the  precipitation 
conditioning (aging) time in the reactor.
Taken together the results detailed in this chapter provide a basis for predicting 
the overall performance of a process by linking the sequence of operations within 
it  via  ultra  scale-down  techniques.  Such  an  approach  offers  considerable 
advantages. For example, using millilitre quantities of process material, a series of 
scale-down tools,  such  as  the  rotating  shear device,  and  CFD  analysis  of flow 
regimes  in  the  full-scale  equipment,  process  engineers  will  be  able  to  rapidly 
assess  potential  process  options  for  a  range  of  drug  candidates  early  in  the 
development cycle of each drug and reduce the need to carry out numerous pilot- 
scale runs.
1254 The Use Of Ultra Scale Down Mimics To Predict The 
Effect Of Changes To The  Operating Conditions  On 
The Characteristics Of Antibody Particles
4.1  Introduction
Once  the  initial  industrial  scale  downstream  purification  process  has  been 
developed,  trials  are  carried out  in order to  optimise the processing  conditions. 
Due however to the constraints discussed in chapter 3 these optimisation trials are 
often  short  lived  or  non-existent.  The  majority  of  downstream  purification 
processes are adaptations of old processes that have not been optimised for the 
new  drug  candidate.  The  use  of ultra  scale  down  mimics  allows  a  process 
engineer to study process options cheaply and quickly.  The results obtained can 
then be utilised when designing scale-up or process optimisation schemes.
This  chapter  describes  the  use  of the  ultra  scale  down  mimics  developed  in 
chapter  3  to  predict  the  effect  that  changes  to  the  operating  conditions  of the 
purification stage will have on the process and on the characteristics of the process 
stream.  Since the mimic has been verified as being accurate, by comparison with 
results obtained at an industrial  scale,  changes made to the operating conditions 
can be assumed with a reasonable degree of certainty to have the same effect on 
an industrial scale as they do when carried out with the ultra scale down mimic.
Four types of changes were made to the operating conditions of the precipitation 
reaction:  solid  sodium  sulphate  was  used  in  the  place  of  liquid,  the  mixing 
conditions  were  altered,  the  temperature  of  the  precipitation  reaction  was 
increased and the effect of altering the percentage sodium sulphate was studied. 
The effects of these changes on the physical properties of the antibody particles 
(viscosity,  density  and  percentage  solids  content,  particle  size  distribution  and 
resistance  to  shearing)  were  assessed,  along  with  the  effect  on  protein 
concentration in each phase.
1264.2  Using Solid Sodium Sulphate Instead Of Liquid
The use  of a solid  precipitation agent,  as opposed to  a liquid one,  immediately 
allows the scale of the operation to be doubled.  For example,  instead of adding 
100L  of  36%  (w/v)  sodium  sulphate  to  100L  of  serum  to  achieve  a  final 
concentration of 18% (w/v),  36Kg of sodium  sulphate can be added to 200L of 
serum  resulting  in  the  same  final  concentration.  Using  a  powder  as  the 
precipitation agent could effect the kinetics of the precipitation process.  Chan, et 
al.  (1986) demonstrated the effect that different precipitation agents have on the 
precipitation of soya protein. They concluded that the type of precipitation agent 
influences the precipitate particle formed.  The mode and rate of addition of the 
precipitating agent also  influence the reaction (Foster, et al.  1976) and different 
reagents have different precipitation kinetics (Chan, et al.  1986). For this reason it 
is  necessary  to  fully  investigate  the  effects  of any  change  to  the  precipitating 
agent.
4.2.1  Methodology
200ml  of serum were thawed  overnight,  0.2pm  filtered and placed  in the  scale 
down reactor. This was placed in a water bath and the serum was allowed to warm 
to 30°C.  Once the correct temperature had been reached the impeller was set to 
555rpm and 36g of sodium sulphate was added at a rate of 1.2g/min, in line with 
the  hypothesised  industrial  procedure.  Once  all  the  sodium  sulphate  had  been 
added,  the  impeller  speed  was  increased  to  1840rpm  and  the  particles  were 
allowed  to  condition  for  15  hours.  At  the  end  of the  conditioning  period  the 
antibody particles were sized according to the protocol outlined in section 2.3.4.1. 
The  physical  characteristics  were  also  determined using the  methods  in  section 
2.3.1.
Following the particle size measurements, the antibody particles were sheared in 
the rotating disc device.  10ml of precipitated antibody solution were sheared at 
different  levels  of energy  dissipation  (shown  in table  4.1)  for  one  minute.  The 
sheared material was then particle sized using the standard methodology.
127Volts Rotating disc speed (rpm) Max energy dissipation (WKg*1)
0 0 0
6 10250 12000
8 16000 46000
10 18000 66000
12 20900 100000
Table 4.1  Rotational  speed  and associated maximum  energy dissipation of the 
rotating disc device
The purpose of these experiments was to determine the impact, if any,  of using 
solid sodium sulphate on the antibody particles characteristics.  Additionally, the 
effect of shear stress on the antibody particles was assessed and predictions of the 
knock on effects that any changes would have on further downstream purification 
operations have been made.
1284.2.2  Results
The particle  size  distribution of the particles produced during precipitation with 
solid sodium sulphate under scaled down conditions was measured and the results 
are  shown  in figure 4.1.  The particle  size distribution of the antibody particles 
produced by the standard scaled down liquid based precipitation is also included 
so that a comparison of the results can be made.
The use of solid rather than liquid sodium sulphate results in an increase in the 
size of the antibody particles from a d0.9 of 29.7pm to a d0.9 of 38.5pm (standard 
deviation +/-3pm at d0.9 (n=5)).
Size (pm)
d(0.1)  d(0.5)  d(0.9)
Scaled down liquid  3.4  15.1  29.7
Scaled down solid  2.9  16.2  38.5
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Figure 4.1  Comparison of the particle size distribution of the antibody particles 
produced with liquid sodium sulphate ■  and with solid sodium sulphate ♦ under 
the same mixing conditions
129Table  4.2  is  a  comparison  of the  physical  properties  of the  precipitant  solution 
produced by the liquid and solid sodium sulphate precipitation systems.  The use 
of solid sodium sulphate causes the viscosity of the solution to rise from 2.4mPa.s 
to 4mPa.s. The solids content of the feed stream also increased from 12% (v/v) to 
25%  (v/v).  The  density  of the  liquid  and  solid  phases  remained  unchanged 
(standard  error:  Viscosity  +/-  0.1mPa.s  (n=5),  Solids  content  +/-  1.3%  (n=5), 
Density solid +/- 0.16g.cm'3 (n=5), Density liquid +/- 0.02g.cm'3 (n=5)).
Viscosity
(mPa.s)
Solids 
Content (%)
Density solid 
(gem'3)
Density liquid 
(gem'3)
Scale Down 2.4 12 1.3 1.17
Scale Down using solid 
precipitant at same Ef
4 25 1.3 1.17
Table  4.2  Physical  properties  of the  antibody  particles  produced  with  liquid 
sodium sulphate and solid sodium sulphate under the same mixing conditions
130The precipitate particles were exposed to various levels of shear in order to assess 
the  impact.  After  exposure  the  particle  size  distribution  was  measured.  The 
resulting particle size data is displayed in figure 4.2.
As  the  level  of energy  the  antibody  particles  are  subjected  to  increases  so  the 
particle size distribution decreases. Exposure to the highest shear rate results in a 
decrease  in particle  size  from  a d0.9  of 38.3pm to  a d0.9  of 26.5pm  (standard 
deviation +/-3pm at d0.9 (n=5)).
Max energy dissipation (WKg1 )  d(0.9)pm
■3  20
0 38.5
12000 30.1
46000 29.2
66000 26.5
100000 26.5
20000  40000  60000  80000  100000  120000
Max energy dissipation (W.Kg’ )
Figure  4.2  Particle  size  (d0.9)  of  the  antibody  particles  produced  during 
precipitation  with  solid  sodium  sulphate  after  being  subjected  to  differing 
maximum energy dissipations in the rotating disc device for one minute
1314.2.3  Discussion
It  is  known that  the  current  scale  of manufacturing will  be  unable  to  meet  the 
forecasted level of demand for the anti-venom.  Therefore, since the anti-venom 
production process has already been validated, methods of increasing the scale of 
production  or  the  yield  that  are  easy  to  implement  and  validate  are  of great 
importance.  Using  solid  sodium  sulphate  offers  the  opportunity  to  double  the 
production scale without having to purchase new vessels and equipment. Since the 
same basic methodology is utilised to purify the antibodies a bridging study need 
only be carried out to validate the process.
It  can  be  concluded  from  figure  4.1  that  the  use  of solid  sodium  sulphate  as 
opposed to liquid sodium sulphate as a precipitating agent causes an increase in 
the particle size distribution of 30%.  It is believed that the cause of this increase 
is the fact that the particles have a solid particle in the form of a sodium sulphate 
crystal to form around.  The poor mixing conditions also contribute, resulting in 
earlier precipitation.  This would make it easier for the particles to form and give 
them  longer  to  grow  during  the  low  shear  mixing  phase  resulting  in  larger 
particles.
During the  addition  of the  powdered  sodium  sulphate  it was  observed  that the 
mixing  conditions  were  not  turbulent  enough  to  properly  mix  the  two  phases. 
Large clumps of un-dissolved sodium sulphate were observed at the bottom of the 
tank.  It was also observed that the antibodies began to come out of solution at a 
lower concentration of precipitant (roughly 10%) than with the liquid version.
Mixing  conditions  within  the  precipitation  vessel  are  an  important  factor; 
determining the  physical  characteristics  of the  particles  (Hoare,  1982;  Bell  and 
Dunnill, 1982a&b).
It is hypothesised that this earlier precipitation is due to the formation of pockets 
of high concentrations of sodium sulphate within the vessel, caused by the poor 
mixing  conditions.  These  pockets  cause  the  premature  precipitation  of  the
132antibodies.  This earlier precipitation could also be the cause of the larger particles 
since they would have longer to grow (Spielman, 1978).  The particles would have 
more time to clump together during the addition phase, before the impeller speed 
is  increased  and  the  balance  of growth  verses  shear  induced  particle  break  up 
changes.
From  a process  engineers  perspective,  larger particles  are  easier to  separate  by 
centrifugation (Bell and Dunnill, 1982b). This is shown by the following equation. 
The effective force acting on a spherical particle in a centrifugal field is given by:
F' = 7  d?& P°)2r O
(equation 4.1)
Where ds = the particle diameter, Ap = the density difference between the particle 
and the suspending fluid, r = the distance from the axis of rotation and co = the 
angular velocity and is given by:
co = 2m
(equation 4.2)
This equation indicates a cube relationship between the force acting on a particle 
and its diameter.  Thus, even a small increase in the particle size, results in a large 
increase in the force acting upon it and hence its sedimentation rate.
By solving equation 4.1 the force acting on a particle 29.7pm in size was found to 
be  l.lxlO'9Kg.ms"1.  Assuming the distance from the axis of rotation is  1   and the 
speed of rotation remains constant at  125rps.  When the particle size increases to 
38.5pm, as is the case when solid sodium sulphate is used, the force acting upon 
these  particles  becomes  2.4x1 O^Kg.ms'1   (the  same  assumptions  as  before  were 
applied).  The  force  has  been  more  than  doubled  with  only  a  30%  increase  in 
particle size.  This increase in the effective settling force acting upon the particle 
could impact the process time required during centrifugation (Leung,  1998).  The 
time may decrease since the particles should settle out faster.
133Table 4.2 indicates that the viscosity of the precipitant solution has increased from 
2.4mPa.s to 4mPa.s when solid sodium sulphate is used as the precipitating agent. 
This increase in viscosity was most likely caused by the increase in solids content 
also  observed.  An  increase  in  the  viscosity  leads  to  a  decrease  in  the 
sedimentation velocity.  This  is  shown by the  equation  below;  settling velocity 
under gravity is determined by:
us =
Where g is gravity and p is the viscosity.
bpd2 g
18/i
(equation 4.3)
Solving the above equation for the standard liquid precipitation system where Ap
1  /
= 130Kgm'  d = 29.7x10  m and p = 0.0024Pa.s. gives a sedimentation velocity of 
2.6x10'5m .s'\  Solving  this  equation  for  the  solid  based  precipitation  system 
where, Ap =  130Kgm*  d = 38.5x10  m and p = 0.004Pa.s. gives a sedimentation 
velocity of 2.6x1 O^m.s’1.  Therefore the increase in the force acting on the particle 
caused  by  the  increase  in  particle  size  has  been  countered  by  the  increase  in 
viscosity.  This results in particles that,  although differ in size,  should sediment 
out at the same velocity.  The  increase in viscosity will also result in increased 
pumping costs, another factor to take into account when implementing the process 
change.
Table 4.2 also shows that the solids content has risen to 25% when solid sodium 
sulphate is used.  This may be due to the fact that solid material has been added to 
the mixture. As a result, some over precipitation of the albumin may be occurring 
due  to  the  poor  mixing  conditions.  This  may  cause  local  areas  of  high 
concentration.  The  industrial  scale  centrifuge  used  at  Protherics  has  a  solids 
holding capacity of 3L.  Therefore when the feed is being pumped in at  120L/hr 
with the liquid precipitation process, the centrifuge needs to be discharged every
12.5  minutes  in  order  to  avoid  breakthrough.  For  the  solid  sodium  sulphate 
process, the centrifuge will need to be discharged every 6 minutes. This is a very 
small  interval  of time between discharge cycles.  Discharging the centrifuge this
134often may interfere with the normal operation.  Also during the discharge cycle a 
small amount of feed material is lost and the centrifuge slows down slightly.  This 
could  result  in  lower  yields.  If this  level  of solids  were  to  be  processed  by 
centrifugation, the feed flow rate would probably have to be slowed down. This 
may have knock on effects for the rest of the  downstream processing operation 
such as increased turnaround time.
4.2.3.1  Impact of shear
When subjected to high levels of shear stress, protein precipitates tend to break up 
(Boychyn, et al. 2001; Neal, et al. 2003).  Figure 4.2 reveals that the particle size 
initially decreases rapidly as energy dissipation increases, until at bbOOOWKg"1  the 
smallest particle size is reached.  Above this level of energy dissipation no further 
degradation in particle  size occurs.  The  d0.9 produced when the  solid particles 
were  exposed  to  a  level  of  shear  equivalent  to  that  found  in  an  industrial 
centrifuge  and  spun  down  at  an  equivalent  Q /Z   as  detailed  in  section  2.1  was 
26.6pm.  Compared  to  13.4pm produced  when the  liquid  system  particles were 
sheared and spun down.
By  solving  equation  4.3  we  can  see  that  this  degradation  in  particle  size  has 
altered the settling velocities.  The solids system particles now settle at a rate of 
l^xlO^m.s"1   whilst the liquid system particles settling velocity becomes 0.5x10" 
5m.s"1.  As a result of the shear stress encountered during centrifugation, the solid 
system particles now have a settling velocity more than double that of the liquid 
system particles. This means that in theory, they should be easier to separate.  The 
reason  that  the  solid  system  particles  become  easier  to  separate  after 
centrifugation, is that they are more resistant to shear than those produced by the 
liquid  system.  Exposure  to  shear  results  in  a  30%  decrease  in  size  after  one 
minute  for those  particles  produced  by  the  solid  system.  Whereas  exposure  to 
shear for one minute causes a 55% decrease in size for those particles produced by 
the liquid system.
1354.3  Using Solid Sodium Sulphate And Altering The Mixing
Conditions
Observation of the reactor vessel whilst mixing the solid sodium sulphate into the 
serum revealed that the current mixing conditions were not turbulent enough to 
properly mix the  solid and  liquid phases.  The  scale down mimic was therefore 
used  to  assess  the  impact  of altering  the  mixing  conditions.  The  new  mixing 
conditions are more turbulent, thus as a direct result the time integrated shear level 
was increased.
The  aim  of these  experiments  was  to  assess  what  impact  changing  the  mixing 
conditions (to ensure good mixing) would have on the physical characteristics of 
the antibody particles and on their resistance to shear damage.
4.3.1  Methodology
200ml of serum were thawed overnight, 0.2pm depth filtered and placed into the 
scale down precipitation vessel. This was placed into a water bath and the serum 
was allowed to warm to 30°C.  Once the correct temperature had been reached the 
impeller was set to  1840rpm and 36g of sodium sulphate were added at a rate of 
1.2g/min, in line with the hypothesised industrial procedure.  Once all the sodium 
sulphate had been added the solution was allowed to condition for 15 hours.  This 
change in the mixing conditions had the effect of increasing time integrated shear 
stress level (Ef) from 2.6x1 O ^m '2 to 2.7x1 O ^m '2.  At the end of the conditioning 
period  the  antibody  particles  were  sized  according  to  the  protocol  outlined  in 
section  2.3.4.1.  The  physical  characteristics  were  also  determined  using  the 
method in section 2.3.1.
Once  sized,  10ml  of the  precipitated  antibody  solution  were  sheared  in  the  in 
house shear device at various energy levels as shown in table 4.1.  The particles 
were subjected to each level of shear for one minute, after-which they were re­
sized to assess the impact of the shear stress.
1364.3.2  Results
By  increasing the  impeller  speed, the  balance  of orthokinetic  growth  and  shear 
induced  break  up  of the  precipitant  particle  was  altered.  Figure  4.3  shows  the 
particle  size  distribution  of  the  antibody  particles,  produced  by  the  standard 
precipitation  method,  compared  to  those  produced  when  using  solid  sodium 
sulphate  and  increasing  the  time  integrated  shear  stress  level.  The  particles 
produced  at the  increased  shear  stress  level  are  significantly  smaller than those 
produced by the standard method.  The increased shear stress level particles have 
a d0.9 of only 7.45pm as opposed to the usual d0.9 of 29.7pm (standard deviation 
+/-3pm at d0.9 (n=3)).
Size (pm)
d(0.1)  d(0.5)  d(0.9)
Scaled down (solid) different Ef  2.95 
Scaled down (liquid) same Ef  3.4
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Figure 4.3  Comparison of the particle size distribution of the antibody particles 
produced  using  liquid  sodium  sulphate  (■)  and  solid  sodium  sulphate  with  an 
increased time integrated shear stress level (♦)
137The physical  properties of the  antibody particles were measured and the results 
can be seen in table 4.3.  For comparative purposes the physical properties of the 
antibody  particles  produced  by  the  standard  liquid  system  are  included.  The 
change  in  the  mixing  conditions  resulted  in  an  increase  in  the  viscosity  from 
2.4mPa.s to 3.4mPa.s.  The solids content also increased from  12% (v/v) to  18% 
(v/v).  The density of the solid and liquid phases remained unchanged (standard 
error: Viscosity +/- 0.1mPa.s (n=3), Solids content +/-  1.3% (n=3), Density solid 
+/- 0.16g.cm'3 (n=3), Density liquid +/- 0.02g.cm’3 (n=3)).
Viscosity
(mPa.s)
Solids 
Content (%)
Density solid 
(gem3)
Density liquid 
(gem’3)
Scale Down 2.4 12 1.3 1.17
Scale Down using solid 
precipitant at different Ef
3.4 18 1.3 1.17
Table 4.3  Physical characteristics of the precipitated antibody particles produced 
with liquid sodium sulphate and with solid sodium sulphate at an increased time 
integrated stress level
138The particles were subjected to various levels of shear stress. Afterwards the size 
distribution was measured. The results are shown in figure 4.4.  The particle size 
distribution  of the  antibody  particles,  after they  were  subjected  to  shear  stress, 
remained unchanged at (d0.9) of 7.5pm even after being subjected to the highest 
level of shear stress (standard deviation +/-3pm at d0.9 (n=3)).
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Figure  4.4  Particle  size  (d0.9)  of  the  antibody  particles  produced  during 
precipitation  with  solid  sodium  sulphate  with  altered  mixing  conditions  after 
being subjected to differing maximum energy dissipation
1394.3.3 Discussion
The  final  size  of a  precipitate  particle  is  determined  by  the  mixing  conditions 
within the reactor vessel (Bell and Dunnill, 1982a; Hoare, 1982; Rothstein, 1994). 
The  mixing  conditions  influence  the  balance  of particle  growth  versus  particle 
break up.  It can be  concluded  from  figure 4.3  that increasing the  stirrer speed 
during the addition phase of the precipitation reaction results in a decrease in the 
size of the antibody particles by 75%.  It is hypothesised that this decrease is a 
result  of  the  increased  turbulence  and  levels  of  shear  present  during  the 
orthokinetic  growth  phase.  This  results  in  shear  induced  break  up  of particles 
playing  a  more  influential  role  in  the  final  particle  size,  resulting  in  smaller 
particles.  Since the levels of shear are higher right from the start, the particles do 
not  have  the  chance  to  form  loose  particles  that  are  later  degraded  during  the 
conditioning phase. The result is smaller particles.  It was however observed that 
the  increase in turbulence  solved the problem of bad mixing;  no clumps of un­
dissolved sodium sulphate were observed and precipitation began to occur at 12% 
in line with the liquid precipitation system.
The effective force acting on particles can be calculated by solving equation 4.1. 
This shows that for particles 7.45pm in diameter the effective force is  1.7xl0"n 
Kg.ms’  compared to  1.1x10' Kg.ms'  for the liquid system and 2.4x10' Kg.ms' 
for the solid system with out the altered mixing conditions.  Taken at face value 
these figures show that the  force acting on the liquid  system particles,  with the 
increased mixing conditions, is two orders of magnitude smaller than that acting 
on the other particles.  This would make them harder to separate and increase the 
processing time.  However both the viscosity and shear effects need to  be taken 
into consideration.
Table 4.3 indicates that the viscosity of the final solution increased from 2.4mPa.s 
to 3.4mPa.s.  The cause of this increase attributed to the addition of solid sodium 
sulphate.  The  viscosity  is  not,  however,  as  high  as  the  solid  system  with  the 
standard mixing conditions.  The decrease in particle size and increase in viscosity
140results in a decrease in the sedimentation velocity to  lxl0"6m.s'1. This is an order 
of magnitude smaller than the other two precipitation systems.
Table 4.3  also shows that the solids content increased to  18% this decreases the 
discharge  time  in  the  industrial  disc  stack  centrifuge  from  12.5  minutes  to  8 
minutes, this length of interval between discharges should be long enough not to 
interfere with the normal operation of the centrifuge.
4.3.3.1  Impact of shear
Figure 4.4 shows that when the particles were subjected to shear no decrease in 
particle  size  was  observed.  This  is  probably  because  the  conditions  already 
experienced by the particles have strengthened them to the point that no further 
degradation  occurs.  Bell  and  Dunnil  (1982b)  concluded  that  the  strongest 
particles result from a Gt of 105 and above. The Gt for this system is 8xl06.  The 
result is that the sedimentation velocity should not be affected when the particles 
are pumped  through  an  industrial  scale  disc  stack  centrifuge  similar to the  one 
mimicked in chapter 3.
4.4  Conclusion
Changing  to  solid  sodium  sulphate  doubles  the  volume  of serum  that  can  be 
processed  per  batch  without  the  need  to  purchase  new  equipment.  Table  4.4 
shown below summarises the particle size, viscosity and resulting sedimentation 
velocities of the three systems after the particles had been sheared.
141Precipitation
System
Particle Size 
(pm) (d0.9)
Viscosity
(mPa.s)
% Solids content Sedimentation 
velocity (m.s1 )
Liquid
13.4 2.4 12 0.5x1 O’5
Solid same 
mixing 26.6 4 25 1.2x1 O’5
Solid altered 
mixing 7.45 3.4 18 l.lxl O '6
Table 4.4  Comparison of the antibody particles characteristics and sedimentation 
velocity after shearing
This  comparison  reveals  that  the  particles  produced  by  using  solid  sodium 
sulphate, without altering the mixing conditions, should be the easiest to separate. 
However, the large solids content may make disc stack centrifugation difficult and 
the  poor  mixing  conditions  could  result  in  poor  precipitation.  The  particles 
produced by the liquid system are next, but the volume would only be  100L per 
batch.  The hardest particles to separate will be those produced by the solid system 
with the altered mixing conditions.  This is the result of the smaller particle size 
coupled  with  the  increased  viscosity.  All  the  factors  outlined  above  plus 
commercial factors like pumping costs and time considerations need to be taken 
into account before any changes are made.
4.5  The Impact Of Increasing The Temperature During
Precipitation
The  effect  on  particle  size  distribution  of  raising  the  temperature  of  the 
precipitation reaction from 30°C to 40°C was studied.  All other parameters were 
kept constant in line with the method in section 2.4.1.
According to equation  1.3  (section  1.3.1),  at higher temperatures there will be a 
greater  rate  of collisions  between  particles  during  a  precipitation  reaction  and 
hence a higher growth rate.  This suggests that by increasing the temperature, the 
precipitation reaction should produce larger particles that will be easier to separate 
by  centrifugation.  Therefore  the  aim  of the  experiment  was  to  determine  the
142impact  of raising  the  temperature  on  the  particle  size  distribution  and  on  the 
resistance of the particles to the shear stress encountered during an industrial scale 
centrifugal separation.
4.5.1  Methodology
The precipitation reaction was run as per the method in section 2.4.1  except that 
the temperature was maintained at a constant 40°C during the conditioning phase. 
At the end of the conditioning period the particles were sized as per the procedure 
in section 2.3.4.1. After-which they were subjected to shear conditions consistent 
with those found in an industrial scale disc stack centrifuge as per the method in 
section 2.4.2 and re-sized.
1434.5.2  Results
At the end of the conditioning phase the particle size distribution was measured. 
Figure 4.5 is a comparison of the particle size distribution of the antibody particles 
produced  at  30°C  and  at 40°C.  As  can be  seen,  increasing the temperature  by 
10°C causes the size of the particles to increase from 29.7pm to 46.2pm (standard 
deviation +/-3pm at d0.9 (n=3)).
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Figure  4.5  Comparison  of  the  particle  size  distribution  of  the  precipitated 
antibodies produced at 30°C ♦  and at 40°C ■
144The antibody particles were exposed to a level of shear consistent with that found 
in the industrial scale centrifuge mimicked in chapter 3 and re-sized. Figure 4.6 is 
a  comparison  of the  particle  size  distribution  before  and  after  shearing.  After 
subjecting the particles to the same level of shear stress as found in an industrial 
scale  centrifuge,  the  particle  size  distribution  decreased  from  46.2pm  to  16pm 
(standard deviation +/-3pm at d0.9 (n=3)).
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Figure  4.6  Comparison  of  the  particle  size  distribution  of  the  increased 
temperature antibody particles before, ■ and after,  A  shearing with an air liquid 
interface followed by centrifugation in a swing out bucket centrifuge at the same 
QfZ as the industrial scale centrifuge
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1454.5.3 Discussion
As indicated by equation  1.3, increasing the temperature results in an increase in 
the particle size distribution, as shown in figure 4.5.  Increasing the temperature 
by  10°C  results  in  a  35%  increase  in  the  particle  size  distribution.  The  extra 
energy  provided  by  the  higher  temperature  may  have  increased  the  number  of 
collisions between precipitate particles, resulting in an increase in the growth rate. 
This increase in size has more than doubled the settling velocity from 2.6x10* m.s*
|  O  1
to  6.3x10" m.s* .  At  face  value  these  particles  would  appear  to  be  easier  to 
separate from the mother liquor by centrifugation.
4.5.3.1  Impact of shear
Precipitant particles aged under the same conditions should have the same relative 
strength. Therefore subjecting them to the same level of shear stress should result 
in  a decrease  in particle  size  similar to that  observed  in  chapter 3.  Figure  4.6 
indicates that when the particles were sheared at a level equivalent to that found in 
an  industrial  disc  stack  centrifuge  and  spun  down  at  an  equivalent  Q/Z  value 
(section  2.4.2),  the  particle  size  distribution  decreased  by  65%.  When  the 
particles produced  at  30°C  were  exposed to  the  same  conditions,  a decrease  in 
particle size of 55% was observed.  This would seem to indicate that the particles 
produced  at  the  higher  temperature  are  not  as  strong  as  those  produced  at  the 
lower  temperature.  This  could  be  attributable  to  the  fact  that  the  increase  in 
temperature results in larger particles, with particles that are loosely bound to each 
other.  The  degradation  in  particle  size  results  in particles that  are  the  roughly 
same size as those produced at 30°C after shearing.
4.5.4  Conclusion
Although the increase in temperature increased the size of the particles, it lowered 
their resistance to shear stress;  since exposure to shear resulted in a 65% decrease 
in size as opposed to 55%. This decreased resistance may be due to the fact that 
the extra energy present has resulted in the formation of particles that are more 
loosely packed than those formed at 30°C.  The conclusion to be drawn from these 
experiments  is  that  increasing  the  temperature  would  have  no  impact  on  the
146centrifugal  recovery  operation;  heating  the  tank  an  extra  10°C  would  merely 
increase the cost of the purification process.
4.6  Altering The Percentage Of Sodium Sulphate
The concentration of sodium sulphate used to precipitate out the antibody product 
is  of critical  importance  to  the  success  or  failure  of the  purification  operation. 
According to the Hofmeister series,  sulphate is relatively effective  at salting  the
protein  out  and  should  only  destabilise  the  protein  at  relatively  high
concentrations.  The experiments in this section examine the effect of varying the 
concentration  of the  sodium  sulphate  on  the  precipitation  reaction  and  on  the 
activity  of the  antibody  of  interest.  The  purpose  of the  experiments  was  to 
determine  the  optimum  concentration  of  sodium  sulphate  for  salting  out  the 
antibodies with out destabilising them.
4.6.1  Methodology
90ml  of serum,  thawed  overnight  and  0.2pm  filtered  was  separated  into  10ml 
fractions and placed into 9 separate test tubes.  An equal volume of liquid sodium 
sulphate at concentrations of 16, 20, 24, 28, 32, 36, 40 and 44% (w/v) was added 
slowly  to  each  tube  resulting  in  serum/sodium  sulphate  mixtures  with  the 
following concentrations:  8,  10,  12,  14,  16,  18, 20, 22 and 24% (w/v).  Each test 
tube  was  mixed  thoroughly  by  inversion  and  left  for  30  minutes  to  allow  the 
precipitation  to  take  place.  After  the  time  had  elapsed,  the  solid  and  liquid 
portions were  separated by centrifugation in a Beckman J2-M1  centrifuge fitted 
with a swing out bucket rotor (JA 13) for 30 minutes at 13,000rpm.  The solid and 
liquid  phases  of  each  concentration  were  then  assayed  for  active  antibodies, 
albumin and total protein content following the method detailed in section 2.3.1.
1474.6.2  Results
The  amount  of antibody  that  binds  anti-venom  present  in  the  solid  phase  was 
measured and the results are depicted in figure 4.7. This shows the concentration 
of active antibody in the solid phase increasing from zero at 8% and  10% to 38% 
at  12%.  The concentration then levels out at around  75% until  at 20% sodium 
sulphate the  level  drops  to  around  63%.  The amount of active  antibody  in the 
supernatant is seen to decrease from 90% at 8% to 85% at  10% sodium sulphate 
then 60% at  12%.  At  14% there are only 5% of the active antibody remaining in 
solution. Above this concentration there are no antibodies which bind anti-venom 
left in solution (standard error +/-9% active antibody (n=3)).
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Figure 4.7  Percentage of active antibody present in the solid (♦) and liquid (■) 
phases at different concentrations of sodium sulphate
148The amount of albumin present in the solid and liquid phases was measured and 
the  results  are  shown  in  figure  4.8.  The  concentration  of  albumin  in  the 
supernatant  starts  at  40mg/ml.  Then  as  the  concentration  of  sodium  sulphate 
increases,  so  the  amount  of  albumin  present  decreases  until  at  24%  sodium 
sulphate only  19mg/ml remains in solution.  Juxtaposed to this, the concentration 
of albumin  rises  from  Omg/ml  to  11 mg/ml  present  in  the  solid  phase  at  24% 
sodium sulphate (standard error +/-0.1 mg/ml (n=3)).
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Figure 4.8  Concentration of albumin found in the solid (■) and liquid (A) phases 
at different concentrations of sodium sulphate
149The total protein content of each phase was measured and is shown in figure 4.9. 
The figure indicates that there is 75mg/ml of protein present at the start.  As the 
concentration of sodium sulphate increases so to does the total protein level in the 
solid phase.  At 24% sodium sulphate the solid phase contains 38mg/ml and the 
liquid phase contains 32mg/ml (standard error +/-0.3mg/ml (n=3))
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Figure 4.9  Total protein concentration in the solid (♦) and liquid (■) phases at 
different concentrations of sodium sulphate
1504.6.3 Discussion
The  amount  of  sodium  sulphate  required  to  precipitate  the  antibodies  out  of 
solution,  without  precipitating  out  an  excess  of  contaminating  proteins  and 
without denaturing the antibodies has been investigated.  As the first step in the 
purification process it is of critical importance that the efficiency and yield of the 
separation is as high as possible as well as the reproducibility.
4.6.3.1  Active antibodies
Precipitation  reactions  provide  a  quick  and  simple  method  of  separating  the 
product from the main contaminant (Bell, et al.  1983;  Hoare, et al.  1983).  The 
experiments described in this section looked at the process of the precipitation and 
sought to determine the optimum amount of salt.
Figure 4.7 shows how the antibodies respond to the addition of sodium sulphate. 
No precipitation occurs between 8 and 10%. However, at 10% saturation the assay 
reveals  that  10-15%  of  the  antibody  has  been  permanently  denatured.  The 
samples were diluted to ensure that the sodium sulphate is not interfering with the 
assay  and  they  were  left  for  24  hours  to  allow the  antibody  to  refold  into  its 
normal conformation.  (A control sample was tested after 24 hours to ensure that 
no  loss  of binding  activity  occurs  as  a result  of the  sample  being  left  at room 
temperature).  Thus any antibody not permanently denatured will be detected.  It 
can be safely concluded then that  10% (w/v) sodium sulphate causes  10-15% of 
the  product  to  be  denatured,  to  the  extent  that  it  no  longer binds  to  the  snake 
venom and is therefore no longer biologically active.
Precipitation begins to occur at 12% (w/v). This is the point where supersaturation 
is just  being  reached  and  the  “salting  in”  effect  becomes  one  of “salting  out” 
(Rothstein,  1994).  At this point  38%  of the  antibody has precipitated  out,  50% 
remains in solution and  10% is denatured.  By 14% (w/v) 75% of the antibody is 
in a solid form,  5% remains  in solution but 20% has been denatured.  At  18% 
sodium  sulphate,  the  concentration  used  at  the  industrial  scale  76%  of  the 
antibodies have been precipitated, the other 24% have been denatured.  The rise in 
salt  of 4%  has  denatured  the  remaining  active  antibody  without  causing  any
151further precipitation.  Above  18% the sodium sulphate denatures around 40% of 
the product.  The level found in the solid drops to around 65% from 75%.  Based 
on these results a concentration of between 14% and 18% would seem to combine 
the best recovery of antibody with the least amount of denaturation.
4.6.3.2  Albumin
The  initial  concentration  of  albumin  in  the  sheep  serum  used  for  these 
experiments was found to be between 35mg/ml and 40mg/ml.  This amount will 
vary from  sample to  sample since this is a biological  system.  In this particular 
instance the initial concentration was 40mg/ml.  A process engineer will wish to 
see high concentrations of albumin in the liquid phase and only minimal amounts 
in the  solid phase.  This will  indicate  a good purification factor and is the main 
purpose of the step.  Figure 4.8 reveals that up to concentrations of 10% sodium 
sulphate,  no precipitation of albumin occurs.  Some denaturation of the protein 
occurs at  10%, roughly 9mg/ml or 25% has been destabilised.  This is seen as a 
drop in the level present in the liquid phase without an opposing rise in the level 
present in the solid phase.
Between 12 and 20% the majority (90% of the un-denatured) albumin remains in 
solution  but the sodium sulphate causes some over precipitation, around  10% of 
the albumin can be found in the  solid phase.  Above concentrations of 20% the 
sodium sulphate starts to cause the albumin to precipitate out as well.  A sharp rise 
in the amount present in the solid is seen coupled with a concurrent drop in the 
amount  in  the  liquid  phase.  Although  the  albumin  is  more  soluble  than  the 
antibodies,  a  large  concentration  of salt  still  causes  it to  come  out  of solution. 
Based  on  this  assay,  a  concentration  below  20%  would  seem  to  offer  the  best 
results, since the majority of the albumin remains in solution.
4.6.3.3  Total protein
The  serum  supplied  by  Protherics  PLC  contains  between  65  and  80mg/ml  of 
protein.  Figure 4.9 which tracks the levels of total protein in each phase, reveals 
the precipitation process as it occurs.  Up to  10% salt no precipitation occurs, at 
12% there is a big drop in the amount remaining soluble. This is the point where
152the antibodies begin to come out of solution.  At 18% the levels of protein found 
in  each  phase  are  roughly  equal.  This  result,  coupled  with  the  gels  shown  in 
chapter 3 demonstrates that other blood proteins are precipitating out. As a basic 
rule,  proteins  will  precipitate  out  of solution  in  order  of decreasing  molecular 
weight  (Rothstein,  1994).  These  proteins  will  need  to  be  removed  by  further 
downstream processing.  When 24% is reached it can be seen that the solid phase 
now contains more protein than the liquid phase. This agrees with the results from 
the other assays which show antibodies precipitating out and over precipitation of 
the albumin occurring at the higher concentrations.
4.6.4  Conclusion
The  ideal  precipitation  reaction  will  remove  100%  of the  antibodies  without 
denaturing them and without precipitating out any other proteins.  Since this is not 
possible,  a balance  has  to  be  struck  between  recovering the  antibodies  without 
denaturing them  and  keeping  the  albumin  and  other proteins  in  solution.  The 
results presented in this section suggest that the optimum concentration of sodium 
sulphate would be between 16% and 18%.  This combines the highest recovery of 
antibody with the lowest levels of albumin. The SDS-page gels shown in figures 
3.5a  and  3.5b  further  back  up  this  conclusion,  as  they  show  the  majority  of 
antibody product in the  solid process  stream whilst the majority of the albumin 
remains  in the  liquid  portion,  when  18%  (w/v)  sodium  sulphate  is  used  as  the 
precipitating agent.
4.7  Overall Conclusions
The  results  presented  in  this  chapter  demonstrate  the  power  of  scale  down 
experiments to provide  valuable process  information without the need  for large 
quantities  of  material.  This  section  demonstrates  that  utilising  solid  sodium 
sulphate; changing the mixing conditions and increasing the temperature alter the 
kinetics  of the  precipitation  reaction  resulting  in  particles  that  have  different 
characteristics.  It was also determined that the optimum concentration of sodium 
sulphate for precipitation of antibodies from ovine serum is between 16 and 18%.
1535  Separation  Of IgG  Precipitate  From  Contaminating
Proteins Using Microfiltration
5.1  Introduction
Microfiltration, utilising a dead end filtration technique with a stirrer at the surface 
of the membrane, as a method to recover the antibody precipitate is an attractive 
process  option,  because  potentially  the  current  four-step  centrifugal  separation 
technique  described  in  chapter  three  could  be  integrated  into  a  single  unit 
operation. This is desirable in terms of a possible reduction in process cycle time 
and an increase in the yield of antibody obtained from a reduction in the number 
of items  of equipment  used  in  the  process.  This  chapter  focuses  on the  use  of 
microfiltration for separating the antibody precipitate.
Membrane  separation techniques  including microfiltration and ultrafiltration are 
used for the recovery and purification of many biological materials. Ultrafiltration 
is traditionally used for separation, concentration and buffer exchange operations 
involving  macromolecules,  typically  less  than  about  lOOnm  (Ayazi  Shamlou, 
2003).  These  include  plasmids,  viruses,  therapeutic  proteins  and  antibodies.  In 
microfiltration,  particle  size  is  typically  above  1pm,  but  normally  less  10pm. 
These include cells, cell debris, protein precipitates and protein crystals (Davies, 
et  al.  2000;  Zeman  and  Zydney,  1996).  In  this  chapter  the  suitability  of 
microfiltration as a means of recovering, cleaning and concentrating anti-venom 
antibody precipitate  from a serum  suspension is assessed.  The contaminants are 
mostly soluble proteins with albumin as the major component. A 200ml (working 
volume in the range of 75ml to 200ml) stirred cell device, equipped with a 3pm 
mixed cellulose ester membrane as the filter/sieving medium, was used to separate 
the anti-venom antibody precipitate from the protein contaminants. An advantage 
of the stirred cell device is that it allows adjustment of both the shear stress at the 
surface  of the  membrane  and  the  transmembrane  pressure  independent  of each 
other. The stirred cell device has been used in the past to mimic the microfiltration 
operation  of biological  materials  (Hawrylik,  et  al.  1994;  Kroner,  et  al.  1987;
154Kroner and Nissinen, 1988; Langeloh, et al. 1998; Mercille, et al. 1994; Vogel and 
Kroner, 1999).
The  performance  of  a  membrane  separation  is  affected  by  fouling  of  the 
membrane. Given the method of filtration (microfiltration) and the solids content 
of  the  feed  stream  used  in  this  study,  both  fouling  by  adsorption  of  the 
contaminating  proteins  in  the  pores  of  the  membrane  and  deposition  and 
formation of a layer on the surface of the membrane are likely to cause clogging 
of the membrane, limiting continuous operation (Baker, et al.  1985; Belfort, et al. 
1994;  Chen,  et  al.  1997;  Field,  et  al.  1995;  Howell,  1995;  Kelly  and  Zydney, 
1996; Marshall, et al.  1993).  This chapter describes how the stirred cell was used 
to determine the optimum load and wash volume for a batch filtration process and 
to obtain experimental flux data on the antibody precipitate as a function of time. 
The  information  was  used  to  study  the  effectiveness  of  microfiltration  as  a 
separation  technique  and  the  performance  of  this  method  of  separation  was 
compared with that of centrifugation.
5.2  Methodology
All  experiments  were  carried  out  with  the  same  stock  of  anti-venom  serum 
supplied by Protherics (Llandusul, Wales, UK). The stirred cell device described 
in  section  2.4.4  was  used  to  conduct  load  and  wash  volume  determination 
experiments,  the  experiments  were  conducted  under  the  operating  conditions 
described  in  section  2.4.4.3.  A  new  3pm pore  size  cellulose  acetate  membrane 
60mm  in  diameter  was  used  for  each  experiment.  It  was  first  necessary  to 
determine  the  optimum  quantities  of  precipitated  serum  to  load  onto  the 
membrane and the optimum volume of washing buffer to be used.  The optimum 
volume is considered the volume which gave the highest antibody yield and best 
albumin removal within the limits of scale imposed by the stirred cell device.
Figure 5.1(A) shows the sequence of full-scale process operations currently used 
to recover large quantities of the immunoglobulins as discussed in chapter three. 
Figure  5.1(B)  shows  the  proposed  scale-down  microfiltration  process  against 
which the industrial centrifugal process is compared.
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Figure  5.1  Process  flow  sheet  detailing  the  initial  serum  purification  at  an 
industrial scale (A) and the proposed purification scheme utilising filtration (B)
Load  and  wash  volume  determination  experiments,  batch  filtration  experiments 
and  continuous  filtration  experiments  were  conducted  as  per  the  methods 
described  in  section  2.4.3.  Each  sample  collected  was  assayed  for  active 
antibody,  albumin  and  total  protein  content.  Sodium  dodecyl  sulphate 
polyacrylamide  gel  electrophoresis  (SDS  page)  was  also  used  to  visualise  the 
proteins within each sample as per the methods described in section 2.3.1.
1565.3 Results
5.3.1 Load and Washing volume determination
Experiments were conducted with load volumes of 75ml and  100ml respectively 
and  with  wash  volumes  of an  equal  volume  and  two  times  the  original  load 
volume.
For  the  first  experiment  100ml  of  precipitated  serum  was  loaded  onto  the 
membrane and the precipitant cake was washed with  100ml of 18% (w/v) sodium 
sulphate.  Samples were assayed for total protein, albumin and active antibodies. 
The mass balance depicted in figure 5.2 is derived from those assays.  85% of the 
antibodies  were  recovered  and  20%  of the  albumin  remains  contaminating  the 
final product after filtration (standard error: Total protein +/- 3% (n=5), Albumin 
+/- 5% (n=5), Antibody +/- 6% (n=3)).
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Figure 5.2  Total protein, albumin and antibody levels in each fraction produced 
during  the  batch  filtration  of  100ml  of  precipitated  antibody  washed  by  the 
addition of 100ml of 18% sodium sulphate
157The volume of washing buffer was doubled to 200ml and the batch filtration run 
again.  Figure 5.3 shows the mass balance resulting form this experiment.  87% of 
the  antibodies  were  recovered  and  12%  of  the  albumin  remains  in  the  final 
product  (standard  error:  Total  protein  +/-  3%  (n=5),  Albumin  +/-  5%  (n=5), 
Antibody +/- 6% (n=3)).
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Figure 5.3 Total protein, Albumin and antibody levels in each fraction produced 
during  the  batch  filtration  of  100ml  of  precipitated  antibody  washed  by  the 
addition of 200ml of 18% sodium sulphate
158Figure  5.4  is  the  mass  balance  for  the  batch  filtration  of 75ml  of precipitated 
serum washed with 75ml  of buffer.  94% of the antibodies have been recovered 
and  10% of the albumin is remaining in the final product after filtration (standard 
error: Total protein +/- 3% (n=5), Albumin +/- 5% (n=5), Antibody +/- 6% (n=3)).
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□ Antibodies (%) 100 0.08 0.67 94
Figure 5.4 Total protein, Albumin and antibody levels in each fraction produced 
during the batch filtration of 75ml of precipitated antibody washed by the addition 
of 75ml of 18% sodium sulphate
159In  the  final  load  and  wash  volume  experiment  75ml  of precipitated  serum  was 
loaded and  150ml of buffer was used to wash the precipitate cake in an effort to 
further reduce albumin contamination.  Figure 5.5 reveals that the antibody yield 
is 96% and that only 3% of the albumin is left in the final product (standard error: 
Total protein +/- 3% (n=5), Albumin +/- 5% (n=5), Antibody +/- 6% (n=3)).
u
Serum Permeate 18% Wash Redissolved cake
■ Total Protein (%) 100 44 19 43
□ Albumin (%) 100 48 48 3
□ Antibodies (%) 100 0.06 0.56 96
Figure 5.5 Total protein, Albumin and antibody levels in each fraction produced 
during the batch filtration of 75ml of precipitated antibody washed by the addition 
of 150ml of 18% sodium sulphate
160A direct comparison of the antibody yields and albumin levels from all the loading 
and washing volume determination experiments is shown in figure 5.6.  Loading 
with  75ml  and  washing  with  150ml  gives  the  highest  antibody  yield  and  the 
lowest  level  of albumin  contamination  (standard  error:  Albumin  +/-  5%  (n=5), 
Antibody +/- 6% (n=3)).
u  1
100ml/200ni 100ml/100ml 75ml/150nnl 75ml/75ml
■ Antibody yield (%) 85 87 96 94
□ % Albumin remaining 12 20 3 10
Figure  5.6  Overall  antibody  and  percentage  albumin  remaining  in  the  final 
product for each of the batch filtration experiments
1615.3.2 Discussion
The amount of antibody precipitant loaded onto the membrane and the volume of 
buffer  used  to  wash  the  precipitate  particles  will  determine  the  yield  of the 
process, in terms of antibody recovery and the degree of purification in terms of 
the amount of albumin removed.  The load volume will also impact on the flux 
rate  across  the  membrane,  which  will  have  a  big  impact  on  the  process  turn 
around time.
At  the  end  of  the  filtration,  when  100ml  of  precipitated  serum  (ratio  of 
precipitated  serum  to  membrane  area  =  3.5ml/cm )  filtered  and  washed  with 
100ml of 18% (w/v)  sodium sulphate, a gelatinous layer of protein was left un­
dissolved on the surface of the membrane.  Examination of the gel layer revealed 
it is a layer of glutinous protein that had formed on the surface of the membrane 
and remained in place after the washing step.  The layer contained a large quantity 
(12%)  of  the  original  antibody  content  which  is  un-recoverable.  It  also 
permanently fouls the membrane as pure water flux rates after cleaning did not 
return  to  the  pre-operation  levels  (data  not  shown).  As  a  direct  result  of the 
formation  of the  gel  layer,  the  final  product  contained  85%  of the  anti  venom 
antibodies along with 20% of the original albumin content.
It was  hypothesised  that  increasing  the  volume  of washing buffer may  help to 
dissolve the gel layer and therefore increase the yield and decrease the amount of 
albumin contaminating the final product.  Figure 5.3  shows the mass balance for 
the batch filtration of 100ml of precipitated serum washed with 200ml of buffer.
Once again the gel layer forms at the surface of the membrane.  It contained 10% 
of the antibody product however the levels of albumin are much lower.  The final 
product  also  contains  a  lower  level  of  albumin  (12%).  This  amount  of 
contamination  is  still  higher  that  the  current  centrifugal  process.  So  whilst  it 
seems increasing the washing buffer volume had some effect, it did not solve the 
problem.  As  a  result  it  was  decided  to  lower the  loading  volume  to  75ml  of 
precipitated serum (ratio of precipitated serum to membrane area = 2.6ml/cm2).
162It can be  seen  from the mass balance shown in figure  5.4 that the gel  layer has 
disappeared.  It  is  suggested  that  at  100ml  loading  volume  the  membrane  is 
overloaded  and  as  a  result  the  proteins  at  the  membrane  surface  become 
compacted  together  during  the  course  of  the  filtration.  Therefore  forming  a 
glutinous un-dissolvable layer.  At 75ml loading volume this does not occur. This 
may be the result of the decreased filtration time.  Because the gel layer did not 
form, the yield rises to  94% and the albumin contamination falls to  10%  in the 
final product.  The level of recovery of antibodies is now in line with that seen in 
the scale-down centrifugal process.  The levels of albumin contamination are still 
high, so again it was decided to increase the quantity of washing buffer.
The  amount  of washing  buffer  was  increased  to  150ml.  (The  mass  balance  is 
shown in figure 5.5).  Immediately it is observed that the levels of albumin have 
dropped to 3% left in the final product.
5.3.2.1  Conclusion
Decreasing the amount loaded from  100ml to 75ml (a decrease in the volume of 
precipitated  serum  loaded  to  membrane  area  ratio  of 3.5ml/cm  to  2.6ml/cm ) 
resulted  in  a  10%  increase  in  antibody  yield  and  a  decrease  in  the  albumin 
contamination  along  with  and  increase  in  the  flux  rate  from  99L/m2/hr  to 
166L/m /hr.  The  increase  in  flux  rate  would  result  in  faster  processing  times. 
Washing with double the volume of 18% sodium sulphate buffer also decreased 
the amount of albumin contaminating the final product. As a result it was decided 
that  the  optimum  conditions  for  further  filtration  experiments  within  the 
limitations of the equipment would be to load 75ml of precipitant and wash the 
cake with 150ml of washing buffer.
1635.3.3  Batch and continuous separation of precipitated IgG by
microfiltration
The  results  detailed  in  this  section  have  been  published  (Neal,  et  al.  2004). 
Microfiltration  is  an  attractive  separation  option,  particularly  for  protein 
precipitate in suspension, which may show susceptibility to shear-induced damage 
in centrifuges (Boulding, et al. 2002; Boychyn, et al. 2001). It is noted that shear 
rates at the surface of the microfiltration membrane can be high. For example, in 
tangential  flow  membrane  separation,  high  linear  fluid  velocities  and  large 
transmembrane  pressures  are  used  intentionally  to  realise  wall  shear  rates, 
typically  in the  region  of 5x10V1   to  lx l0 V 1   (Wilson,  et  al.  2003)  in order to 
reduce  the  thickness  of any  deposited  layer  on  the  membrane  surface.  These 
values, however,  are  still typically an order of magnitude lower than shear rates 
that have  been  reported  in  industrial  centrifuges  (Boychyn,  et  al.  2001).  It was 
hypothesised  therefore  that  the  hydrodynamic  conditions  in  microfiltration  are 
unlikely to cause damage to the antibody precipitate and no loss of product to the 
filtrate fraction should occur, provided the auxiliary pumps are selected to avoid 
shear  damage  during  pumping  of the  suspension.  In  what  follows  we  provide 
experimental data to test this hypothesis.
The  choice  of a  3 pm  pore  size  cellulose/acetate  membrane  filter  medium  was 
based  on  the  size  distribution  of the  antibody  (precipitate)  particles  shown  in 
figure 5.7 included below for reference. It is noted that the presence of the fines in 
the feed material had little impact on the performance of the filter.  Measurements 
of  the  flux  using  pure  water  before  and  after  filtration  (data  not  included) 
indicated no evidence of permanent fouling of the filter medium.
5.3.4  Methodology
A  stirred  cell  filtration  device  was  operated  in  two  different  modes:  batch  and 
continuous.  It has a diameter of 0.063m with a total volume of 200ml and was 
modified for use as a small-scale microfiltration device. A 3 pm pore size cellulose 
acetate  membrane  90mm  in  diameter  (Millipore,  Watford,  UK)  was  cut to  the 
correct diameter,  as 3 pm pore  size membranes were not available in the correct
164diameter. These were then placed at the bottom of the cell.  The cell was equipped 
with a single paddle impeller (width = 4.3mm, height = 8.4mm, length = 49.6mm) 
positioned  centrally  in  the  cell  in  close  proximity  to  the  surface  of the  filter 
membrane.  The shaft was driven from the top by a variable speed motor having a 
maximum speed of 242rpm. The rotational speed of the shaft was measured using 
a digital tachometer. The cell was hermetically sealed, once the lid was screwed in 
place,  and  was  supplied  with  an  air  inlet  and pressure  control  system  allowing 
precise setting of the air pressure above the solution in the cell during operation.
Standard  batch  filtration  tests  were  carried  out  as  follows:  75ml  of suspension 
containing the precipitated antibody was placed in the stirred cell. The rotational 
speed of the paddle was set at a pre-determined value and an air pressure applied. 
The  permeate  was  collected  (sample  2a,  Figure  5.1b)  until  the  permeate  flow 
stopped and a filter cake formed on the membrane. In the second part of the test, 
the cake  was washed,  as  described next.  The operation was stopped,  150ml of 
18% sodium sulphate (w/v) was added to the vessel and the paddle speed was set 
to the same speed as before. The mixture was stirred for ten minutes to break and 
resuspend the cake of precipitated antibody. The air pressure was re-applied and 
the  filtrate  was  collected  and  measured  every  minute  until  the  permeate  flow 
stopped.
In diafiltration mode,  75ml of precipitated antibody was placed in the cell.  The 
speed of the paddle was set at the pre-determined value and air pressure applied. 
A buffer solution of 18% sodium sulphate (w/v) was drawn in at the same rate that 
the  permeate  was  collected,  thus  maintaining  a  constant  level  of liquid  in  the 
vessel.  The flow of buffer was stopped after  150ml of buffer solution had been 
added and the operation switched to cake-filtration mode until the permeate flow 
stopped  and  a  filter  cake  of the  antibody  precipitate  formed.  The  225ml  of 
permeate was collected in three separate 75ml fractions for analysis.
The  final  step  for  both  modes  of operation  consisted  of adding  75ml  of warm 
(37°C) phosphate buffered saline (PBS) pH 7.4 to the solid cake in the cell. The 
antibody rich filter cake was allowed to dissolve over approximately ten minutes.
165The air pressure was applied as before and the antibody rich permeate collected 
for analysis.
5.3.5  Results
Figure  3.2  is  reproduced  below  for  ease  of  reference.  The  precipitate  was 
produced under exactly the same conditions as described in section 2.4.1.
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Figure  5.7  Particle  size  distribution  produced  during  the  precipitation  of 
antibodies  with  sodium  sulphate  by  a  1000  fold  scale-down  mimic  equipment, 
operating  at  equal  same  time-integrated  shear  stress  as  the  industrial  scale 
(standard deviation +/-3pm at d0.9 n=5)(sample point 2, Figure 5.1a)
166The  permeate  flux  rate  across  the  membrane  was  measured  at  intervals  of one 
minute for three different pressures and three different stirrer speeds.  Figure 5.8A 
is the flux profile at 0.5bar.  It can be seen that the flux rate decreases rapidly and 
then  levels  out  at  roughly  40L/m2/hr.  The  data  also  suggests  that  altering  the 
stirrer speed did not affect the flux rate.
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Figure 5.8A  Comparison of flux rates measured at 0.5bar and different shear
2 rates during diafiltration (standard deviation +/-5L.m .hr, n=3)
167The applied pressure was increased to 1  .Obar and the flux rate was again measured 
at one minute intervals.  The results are shown in figure 5.8B, again the initial flux 
rate falls off rapidly and levels out at roughly 60L/m /hr.
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Figure 5.8B Comparison of flux rates measured at 1  .Obar and different shear rates 
during diafiltration (standard deviation +/-5L.m .hr, n=3)
168The pressure was finally increased to 1.5bar at the flux rate was again measured at 
one  minute  intervals.  As  shown  in  figure  5.8C  the  flux  rate  again  decreases 
rapidly and levels out at around 40L/m2/hr.
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Figure 5.8C Comparison of flux rates measured at 1.5bar and different shear rates 
during diafiltration (standard deviation +/-5L.m .hr, n=3)
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The experimental  flux data was plotted in terms of the model equations 5.1  and
5.2  described in section 1.3.5.5 in order to determine the method of fouling. These 
plots are shown in figures 5.9A-C.
8
7
6
5
4
3
R2  = 0.9976
2
1 0.6 0.4 0.8
Time (h)
0
0 0.2 1 0.4 0.6 0.8 1.2 1.4 1.6
Time (h)
R2  = 0.9968
0  -j------------------------- 1 --------------------------1 ------------------------- 1 -------------------------1 -------------------------1
0  0.05  0.1  0.15  0.2  0.25
Volume (L)
Figure 5.9A Experimental flux data plotted in terms of fouling model equations
(5.1)  and  (5.2).  Data  refer  to  experiments  carried  out  under  constant  volume 
(continuous/ diafiltration) mode at 242rpm and 0.5bar
170Figure 5.9B shows the experimental flux data at 242rpm and l.Obar plotted in
terms of the model equations 5.1 and 5.2.
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Figure 5.9B Experimental flux data plotted in terms of fouling model equations
(5.1)  and  (5.2).  Data  refer  to  experiments  carried  out  under  constant  volume 
(continuous/ diafiltration) mode at 242rpm and l.Obar
171Figure 5.9C shows the experimental flux data at 242rpm and 1.5bar plotted in
terms of the model equations 5.1 and 5.2.
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Figure 5.9C Experimental flux data plotted in terms of fouling model equations 
(5.1)  and  (5.2).  Data  refer  to  experiments  carried  out  under  constant  volume 
(continuous/ diafiltration) mode at 242rpm and 1.5bar
172Figure  5.10  is  a  sensitivity  analysis  of filtration  area  versus  processing  time, 
determined using the values of Vm ax  and Fo obtained from experimental data. This 
was performed on the experimental flux data in order to determine the membrane 
area required to process a 250L of precipitated antibody serum at 0.5bar,  l.Obar 
and 1.5bar.
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Figure  5.10  Sensitivity  analysis  of the  area  of membrane  required  to  process 
250L of precipitated serum versus time
173Reducing  SDS  page  gel  electrophoresis  was  used  to  visualise  the  proteins 
contained in various samples.  Figure 5.11a is a photograph of the gel produced 
during the diafiltration process.  The albumin is gradually washed away leaving a 
purified antibody product.
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Figure  5.11 A  SDS  denaturing page  gels  showing  a  comparison  of the  protein 
content of each intermediate purification stage during the diafiltration process
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174The proteins contained in each sample of the dead end filtration process were also 
visualised  by  reducing  SDS  page.  Figure  5.1 IB  is  a  photograph  of the  gel 
showing  the  different  proteins.  The  photo  shows  the  albumin  gradually  being 
removed with some remaining in the final product.
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Figure  5.1 IB  SDS  denaturing  page  gels  showing  a comparison  of the  protein 
content  of  each  intermediate  purification  stage  during  the  dead  end  filtration 
process
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175The reducing SDS-page gel showing the proteins present during the industrial 
precipitation/centrifugation purification process has been included in figure 
5.11C, shown below for reference.
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Figure  5.11C  SDS  denaturing  page  gels  showing  a comparison  of the  protein 
content of each intermediate purification stage during the industrial centrifugation 
process
176During  the  diafiltration  separation  process  samples  were  taken  and  assayed  for 
total protein, albumin and active antibodies.  The results were used to produce the 
mass balance shown in figure 5.12A.  The albumin is removed during the washing 
phase,  whilst the  majority  of the  antibodies  are  recovered  scale  (standard  error: 
Total  protein  +/-  4%  (n=5),  Albumin  +/-  5%  (n=5),  Active  antibody  +/-  8% 
(n=3)).
(%)
u  -
1 1st 75ml 2nd 75ml 3rd 75ml 4
■  Average Total Protein (%) 100 40 14 10 38
□  Average Albumin (%) 100 38 33 28 1.5
□  Average Active Antibodies 100 0.5 0.5 0.4 95
Figure  5.12A  Mass  balance  for the diafiltration process,  showing the  levels of 
total protein (%), the main contaminant albumin (%) and the product (%)(sample 
numbers correspond to those in figure 5.1)
177Samples were also assayed for total protein, albumin and active antibodies during 
the dead end filtration process.  Figure 5.12B shows the mass balance produced as 
a  result  of these  assays.  The  albumin  is  removed  during  the  washing  phase 
leaving  a  small  amount  present  in  the  final  product  and  the  majority  of  the 
antibody is recovered (standard error: Total protein +/- 4% (n=5), Albumin +/- 5% 
(n=5), Active antibody +/- 8% (n=3)).
M Average Total Protein (%)
□ Average Albumin (%)
□  Average Active Antibodies (%)
Figure 5.12B  Mass balance for the batch filtration process, showing the levels of 
total protein (%), the main contaminant albumin (%) and the product (%)(sample 
numbers correspond to those in figure 5.1)
178The mass balance for the industrial scale centrifugal process is reproduced below 
in figure 5.12C for reference (standard deviation: Total protein +/- 3% (n=5), 
Albumin +/- 5% (n=5), Active antibody +/- 8% (n=3)).
M Average Total protein (%)
□  Average Albumin (%)
SB  Average Active Antibody (%)
Figure  5.12C  Mass  balance  for  industrial  centrifugation  process,  showing  the 
levels  of total  protein  (%),  the  main  contaminant  albumin  (%)  and  the  product 
(%)(sample numbers correspond to those in figure 5.1)
1795.3.6 Discussion
The  initial  permeate  fluxes  (F0)  were  107L.m2.hr,  175L.m2hr and  86L.m2.hr  at 
0.5bar  l.Obar  and  1.5bar  respectively;  the  reduction  in  flux  rate  at  1.5bar  is 
attributed to compaction of the filter cake caused by the higher pressure.  In each 
case the flux declines rapidly indicating the deposition of a layer of particles on 
the surface of the filter membrane. To a first approximation flux profiles depicted 
in  figures  5.8A-C  are  unaffected  by  stirrer  speed  (shear  rate  at  the  membrane 
surface) and the applied pressure. Different models of filtration are available that 
account  for  the  effect  of  suspension  properties  (pH,  ionic  strength),  filtration 
operation  (flow  rate,  pressure)  and  filter  media  (structure,  charge).  For  depth 
filtration, all these properties are critically important.
Permeate flux is expected to increase with an increase in shear rate, the extent of 
the  dependency  is  determined  by  assumptions  made  with  respect  to  particle 
diffusion  coefficient.  For  example,  the  hydrodynamic  shear  induced  diffusion 
model  of  Zydney  and  Colton  (1986)  predicts  that  permeate  flux  is  directly 
proportional  to  the  applied  shear  rate,  while  the  inertial  lift  model  of Belfort 
(1994) predicts an even stronger dependency with permeate flux increasing with 
the square of the shear rate. These models are essentially extensions of the basic 
Brownian diffusion theory based on the effect of concentration polarization (the 
stagnant film) model proposed by Blatt, et al. (1970). In the case of surface (cake) 
membrane filtration, flux is largely unaffected by operational parameters and the 
physico-chemical properties of the buffer/suspension.  The data shown in figures 
5.8A-C  and  5.9A-C  appear to  support the  hypothesis  that the  separation of the 
antibody precipitate is determined by both surface (cake) membrane filtration and 
gradual  pore  blocking  filtration  mechanisms.  Marshall,  et  al.  (1993)  concluded 
that during microfiltration the  main mechanism  of fouling  is pore plugging and 
that in systems where the concentration of solids within the feed stream is high 
fouling  by  surface  deposition  dominates.  In  this  system  microfiltration  is  the 
filtration  method  and  the  solids  content  of the  feed  stream  is  high,  resulting  in 
both methods of fouling occurring.  This is supported by further analysis of data 
discussed below.
180The data in  figures  5.8A-C  show that despite the high permeate flux the rate of 
filtration  decreases  continuously  and  rapidly  during  the  filtration  operation. 
Fouling  of the  filtration  medium  is  normally  presented  in  terms  of two  basic 
models:
(a)  Fouling by the deposition of material that forms a layer on the surface of the 
membrane has been analysed by using Darcy’s equation of flow through a porous 
medium (Jomitz and Meltzer,  1988) which leads to the following cake deposition 
model (CDM) equation (Jomitz and Meltzer, 1988):
t f V1
r  n
— = K. +
V  1,2 ,
equation 5.1
where V is total volume of permeate collected during the time, t. F0 is the initial 
flux rate  and Ki is an empirical constant obtained from experimental data.
(b)  Adsorption  of macromolecules,  such  as  proteins,  in  the  pores  of the  filter 
media may also cause a reduction in permeate flux, which may be described by 
the  following  expression  according  to  the  gradual  pore  blocking  model  (PBM) 
(Jomitz and Meltzer, 1988):
ro f M — +
^2, <^0 j
equation 5.2
where K2 is another constant obtained from experimental data.
According to the gradual pore blocking model a linear plot is expected when t/V 
is plotted against t, while if cake deposition model controls fouling a linear plot is 
obtained when t/V is plotted against V.  Figures 5.9A-C shows the filtration data
181(of figures 5.8A-C) plotted in terms of both model equations (5.1) and (5.2). The 
plots indicate that for all transmembrane pressures tested, both the cake deposition 
model  and  gradual  pore  blocking model  give  linear plots.  Indicating that both 
methods of fouling are occurring and contribute to the observed flux.
With  gradual  pore  blocking  the  flow  rate  of  fluid  through  the  filter  follows 
equation 5.3 shown below:
F = Fn
V _
V2y
equation 5.3
When  the  flow  rate  drops  to  zero  (F=0)  the  maximum  volume  of precipitated 
antibody serum that could be processed (Vm ax) can be determined.
V  = m ax
equation 5.4
Substituting for V max  into equation 5.2 gives the V max equation:
/  1
+  ■
V  V  F Y  max  r 0
Therefore using the experimental  data obtained from the stirred cell device and 
assuming  that  the  same  filter  media  and  feed  composition  are  employed,  it  is 
possible  to  calculate  the  operating  and  process  parameters  for  a  large-scale 
dynamic microfiltration unit based on the scale-up criterion of Vm ax  and the initial 
flux  rate  (F o )  .  The  area  of membrane  needed  to  process  a  given  volume  of 
precipitated serum can be deduced from equation 5.5, shown below.
Area =
V \   m ax J
+
F \ ro  y
equation 5.5
182Where V b  is the batch volume (L), V t is the filtration time, V max is the normalised 
Vm ax (L/m2) and Fo is the initial flux (L/m2/h).
The  maximum  volume  ( V max)  capable  of being  filter by  lm2  of membrane  has 
been calculated for each of the three pressures used and can be seen in figure 5.10. 
lm  of membrane  could process  148L,  147L and  186L of precipitated antibody 
serum at 0.5bar,  l.Obar and 1.5bar respectively. At 1.5bar it is possible to process 
a  larger  volume  of precipitated  serum  however,  the  initial  flux  at  1.5bar  was 
86L.m'2.h_ 1   compared  to  lOTL.m^.h'1   at  0.5bar  and  175L.m"2.h_ 1   at  l.Obar.  The 
flux  at  1.5bar has  decreased  substantially,  it  is  hypothesised that this  is  due to 
infilling and compaction of the filter cake leading to increased resistance to flow. 
This  has  the  impact  of  increasing  the  processing  time  which  may  effect  the 
process economics. Based on the sensitivity analysis conducted for figure 5.10 an 
operational pressure of 1  .Obar would give the most efficient process, in terms of 
the time taken to process 250L of precipitated serum.
The  stirred  cell  had  a 0.063m  diameter disc  with  an effective  filtration  area of 
0.0028m . Using this information and the  V max  method for scale-up a sensitivity 
analysis  of filtration  area versus  processing  was  carried  out.  Figure  5.10  is the 
result of the  sensitivity  analysis,  it  can be  seen that a stirred filtration machine 
with an effective filtration area of 2.5m  would be sufficient to process a batch of 
250L  of  antibody  suspension  in  ~2hours.  It  is  noted  that  agitation  did  not 
influence the filtration operation. However its inclusion in a full-scale operation is 
recommended to provide a means for re-suspending and dissolving the antibody 
layer in the  final  stage  of the process.  The  specification of minimum agitation 
speed  of impellers  for  particle  suspension  has  been  studied  previously  (Ayazi- 
Shamlou, P. et al.  1994; Ayazi-Shamlou, P.  1993) and is thought to be well within 
the ability of commercially available stirred microfiltration equipment (Langeloh, 
et al. 1998).
Figure 5.11 A shows the SDS-page gels for samples removed periodically during 
the continuous (diafiltration) operation of the unit. For comparison, data are also 
shown  for the  same  starting precipitate  in  suspension  separated by  running the
183stirred cell  in a standard batch (cake filtration) mode of operation, figure 5.1 IB, 
and by centrifugation as detailed in chapter three, figure 5.11C.
Lanes 3,4 and 5  in figure 5.11A track the main protein (albumin) contaminant in 
the permeate fraction.  The contaminating albumin is substantially removed from 
the  retentate  as  the  buffer  is  added  to  the  suspension  in the  stirred  cell  during 
continuous operation.  No antibody was detected in the permeate fractions during 
washing stage as indicated by the gel electrophoresis. At the end of the washing 
period, the operation was switched to the batch (cake) filtration mode to remove 
the  sodium  sulphate  buffer used  to  wash  the  precipitate.  The  layer of antibody 
precipitate formed on the membrane filter was dissolved in a solution of PBS at 
37°C  by  using  the  stirrer  to  re-suspend  and  dissolve  the  antibody  layer  in  the 
buffer. Once the dissolution operation was complete, a pressure of l.Obar (lxl05  
N/m )  was  applied  and  the  permeate  containing the  dissolved  antibody  fraction 
collected.  It  may  be  seen  from  lane  6  (figure  5.11 A)  that  the  product  stream 
contains only  a negligible  quantity  of the contaminating albumin.  In the batch 
operation the total volume of buffer used to wash the cake was the same as that 
used during the constant volume operation. The gels in figure 5.1 IB show that the 
albumin is removed during both the cake filtration and washing stages (lanes 3 & 
4). Again, no antibody was detected in any of the permeate fractions.  The gels in 
figure  5.11C  were  obtained  by  separating  the  antibody  precipitate  using  an 
industrial centrifuge,  details of which are  given in chapter three.  Comparing the 
results with the microfiltration operation indicate that the microfiltration scheme 
provides comparable outcomes in terms of purity of the antibody precipitate.
Figure  5.12A-C  provides  the  results  of a  mass  balance  carried  out  on  the  key 
components during the microfiltration of the antibody precipitate. Data are shown 
for the stirred cell device operating in continuous mode and comparative data are 
given for batch mode as well as for the industrial disc stack centrifuge (Neal, et al. 
2003).  The  final  product  for  all  three  systems  contains  similar  percentage  of 
albumin (±5%).  However, if we define the relative potency of the final product as 
the percentage antibody content divided by the percentage total protein content, 
then  it  can be  seen that the  continuous  filtration operation has the  best relative
184potency  (2.5)  this  is  followed  closely  by  the  dead  end  filtration  (2.2)  with  the 
centrifugation process giving the lowest value (1.2).
There are two possible reasons for this. The first is the potential shear associated 
damage to the product antibody in the high shear zones in an industrial centrifuge 
(Boychyn, et al. 2001; Boulding, et al. 2002; Neal, et al. 2003). The second is the 
capacity of the continuous microfiltration to increase the overall process yield by 
integrating  several  operations  (concentration,  diafiltration,  washing  and  buffer 
exchange)  in  a  single  piece  of equipment.  The  improvement  in  yield  may  be 
considered  significant  given  the  high  cost  of the  antibody  product  (Neal,  et  al. 
2003).
5.4  Conclusions
It  is  known  that  current  manufacturing  capacity  for  rattlesnake  venom-specific 
Fab antibody is unable to keep up with the growth in demand.  In this chapter a 
modified  stirred  cell  device  was  used  to  mimic  the  operation  of  dynamic 
microfiltration to separate an intermediate antibody precipitate from a suspension 
containing  contaminating  soluble  proteins.  Constant  volume  flux  data  were 
obtained  as  a  function  of  shear  rate  at  the  surface  of  the  membrane  and 
transmembrane  pressure  and  analysed  to  establish  the  limits  of the  filtration 
operation. The results were compared with an existing centrifugation process. The 
analysis indicated that dynamic microfiltration may be used as a single step for 
separation;  purification  and  concentration  of antibody  precipitate  and  offers  an 
attractive process option to centrifugation.
1856  Purification  Of  Ovine  Polyclonal  Antibodies  By
Protein  G  Affinity  Chromatography  And  The
Prediction Of Breakthrough Curves
6.1  Introduction
Affinity chromatography  is  a powerful  tool  for the  isolation and purification of 
intact  proteins.  Advances  in  matrix  and  ligand  technology  mean  that  affinity 
chromatography has now found widespread use and is a well recognised technique 
within the biopharmaceutical industry (Subramanian,  1995). This technology has 
been used  for the purification  of many  different types  of product ranging  from 
antibodies (Huse, et al. 2002; Lowe, et al. 2001), to plant proteins (Weselake and 
Jain, 1992), to proteases (Ibrahim-Granet and Bertrand, 1996).
It is also a potentially attractive process option as a method to purify polyclonal 
immunoglobulins  because  in  principle  the  current  four-step 
precipitation/centrifugal  recovery  technique  described  in  chapter three  could  be 
carried out in one step. Protein A affinity chromatography is regularly used for the 
initial  purification  of  monoclonal  antibodies  from  clarified  cell  culture  fluid 
(Birch, et al.  1995; Blank, et al. 2001; Fahmer, et al.  1999a; Fahmer, et al.  1999b; 
Fahmer,  et al.  1999c;  Grant,  et al.  1999;  Schwarz,  2000;  Walter, 2000)  and the 
same principles could be applied for this purification.
In this instance however, protein G was chosen instead of protein A as it exhibits 
a higher affinity  for ovine  IgG  antibodies  (Bjorrck and Kronvall,  1984).  It has 
been reported that conventional separation techniques, like precipitation, are being 
replaced by  affinity  separations  (Bonneijea,  et al.  1986).  Figure 6.2  details the 
proposed  process  flow  sheet  for  the  purification  process,  with  the  Protein  G 
separation replacing the precipitation and centrifugation steps.
A  one  step  primary  separation  is  extremely  desirable  because  of the  potential 
decrease in process time and potential increase in yield obtained from a decrease
186in the number of separation steps used to achieve the purification. The flow sheet 
detailed in figure 6.1  has eight discrete stages where as the process sheet in figure
6.2  has  five.  The  degree  of purification  obtained  from  a  protein  G  (affinity) 
purification step may also be greater than the current precipitation/centrifugation 
step,  due  to  the  specific  nature  of the  protein  G  immunoglobulin  interaction. 
There  is  also  general  agreement  within  the  biopharmaceutical  industry  that 
decreasing the number of steps in a process and increasing the yield will generate 
higher returns (Lowe, et al. 2001).
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Figure 6.2 Process flow sheet for modified chromatographic separation process
The steps following the protein G affinity purification are required to remove the 
contaminating Fc fragments produced during the digestion step. Changes to them 
will not be considered here.
This chapter focuses on the use of protein G for separating polyclonal IgGs from 
ovine serum and assesses the suitability of affinity chromatography for the initial 
purification step. This method of separation was also compared to the centrifugal 
method described  in chapter 3  and the filtration separation method described  in 
chapter 5.
Values for the maximum monolayer capacity ( q m) , the dissociation constant ( K d ), 
and the apparent adsorption constant (Kj) were  determined from batch and rate 
adsorption  data.  The  results  were  then  used  in  the  kinetic  rate  constant  model 
developed by Chase (1984) to build a mathematical model capable of predicting 
the breakthrough curves of IgG  separations.  Predictions were made  for various 
bed  heights/diameters,  antibody  feed  concentrations  and  feed  flow rates.  These 
predictions were tested by comparison to experimentally produced breakthrough 
curves.
1886.1.1  Theory
Adsorption isotherms and modelling
Batch adsorption experiments were conducted to generate information about the 
binding  characteristics  of  the  matrix.  The  results  from  the  batch  adsorption 
experiments,  for  both  IgG  and  albumin,  were  analysed  using  the  Langmuir 
isotherm (equation 1.19, detailed in section 1.3.6.5 is shown below for reference). 
It has been used extensively in the past to analyse binding characteristics (Bellot 
and Condoret, 1993; Chase, 1984; Jacobson, et al.  1984; Mao, et al.  1995; Weaver 
and Carta, 1996).
q  _  CMqm   _  CM qm KA  
s  Cu +Kd  CuKa +1
(equation 6.1)
Where  Cs  is  the  concentration  of  absorbed  solute  at  equilibrium,  Cm  is  the 
concentration of solute  in the  mobile  phase  at equilibrium,  qm   is the  maximum 
monolayer capacity of the matrix, Kd  is the disassociation constant and Ka is the 
association constant.
The applicability of this model to describe the batch adsorption experimental data 
was assessed using the  Scatchard plotting technique (Andrade,  1985; Blanco,  et 
al.  1989;  Scatchard,  1949).  A linear Scatchard plot indicates the applicability of 
the Langmuir model, where as a non-linear plot suggests a violation of the basic 
assumptions inherent to the model. Rearranging equation 6.1 yields:
^  = qm KA-K A Cs
M
(equation 6.2)
189This equation implies that a plot of Cs/Cm versus Cs should yield a straight line of 
slope - K a and intercept qmKA  if the basic assumptions of the Langmuir model are 
adhered to.  Experimental work (Anspach, et al.  1990; Blanco, et al.  1989; Boyer
et al.  1989) has however demonstrated that many cases of protein adsorption show 
deviations from linearity.  If the Scatchard plot results in a concave-up curvature, 
this suggests either negative co-operativity i.e. two different species of protein are 
competing  for  the  same  binding  site,  or  the  presence  of  two  or  more 
heterogeneous  binding  sites.  A  concave-down  curvature  indicates  positive  co- 
operativity, i.e. one binding site binds more than one protein at a time.
Simulations of the breakthrough process can be conducted by determining the rate 
constant  (Kj)  and  using  the  kinetic  rate  constant  model  developed  by  Chase 
(1984) to describe the  adsorption  and  desorption process.  This model  assumes 
that the  surface  reaction  rate  is  slow compared  to  the  mass transfer rate.  This 
assumption means that the rate  at which the antibodies bind to the protein G  is 
slow  compared  to  the  rate  at  which  they  move  from  the  solution  they  are 
contained within to within the matrix.  This implies that the protein concentration 
inside the adsorbant particle is the same as outside.  The rate function accounts for 
the reversible nature of the solute-adsorbent interaction:
and Hsu, 1990; Huang, et al.  1990;  Ruaan, et al.  1988; Sada, et al.  1986; Whitley,
-±  = K,Cu (qm-C s)-K_lCs 
at
(equation 6.3)
(bta)(  1  -  exp{- 2(av / V)Kx t})
\b -a )
—  -exp{-2(av/F)£,/}
(equation 6.4)
190Where
a rc„v\
(equation 6.5)
and
6 = 1
C0V  k dv
— + 9,« + - e-
V  V
(equation 6.6)
Where  K_i  is  the  reverse  reaction  rate  constant,  Co  is  the  initial  protein 
concentration, u is the volume of matrix and V is the volume of solution (Chase, 
1984).
This model was originally developed to describe ion-exchange processes. It lumps 
all the mass transfer resistances into one interaction rate constant.  The model also 
assumes that one protein molecule adsorbs to one functional group.
6.2  Methodology
A  0.7cm  diameter,  2.5cm high column with a capacity of 0.96ml,  packed with 
protein G sepharose 4 fast flow (Amersham Biosciences, Buckinghamshire, U.K.) 
was used to separate polyclonal IgGs from ovine serum.  The main contaminants 
within  the  serum  are  albumin  and  other  blood  proteins.  The  column  was  run 
according to the method detailed in section 2.5.3. The chromatograms of the first 
and twentieth purification run on the 0.96ml capacity column are included in the 
results section in order to show that the column has not significantly deteriorated 
with repeated use.  A mass balance has been produced in order to determine the 
levels of recovery and the amount of IgG bound to the column.  A non reducing 
SDS-PAGE gel, produced as per the method detailed in section 2.3.3.2, was used 
to visualise the proteins contained in the un-purified serum, the flowthrough/wash 
fractions  and  the  elutant  fractions.  These  fractions  were  produced  during  the 
protein G purification.
191Column  experiments  also  provided  purified  IgG  for  use  during  the  batch  and 
breakthrough curve experiments.
Isotherm measurements
Isotherm  measurements  were  conducted  using  a  batch  method.  Section  2.5.1 
details  the  method  used  for  the  twenty-four  hour  equilibrium  experiments. 
Solutions of IgG and albumin at various starting concentrations were placed into 
eppendorfs containing an equal volume of matrix. They were left for twenty-four 
hours in order to allow the protein concentrations to come to equilibrium.  These 
experiments  allow  the  maximum  capacity  (qn)  of the  matrix  to  be  determined 
along with the dissociation constant (K0.
Dynamic equilibrium experiments were used to determine the apparent adsorption 
constant (Kl). This constant describes the rate of adsorption of the solute to the 
support;  in  this  case  the  antibodies  to  protein  G.  Section  2.5.2  describes  the 
method utilised to determine the dynamic equilibrium.  Known concentrations of 
IgG and Albumin were placed in a stirred vessel containing an equal volume of 
protein G matrix.  Samples of the mobile phase were then removed at different 
times. The concentrations of protein were determined by Bradford assay using the 
methodology  detailed  in  section  2.3.1.1.  It  was  assumed  that  adsorption  and 
desorption take place simultaneously at the surface of the matrix.
Equation  6.4  was  solved  using  Matlab  and  the  experimentally  determined 
adsorption values. The predicted breakthrough curves were drawn from the results 
(Dr Hu Zhang, private communication).
The breakthrough curve predictions were tested by comparison with breakthrough 
curves  produced  using  varying  bed  heights,  different  flow  rates  and  different 
starting concentrations of IgG.  The method is described in section 2.5.4.
1926.3  Results
The chromatogram for the 0.96ml volume column purification of IgG from ovine 
serum after the first run are shown in figure 6.3.
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The chromatogram for the 0.96ml volume column purification of IgG from ovine 
serum after the twentieth run is shown in figure 6.4.
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Figure 6.4  Purification of ovine polyclonal antibodies from serum (run number 
20) 2ml of 32.5mg/ml (total protein) 15mg/ml (IgG) at 157.89cm/hr
194The concentration of proteins in the flowthrough/wash and in the elution portion 
of the chromatographic run were measured and used to produce the mass balances 
shown below in tables 6.1 and 6.2.  1ml of protein G matrix binds around 19mg of 
ovine IgG from within the mixed protein starting serum solution when the flow 
rate is 157.89cm/hr and the concentration of antibodies in the feed is 15mg/ml.
Run No. Total protein 
Loaded (mg)
Total IgG 
Loaded (mg)
Total protein in 
Wash/Flowthrough (mg)
Product(eluant)
(mg)
1 65 30 46.1 18.9
5 65 30 46.1 18.9
10 65 30 46.4 18.6
15 65 30 46.4 18.6
20 65 30 45.7 19.3
Table 6.1  Mass balance for protein G affinity chromatography runs  1,5,  10,  15, 
and 20
Run
No.
IgG recovered 
(mg)
IgG in 
flowthrough (mg)
% IgG recovered 
from column
% IgG 
yield
1 18.9 10 96 63
5 18.9 9.8 96 63
10 18.6 10.2 96 62
15 18.6 9.9 95 62
20 19.3 10 97 64
Table 6.2  Antibody yields for protein G affinity chromatography runs  1,  5,  10, 
15, and 20
195A  non  reducing  SDS  PAGE  gel  was  used  to  visualise  the  proteins  contained 
within  the  various  fractions.  The  antibody  is  purified  out  from  the  other 
contaminating proteins and is found in the elutant fraction.
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Figure 6.5  SDS page non reducing gel showing the protein content of the various 
fractions  produced  during  the  chromatographic  separation  of  antibodies  from 
ovine serum by protein G affinity chromatography
196The  total  protein  concentration  at  equilibrium  in  the  mobile  and  solid  phase  at 
various  starting  concentrations  were  determined  by  batch  uptake  experiments. 
The results are plotted below in figure 6.6.  The Langmuir equation was used to 
produce the predicted isotherm based on the experimentally determined value of 
KAfor IgG antibodies and Albumin.
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Figure 6.6  Langmuir isotherms showing predicted IgG concentrations (solid line) 
the predicted Albumin concentrations  (dashed line) the measured concentrations 
of IgG(A)  and  the  measured  albumin  concentrations  (■)  present  in  the  solute 
fraction and bound to the matrix at different initial starting concentrations after 24 
hours
197C
s
/
C
m
The method of Scatchard was used to determine the applicability of the Langmuir 
model for describing the IgG experimental data.  The plot shown below in figure 
6.7 is for the batch uptake of IgG onto protein G matrix.
2
Figure 6.7  Scatchard plot of IgG adsorption data, the solid line is the fitted curve 
using the Langmuir equation the (■) represent the IgG experimental data
198The  method  of  Scatchard  was  also  used  to  determine  the  applicability  of the 
Langmuir model for describing the Albumin experimental data.  The plot shown 
below in figure 6.8 is for the batch uptake of Albumin onto protein G matrix.
Figure 6.8  Scatchard plot of albumin adsorption data, the solid line is the fitted 
curve  using the  Langmuir  equation  the  (■)  represent the  albumin experimental 
data
199Dynamic equilibrium experiments were conducted and the concentration of both 
IgG  and  Albumin  remaining  in  solution  were  measured  after  different  time 
intervals.  The results are shown below in figure 6.9. The protein G binds IgG in 
large  amounts  and  reaches  its  maximum  capacity  after  5  minutes,  whilst  the 
albumin barely binds to the matrix.
35
30
25
20
15
10
5
0
20 25 30 15 10 0 5
Time (mins)
Figure 6.9  Concentration of Albumin (■) and IgG (A) remaining in the mobile 
phase at different times after the addition of the protein solution to the equilibrated 
protein G matrix
Table 6.3, shown below details the experimentally determined values for Kd Kl 
and qm
Protein
(kjm 3) 3K1  (m /kg/hr)
Max capacity 
(qmkg/m3)
IgG 0.5 12 28.5
Albumin 5 3.6 3
Table 6.3  Experimentally determined values of Kq Kl and qmfor the interaction 
of protein G matrix with IgG and albumin
200Predicted and experimental breakthrough curves were determined for a variety of 
different  bed  heights,  flow  rates  and  feed  concentrations,  in  order  to  test  the 
robustness of the  mathematical  model.  Table  6.4,  shown below summarises the 
conditions.
Experiment No. 1 2 3 4 5
Feed concentration 30mg/ml 30mg/ml 15 mg/ml 15mg/ml 30mg/ml
Bed Height 2.5cm 2.5cm 2.5cm 2.5cm 5cm
Flow rate 157cm/hr 316cm/hr 157cm/hr 316cm/hr 76cm/hr
Column diameter 0.7cm 0.7cm 0.7cm 0.7cm 1cm
Experiment No. 6 7 8 9 10
Feed concentration 15 mg/ml 30mg/ml 30mg/ml 30mg/ml 30mg/ml
Bed Height 5cm 10cm 10cm 15cm 15cm
Flow rate 76cm/hr 76cm/hr 38cm/hr 120cm/hr 60cm/hr
Column diameter 1cm 1cm 1cm 0.8cm 0.8cm
Table 6.4  Summary of the different conditions utilised during the breakthrough 
curve experiments
201Predicted  and  experimental  breakthrough  curves  for  a  bed  2.5cm  high,  0.7cm
diameter with a feed concentration of 30mg/ml and a flow rate of 157cm/hr and
316cm/hr. The predicted curves closely match the experimental curves.
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Figure  6.10  Simulated  (red  line)  and  experimental  (black  line)  breakthrough 
curves  (2.5cm  high  column,  0.7cm  diameter,  30mg/ml  feed  concentration, 
157cm/hr flow rate)
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Figure  6.11  Simulated  (red  line)  and  experimental  (black  line)  breakthrough
curves  (2.5cm  high  column,  0.7cm  diameter,  30mg/ml  feed  concentration,
316cm/hr flow rate)
202Predicted  and  experimental  breakthrough  curves  for  a  bed  2.5cm  high.  0.7cm
diameter with a  feed  concentration of 15mg/ml  and a  flow rate of 157cm/hr and
316cm/hr. The predicted curves do not closely match the experimental curves.
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Figure  6.12  Simulated  (red  line)  and  experimental  (black  line)  breakthrough 
curves  (2.5cm  high  column,  0.7cm  diameter,  15mg/ml  feed  concentration, 
157cm/hr flow rate)
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Figure  6.13  Simulated  (red  line)  and  experimental  (black  line)  breakthrough
curves  (2.5cm  high  column,  0.7cm  diameter,  15mg/ml  feed  concentration,
316cm/hr flow rate)
203Predicted  and  experimental  breakthrough  curves  for  a  bed  5cm  high,  1.0cm
diameter  with  a  feed  concentration  of 30mg/ml  and  15mg/ml  at  a  flow  rate  of
76cm/hr. The predicted curves do not closely match the experimental curves.
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Figure  6.14  Simulated  (red  line)  and  experimental  (black  line)  breakthrough 
curves  (5cm  high  column,  1cm  diameter,  30mg/ml  feed  concentration,  76cm/hr 
flow rate)
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Figure  6.15  Simulated  (red  line)  and  experimental  (black  line)  breakthrough
curves  (5cm  high  column,  1cm  diameter,  15mg/ml  feed  concentration,  76cm/hr
flow rate)
204Predicted  and  experimental  breakthrough  curves  for  a  bed  10cm  high,  1.0cm
diameter  with  a  feed  concentration  of 30mg/ml  at  a  flow  rate  of 76cm/hr  and
38cm/hr. The predicted curves do not closely match the experimental curves.
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Figure  6.16  Simulated  (red  line)  and  experimental  (black  line)  breakthrough 
curves (10cm high column,  1cm diameter, 30mg/ml feed concentration,  76cm/hr 
flow rate)
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Figure  6.17  Simulated  (red  line)  and  experimental  (black  line)  breakthrough
curves (10cm high column,  1cm diameter,  30mg/ml  feed concentration,  38cm/hr
flow rate)
205Predicted  and  experimental  breakthrough  curves  for  a  bed  15cm  high,  0.8cm
diameter with  a  feed  concentration  of 30mg/ml  at  a  flow  rate  of 120cm/hr and
60cm/hr. The predicted curves do not closely match the experimental curves.
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Figure  6.18  Simulated  (red  line)  and  experimental  (black  line)  breakthrough 
curves  (15cm   high  column,  0.8cm   diameter,  30m g/m l  feed  concentration, 
120cm/hr flow  rate)
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Figure  6.19  Simulated  (red  line)  and  experimental  (black  line)  breakthrough
curves (15cm high column, 0.8cm diameter, 30mg/ml feed concentration, 60cm/hr
flow rate)
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A  small-scale  protein  G  column  (2.5cm  x  0.7cm)  has  been  used  to  study  the 
feasibility of using affinity chromatography to purify polyclonal immunoglobulins 
from ovine serum in one step (figure 6.2).  Thereby replacing the current four-step 
precipitation and centrifugal recovery process shown in figure 3.1a.
Values  of Kd,  K i  and  qm  were  determined.  These  values  were  then  input  into  a 
mathematical  model,  which  was  used  to  predict  the  shape  and  position  of 
breakthrough  curves  produced  during  the  binding  of  ovine  polyclonal 
immunoglobulins to protein G.  The model was tested by comparing the predicted 
curves  against  curves  produced  by  frontal  analysis  experiments.  These  were 
conducted with columns of varying lengths/diameters, with varying flow rates and 
varying feed inlet concentrations.
Figures 6.3  and 6.4 show the chromatograms produced during the purification of 
antibodies from ovine serum using the 0.96ml volume protein G column.  Figure
6.3  is  the  chromatogram  for  the  first  run  and  figure  6.4  is  the  chromatogram
th
produced during the  20  run.  As can be seen, the  size and shape of the elution 
peak  remained  consistent,  indicating  that  the  column  is  still  binding  the  same 
quantity of IgG  after twenty runs.  It is  also worth noting that the  backpressure 
within the system did not noticeably increase, indicating that the column was not 
clogging (data not shown).
Tables  6.1  and  6.2  are  the  mass  balances  for  runs  one,  five,  ten,  fifteen  and 
twenty;  the  extra runs  have  been  included  for comparative purposes.  The mass 
balance  reveals  that  when  30mg  of  IgG  is  loaded  around  19mg  binds  to  the 
column  whilst  lOmg  flows  through  to  waste.  These  levels  remained  the  same 
from runs one through twenty, again indicating that the column is not degrading. 
It is particularly important from an industrial point of view that the column gives a 
consistent yield, since a purification process needs to be robust in order for it to be 
validatable.  A  long column life will  also  improve the  economics  of the process. 
The  mass  balance  indicates  that  the  yield  is  63%  compared  to  80%  for  the
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microfiltration process  (see  figures  3.8b  and  5.12a respectively).  At  first glance 
this yield does not compare  favourably with the yields from the other processes. 
However, this is an initial set of experiments, designed only to test the feasibility 
of using protein G to bind and separate the ovine polyclonal antibodies from the 
rest of the contaminants.  Further experimental work would have to be conducted 
in order to  determine  the  most efficient amount of serum  to  load as well  as the 
optimum  flow  rate  and  buffering  conditions  required  to  gain  the  highest  yield, 
before an accurate comparison could be drawn.
Figure 6.5 is a non-reducing SDS-page gel depicting the proteins contained within 
the process stream at various points during the protein G separation process.  Lane 
2  contains the  starting serum  showing the antibody and the major contaminants. 
Lanes 3  and 4 contain the flowthrough/column wash fraction.  As can be seen a 
large  quantity  of IgG  remains  unbound  and  is  lost.  Determining  the  optimum 
loading conditions could reduce this loss.  Lanes 5 and 6 contain the elution peak. 
The  purity  of the  final  product  is  excellent,  with  only  one  major  band  of IgG 
present. This compares very favourably with both the precipitation/centrifugal and 
microfiltration  purification  processes  (figures  3.4a  and  5.11a),  where 
contaminating proteins are still present.
Isotherms
Batch  and  dynamic  experiments  were  used  to  determine  experimental  values 
which  describe  the  adsorption/desorption  process.  The  Langmuir  equation  has 
been used extensively in the past to describe interactions between chromatography 
media  and  various  substrates  (Gritti  and  Guiochon,  2003;  Hahn,  et  al.  2003; 
McCue, et al.  2003;  Weaver and Carta,  1996).  Here it has been used to describe 
the  adsorption/desorption  process  occurring  between  protein  G  and  ovine 
polyclonal  antibodies.  The  applicability  of  this  method  to  describe  the 
adsorption/desorption  process  was  assessed  through  the  use  of Scatchard  plots 
(Scatchard,  1949).  The  experimentally  determined values  were  used to  build  a 
mathematical  model  capable  of  predicting  the  shape  of  breakthrough  curves 
produced during the protein G separation process.  The mathematical model was
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should be noted that Yang and Tsao (Yang and Tsao,  1982) have highlighted that 
the  assumptions  of  linear  adsorption  isotherms  or  linear  adsorption-desorption 
kinetics,  which  have  been  used  frequently  to  describe  liquid  or  gas 
chromatography  systems  (Bellot and Condoret,  1993;  Chase,  1984;  Jacobson,  et 
al.  1984; Mao, et al.  1995;  Weaver and Carta,  1996), might not be applicable to 
affinity  chromatography.  Another assumption  of this  model  is  that the  binding 
sites on the matrix have affinity for only one type of adsorbate. However protein 
G recognises and binds to many species of IgG and the feed material is polyclonal 
in  nature.  This  means  that  reactions  with  different  rate  kinetics  may  be  taking 
place when the matrix and the serum are combined.
Adsorption  isotherms  were  measured  for  the  binding  of polyclonal  anti-snake 
venom antibodies and albumin to immobilised protein G. The antibodies/albumin 
were buffered in 0.2M sodium phosphate buffer pH 7.4.  Figure 6.6 is a plot of the 
experimentally  determined  values  for  the  concentration  of  IgG  and  albumin 
remaining in the mobile phase at different starting concentrations after the system 
had  reached  equilibrium.  The  plot  shows  good  agreement  between  the 
experimental  and the  Langmuir predicted curves  for both the  antibodies  and the 
albumin.  The shape of the curve shown in figure 6.6 for the antibody-protein G 
interaction is indicative of a favourable adsorption isotherm (Langmuir, 1918).
The Scatchard plot for the antibody adsorption data is shown in figure 6.7 and the 
albumin adsorption data is shown in figure 6.8.  A straight line indicates that the 
Langmuir  curve  can  be  used  to  describe  the  experimental  data.  The  antibody 
adsorption data, when plotted out, gives a r2 value of 0.88 indicating a reasonable 
correlation.  The discrepancies could be attributed to the polyclonal nature of the 
immunoglobulins,  which  may  mean  that  the  different  types  of antibody  have 
different affinities for the protein G, thus resulting in a mixture of rate constants.
The Scatchard plot for the albumin adsorption data shown in figure 6.8 gives an r 
value of 0.15, indicating that the Langmuir isotherm does not accurately describe 
the interaction between albumin and the protein G matrix.  This is to be expected 
since the protein G molecule has been genetically modified to remove its albumin-
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interaction with the solid support.
The values for the effective dissociation constant (Kd), forward rate constant (Ki), 
and the maximum capacity (qm) for the binding of IgG and albumin to protein G 
were determined using equations 6.1  to 6.6 with reference to figures 6.6 and 6.9 
the results are shown in table 6.3.
For  the  IgG  system  at  equilibrium  the  dissociation  constant  ( K d )  equalled
0.5kg/m3,  the  forward rate  constant (Ki) equalled  12m3/kg/hr and the maximum 
binding capacity of the protein G matrix was 28.5kg/m3 of gel.  These values are 
comparable  to  those  obtained  for  the  interaction  between  different  protein  A 
matrices and polyclonal IgG (Hahn, et al. 2003).
For  the  albumin  system  at  equilibrium  the  dissociation  constant  ( K d )  equalled 
5kg/m3,  the  forward  rate  constant  (Ki)  equalled  3.6m3/kg/hr and  the  maximum 
binding capacity of the protein G matrix was 3kg/m3  of gel.
As expected the association constant for IgG was much larger than for albumin as 
was the maximum capacity of the resin. This maximum capacity would probably 
not be achievable under column separation conditions since this value represents 
the amount bound after 24 hours without any interfering proteins.  During column 
separation the residence time will be a matter of minutes not hours and this is one 
of the  main  factors  influencing  the  amount of IgG bound  (McCue,  et  al.  2003). 
The  dynamic  equilibrium  plot  shown  in  figure  6.9  reveals  the  rate  at which the 
antibodies  and  the  albumin  bind  to  the  matrix.  After  5  minutes  the  matrix  has 
almost reached its maximum capacity for the antibodies or the albumin.  This plot 
was used to calculate the value of Kj.
Breakthrough curves
Experimental breakthrough curves were determined for packed columns in order 
to  study  the  effect  of changing  operating  variables  such  as  the  flow  rate,  the 
concentration  of the  adsorbate  and  the  size  and  shape  of the  column  on  the
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mathematical models ability to predict the shape and position of the breakthrough 
curve under different operating conditions.  Table 6.4 summarises the conditions 
used  during  the  breakthrough  curve  experiments  and  figures  6.10  through  6.19 
show the experimentally produced curve with the predicted curve overlaid.
Figures 6.10 and 6.11  are the experimental and predicted breakthrough curves for 
a 2.5cm long bed, 0.7cm in diameter run at a feed inlet concentration of 30mg/ml 
at a flow rate of 157cm/hr and 316cm/hr.  The predicted and experimental curves 
closely match, indicating a good correlation between the mathematical model and 
the reaction  occurring during the experimental run. The column conditions match 
those  used  during  the  batch  update  experiments  with  regard  to  the  feed  inlet 
concentration.
Figures 6.12 through 6.19 are the experimental and predicted breakthrough curves 
for columns run under different operating conditions as detailed in table 6.4.  The 
predicted and the experimental curves differ in the predicted time it will take for 
breakthrough to occur; this indicates a possible flaw in the model used to predict 
the  breakthrough  curves.  The  possible  reasons  for  these  discrepancies  will  be 
discussed later.
The breakthrough curve model is based on several assumptions as well as relying 
on the accuracy of the experimentally determined values of Kj  and qm  to predict 
the shape and position of the curve.  The Langmuir curve and the  Scatchard plot 
of the  antibody  adsorption  data  indicated  that  a  simple  equilibrium  relationship 
could  be  used  to  describe  the  system  and  the  interactions  occurring  during  the 
affinity separation (figures 6.6-6.8).  However the lack of agreement between the 
predicted  and  experimental  breakthrough  curves  suggests  that  some  of  the 
assumptions the model is based on do not fully describe what is occurring within 
the system.  The model assumes that the adsorbent-adsorbate reaction takes place 
between one molecule and one functional group.  However, the antibody solution 
is  polyclonal  and  contains  many  different  types  of antibody,  which  could  have 
different binding affinities (Bjorrck and Kronvall, 1984).  The model also assumes 
that the protein concentration inside the matrix is the same as outside i.e. the rate
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transfer  rate.  Both  factors  could  be  contributing  to  the  rate  of  uptake  which 
impacts the accuracy of the model.  The experimentally determined values of Ki 
or qm  could be inaccurate, which would introduce discrepancies when the model is 
tested  under  conditions  different  from  those  the  values  of  qm   and  Ki  were 
determined at.  It  should also be  noted that the values of the parameters  for the 
interaction between adsorbent and adsorbate are only applicable to the conditions 
under which they were  measured.  Differences  in the temperature, pH and ionic 
strength may alter the binding kinetics, resulting  in a shift in the position of the 
breakthrough curve.
The shape of a breakthrough curve can also be used to determine when the most 
efficient adsorption process is achieved.  This is obtained when the curve is at its 
sharpest.  Chase  (1984)  determined  that the  sharpest  breakthrough  curve  is  seen 
with  the  lowest  feed  flow  rate  and  the  highest  feed  concentration.  Within  an 
industrial  setting these  parameters  may not be  achievable  since  time  constraints 
may restrict the  flow rate allowable and the feed inlet concentration is governed 
by  the  concentration  within  the  ovine  serum  and  the  amount  of binding  buffer 
added to it.
6.5  Conclusions
This chapter demonstrates the feasibility of using protein G as a replacement for 
the current precipitation/centrifugation purification process. Although the yield of 
63% is  less than the current process, optimisation of the technique may improve 
yields to levels comparable to those of the current purification process.  The use of 
protein G affinity chromatography may also present cost saving opportunities  in 
terms of the time taken to complete the initial purification step.
The  mathematical  model  devised  can  predict  the  shape  and  position  of 
breakthrough curves with some success.  Further work is required in order to gain 
a  better  understanding  of the  equilibrium  reactions  that  govern  the  protein  G 
polyclonal  immunoglobulin  interaction.  The  mathematical  model  provides  a
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position  were  only  partially  successful,  possibly  due  to  either  one  of  the 
assumptions the model  is based on is incorrect or the experimentally determined 
values  of Ki  or qm   are  inaccurate.  As  it stands the  model  could not be used to 
correctly  predict  the  effect  of altering  separation  conditions  and  parameters  i.e. 
bed height. However with refinement and further experimental work it should be 
possible  to  improve  the  model  so  that  it could be  used to  predict the  impact of 
changes  to  the  operating  parameters;  such  as  the  flow  rate  and  the  feed  inlet 
concentration.
2137  Future Work
This thesis describes the development of an integrated ultra scale down mimic and 
its  use  for  studying  process  changes.  Future  work  in this  area  could  be  on the 
optimisation  of  the  current  industrial  scale  manufacturing  process  and  on  the 
production  of a  whole  bioprocess  mimic  encompassing  the  ion  exchange  and 
affinity chromatography steps.  A fully linked bioprocess mimic would afford the 
opportunity to be able to study the knock on effects of process changes the whole 
way down the process stream.
Chapter five looked at an alternative purification method.  A more in depth study 
on  microfiltration  membrane  properties  and  their  effect  on  the  flux  rate  and 
transmission of the protein would be beneficial in expanding the understanding of 
filtration.
The  ability  to  purify  antibodies  from  mammalian  serum  in  one  step  (as 
demonstrated  in  chapter  six)  may  reduce  both  processing  time  and  costs;  this 
could  also  be  the  focus  of future  studies.  Work  needs  to  be  conducted  on the 
properties of the matrix, such as its life span and capacity as well as the durability 
of the  ligand  when  dealing  with  feed  solutions  that  contain  large  quantities  of 
contaminating  material  and  are  of  high  viscosity.  New  matrices  are  also 
continually  being  developed.  A  study  into  the  new  types  of  matrices  being 
produced, their properties and their applicability to antibody purification would be 
valuable.  Work  could  also  be  conducted to refine the  basic mathematical  model 
developed in chapter 6 for predicting breakthrough curves. A study optimising the 
process conditions used during the protein G affinity chromatography separation 
would  enable  an  accurate  comparison  of  the  yields  between  the  different 
separation techniques to be conducted.
The current affinity purification step represents a large proportion of the process 
costs.  Experimental  work  optimising  the  process  would  be  beneficial.  The 
theories developed in chapter six could be applied to the current affinity process in 
order to refine the model and predict beneficial process changes.
2148 Ultra Scale Down Solutions
8.1  Introduction
The purpose of the Engineering Doctorate scheme is to ensure that during the four 
years  of the  course,  candidates  receive  training  in  management,  validation  and 
commercial awareness as well as carrying out novel research.
The work described in the previous chapters details the research conducted during 
the  completion  of  this  thesis  on  Ultra  Scale  Down  methods  for  mimicking 
downstream operations and small-scale experiments for determining or predicting 
the  behaviour  of  the  process  feed  stream  at  a  large  scale.  The  purification 
operations  studied  include  precipitation,  centrifugation,  filtration  and 
chromatography.
The  equipment  and  methodology  used  to  predict  and  study  the  downstream 
purification process may have commercial uses.  The executive summary detailed 
in this chapter gives a brief overview of the potential commercialisation of Ultra 
Scale  Down,  its  benefits  and  drawbacks,  if it  were  to  be  used  in  an  industrial 
setting, along with a brief financial appraisal.
2158.2 Executive Summary
8.2.1  USD concept
Ultra  Scale  Down  (USD)  solutions  will  provide  services  to  enhance  current 
manufacturing  process  development  activities  carried  out  by  the  top  ten 
pharmaceutical  companies,  using  the  unique,  patented  USD  tools  and  software 
developed by University College London (UCL).  USD tools accurately mimic the 
downstream purification process of a biopharmaceutical drug at a laboratory scale. 
USD is seeking $6 mn in seed funding to finance working capital requirements for 
the  first two  years,  during which time  the  technology will  be  upgraded to  meet 
current  industry  standards  and the  benefits  further demonstrated  in an  industrial 
environment.
The key financial data for the proposed business is shown below:
Year 1 2 3 4 5 6 7 8
Revenues($ ‘000) 0 0 9,000 9,000 9,000 9,000 34,000 67,000
Operating Profit ($ ‘000) -3,700 -1,800 6,900 6,900 6,900 6,900 30,200 61,500
Operating  Profit  as  %  of 
Revenue
77% 77% 77% 77% 89% 92%
Head Count 15 16 17 17 18 18 18 18
Cumulative  Capital 
Required 
($ ‘000)
4,000 6,000 6,000 6,000 6,000 6,000 6,000 6,000
Table 8.1 Projected Financial Summary
2168.2.2 Value proposition
The key benefits of USD’s service are as follows:
1.  Enhanced optimisation of the manufacturing process.  This would result in 
better product yields, thereby reducing the costs of manufacturing.  Initial 
estimates  suggest  a  10-20%  potential  reduction  in  manufacturing  costs. 
Furthermore,  superior process optimisation may allow better definition of 
equipment requirements, with resultant capital expenditure savings.
2.  Optimising process development increases the probability of being first-to- 
market  with  a  novel  drug,  through  reduced  regulatory  review  times. 
Moreover,  due to  limited patent lives,  speeding up drug launch increases 
the amount of protected sales.
3.  A more robust process reduces risk of product recall due to manufacturing 
problems.
4.  Savings  in  time  and  costs  associated  with  the  process  development 
activities.
8.2.3  The Current Problem
Increasingly,  the  global  biopharmaceutical  industry  is  facing  cost  and  time 
pressures in the drug development process.  These result from:
Cost  containment  drives  by  drug  purchasers  (typically  national  health 
organisations) tend to focus on the most visible area -  drug pricing;
Increasing  competitive  pressures  call  for  rapid  launch  of new  drugs.  Industry 
experience  indicates that the  first entrant in a given therapeutic area can capture 
up to  80%  market  share.  Advances  in other areas of product development (e.g. 
bioinformatics)  have  also  shifted  the  bottleneck  to  the  process  development 
activity.
The  purification processes  for new drugs  are  becoming increasing  complex and 
costly as a result of increasing complexity of the drugs themselves;
New drug approval times by regulatory authorities (e.g. FDA) are decreasing and 
these bodies are starting to require that process definition be undertaken earlier in 
the product development cycle.
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biopharmaceuticals are “scale-up” effects, i.e. taking a laboratory-scale production 
process and defining the appropriate parameters to produce equivalent material at 
bulk  scale.  Unlike  for  synthetic  chemicals,  scale-up  effects  for 
biopharmaceuticals are difficult to predict (i.e. during fermentation), because there 
is  little theory or previous experience in this area.  Therefore, pilot scale  studies 
are  used  to  generate  the  requisite  empirical  data.  This  procedure  is  relatively 
costly, time consuming and may not define an optimum process.
8.2.4  Solution
USD  tools  accurately  mimic  the  downstream  purification  process  of  a 
biopharmaceutical drug at a laboratory scale.  The material produced during USD 
studies has been proven to  be  comparable with the material obtained at bulk scale.
Therefore, process options  can be investigated within a laboratory  early on  in the
drug  development  cycle  and  an  optimised  purification  process  delivered  to  the 
pilot plant for verification.  USD tools eliminate the need for continual repetition 
of pilot plant trials, and because the  scale  is  so small the work can be done at a 
fraction of the time and cost compared to the current process.  Software has also 
been  developed  that  allows  the  results  from  each  individual  operation  to  be 
integrated together into  a whole  process  model.  USD tools  are  available  for the 
seven  main  purification  methods  that  are  used  in manufacturing  most marketed 
biopharmaceuticals currently.  Further research is being conducted into other key 
operations  (e.g.  fermentation).  It  is  expected  that  working  models  for  these 
operations will be developed over the next three years by UCL.
8.3  Customers
The biopharmaceutical industry consists of four key segments:
Drug Discovery:  small  companies  which  focus  on  the  process  of discovering 
novel  drugs.  After  discovery,  the  drugs  are  licensed  to  larger  companies  for 
clinical trials and marketing;
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in all areas of the value chain from drug discovery and development to marketing; 
Big Pharma:  traditional large companies which manufacture biopharmaceuticals 
as  part  of  a  portfolio  of  both  synthetic  and  bio  drugs.  The  top  ten  pharma 
companies  dominate  the  global  pharmaceuticals  market.  Typically,  these 
companies are active in all areas of the value chain.
Contract Manufacturing Organisations (CMO):  about ten companies in the UK 
manufacture  biopharmaceuticals  on  behalf of big  pharma  and  specialist biotech 
companies.  Many  of  these  CMOs  also  provide  manufacturing  process 
development services to their clients.
USD will aim to target Big Pharma companies initially, given that:
This  segment  stands  to  gain  most  directly  from  the  potential  benefits  of USD, 
particularly  given  the  intensity  of rivalry  and the  fact that they  are  active  in all 
areas  of  the  value  chain,  including  process  development,  manufacturing  and 
marketing;
They  offer  the  best  probability  of  demonstrating  USD  capability  on  lead 
blockbuster  drug  candidates,  thereby  maximizing  USD’s  financial  returns  and 
market credibility;
The  potential  for  maximizing  the  financial  value  of the  USD  service  will  be 
highest,  given these  companies’  scale  of operations  and hence  financial  strength 
and ability to afford the service.
The  initial  geographic  target  market  will  be  the  UK  and  US,  depending  on the 
location of the development team  for the drug candidates to be studied by USD. 
All the Big Pharma companies have a substantial presence in the UK and US. The 
UK also leads Europe in growth in the biopharmaceuticals market.
8.3.1  Competitors
Two  main  process  simulation  software  packages  are  currently  used  in  the 
biopharmaceutical  industry,  sold  by  Intelligen  and  Aspentech.  USD’s  key 
advantages over these are:
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the  USD  tools.  The  resultant  process  models  are  superior  in  validity  and 
comprehensiveness to the simulation models based on theoretical algorithms only; 
A  more  comprehensive  offering  than  Aspentech  in  terms  of  number  of 
purification methods simulated  (Aspentech focuses largely on a single operation 
-  chromatography).
The  USD  service  will  present  competition  to  the  CMOs  that  currently  provide 
process  development  services.  However,  USD’s  market  entry  strategy  of 
targeting selected Big Pharma clients, should mitigate some of the risk of potential 
competitive responses by the CMOs. Big Pharma companies represent a relatively 
small  proportion  of CMO  process  definition revenue,  as  they tend to  undertake 
most process definition work in-house, before contracting out manufacturing.
8.3.2  Accessing the market and extracting financial value
The  first two  years  will  be  devoted to  developing the hardware  and software  in 
order  to  bring  it  up  to  current  good  manufacturing  practice  standards  (cGMP). 
During this time, we will work in parallel with the process development team of a 
Big  Pharma  company  such  as  Pfizer  or  Glaxo  (which  have  the  largest  drug 
development pipelines  currently).  Work will be undertaken on several different 
projects  encompassing  the  major  drug  classes  in  order  to  demonstrate  the 
technology.  Direct comparison with the traditional process development scheme 
will enable quantification of the cost benefits obtained using USD.
The  Big  Pharma  company  will  be  persuaded  to  allow  USD  to  conduct  these 
studies by:
Utilising UCL’s contacts and reputation as leverage;
Emphasising that the Big Pharma company has nothing to lose since we will not 
charge a fee initially, on the condition that we can use the trial results to promote 
our product.  If,  however,  the  company  elects  to  use  USD  results  for the  final 
manufacturing process, a fee will be charged to cover costs.
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proven  to  be  invaluable  to  any  pharmaceutical  company  that  wishes  to  be 
successful  within  the  current  climate  of  shrinking  profit  margins  and  rising 
manufacturing costs.  Therefore, once the trial is complete, the founders will tour 
conferences and trade shows marketing USD and demonstrating how effective it 
is by reference to the trial with the Big Pharma company.
Early studies conducted at UCL show that cost savings to the client will be in the 
form  of decreased manufacturing costs  (10-20%  per year) and decreased capital 
costs (~$15mn).  A further benefit will derive from the increased chance of being 
first to  market  and  the  associated  revenue  benefits.  Based  on these  savings,  we 
would negotiate a royalties based method of payment, which is an industry norm. 
We would expect a 0.5-1.5% share of the future sales revenue for the drug, with 
the exact clauses and percentages being negotiated on an individual project basis.
8.3.3  Management and culture
The  founders  will  form  the  initial  management  team,  focusing  on  technical 
aspects  and  business  development.  The  founding  team  comprises  significant 
experience  in  the  pharmaceutical,  biochemical  engineering,  finance  and 
consulting sectors, specifically:
Greg  Neal:  EngD  (Biochem)  will  assume  the  role  of Technical  Director,  with 
responsibility for the overall technical aspects of studies, management of technical 
staff and  laboratory  facilities,  and  liaison with UCL on technology strategy and 
development  issues.  He  has  significant  direct  experience  with  the  USD 
technology.
John  McNulty:  BEng  (Chem)  MSc  (Pharm  Eng)  will  be  one  of the  Business 
Development  Directors,  with  responsibility  for  marketing  USD’s  services  and 
serving as Client Account Manager for selected clients. John is an MBA student at 
London  Business  School,  with  a  background  in  various  technology  transfer,
221technical  support  and  project  management  roles  in  the  bulk  pharmaceutical 
manufacturing sector, working with Merck Sharp & Dohme (Irl) Ltd.
Stuti  Sahajpal:  MEng  (Chem)  will  also  undertake  the  role  of  Business 
Development  Director.  She  will  also  undertake  financial  and  accounting  tasks 
initially.  Stuti  is  an  MBA  student  at  London  Business  School.  Her  previous 
experience includes management consultancy (including business development) at 
Arthur D. Little and equity analysis at Citibank.  Most recently, Stuti has worked 
as  a  planning  manager  in  a  small  printing  firm,  giving  her  exposure  to  the 
challenges of managing a small company.
The founding team will manage the process of shaping USD and securing initial 
funding.  Thereafter,  USD  will  seek  to  recruit,  as  soon  as  possible,  a  Chief 
Executive  Officer  with  relevant  industry  experience  to  enhance  USD’s  market 
access, visibility and credibility.
8.3.4  Profit potential and funding requirements
The cost of manufacturing a biopharmaceutical drug represents 24% of the sales 
revenue.  Therefore,  for  an  average  drug  that  has  annual  sales  of $265mn,  the 
manufacturing  costs  are  $63mn.  A  saving  of  10-20%  is  therefore  ~$6-12  mn 
annually.  Our fee of 0.5-1.5% of sales would cost the customer ~$l-4 mn. For a 
blockbuster  drug  with  annual  sales  typically  of $2.5  bn,  the  profit  potential  is 
significantly  larger.  The  cost of manufacturing a blockbuster rises to  $600 mn, 
and therefore the saving for the client rises to $60-120 mn.  The royalty charge on 
sales now represents annual revenues to USD of $13-38 mn.
We estimate that to run a facility with a capacity for six projects per year would 
cost nearly $3 mn/year.  Therefore, even without participating in the development 
of a blockbuster drug, the profit margin is still substantial.  In addition, since the 
life  cycle  of a  drug  is  between  10  and  15  year,  the  royalty  revenue  would  be 
ongoing  over  this  time,  without  incurring  further  costs  directly  related  to  that 
drug.
222Given the anticipated growth  in drug candidates under development, going from 
45 to 620 (15% of which will  be Biopharmaceuticals -  approximately  100 drugs 
per  year)  by  2005,  prospects  for  scaling operations  to  conduct  studies  on  more 
than  six  drugs (i.e.  increasing  from a 6% market  share)  per year are  promising. 
See Table 8.1  for Financial Summary.
Company 
Savings 
$ 9.3S mn
Revenue
Figure 8.1  Customer Benefits and USD Revenue Model for an “average” drug
BLOCKBUSTER DRUG • Annual Revenue & 
Costs
Company 
Savings 
$ 90 mn
Revenue
Figure 8.2  Customer Benefits and USD Revenue Model for a “Blockbuster” drug
2239 T he  Im pact  O f  U ltra  Scale  Down  M imics  On  The 
M anagem ent  O f  Purification  Process  Developm ent 
A nd T he  R egulatory  Issues A rising  From  T here Use
Chapters three and four describe the design and use of ultra scale down mimics of 
precipitation and centrifugation to  mimic an  industrial  scale purification process 
and study the effects of changes to the purification process. The results presented 
in  chapter  three  show  how  individual  purification  operations  can  be  linked 
together  and  how  the  laboratory  scale  results  compare  to  the  industrial  scale 
process.  Chapter  four  goes  on  to  utilise  the  mimics  to  explore  the  effects  of 
process changes.
The ability to produce information at a laboratory scale, that predicts and mimics 
the industrial scale, has interesting implications for the initial downstream process 
design and optimisation and how it is managed.
9.1  The Traditional Biopharmaceutical Drug Development Cycle
The average time to develop and market a new medicine is roughly seven years, 
but varies widely with some drugs only taking four years and others taking as long 
as fifteen.  The development cycle varies for each drug but the process follows a 
structure defined by the regulatory environment.  The chart below details a typical 
development cycle and the different stages are generic for every process.
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Regulatory approval
Process R&D Pilot development and  nianukiciuririL' start-up
0 2 3 4 5 6 7
Figure 9.1  Typical Drug Development Process
224Process research and development is on the critical path since the manufacturing 
process needs to be  defined before Phase  III clinical trails can commence.  Any 
changes  after the  start of Phase  III  will  result  in more  consistency  and  efficacy 
studies.  These  can  result  in  a  delay  to  Phase  III  clinical  trials  and  regulatory 
approval.
9.1.1  Downstream process research and development
“The  goal  of  process  development  is  to  move  from  a  process  that  has  been 
developed for laboratory developmental work and that is complex, inefficient and 
potentially  unsafe  to  one  that  is  practical,  efficient,  robust  and  safe”  (Pisano, 
1997). The table below highlights the difference between initial discovery and the 
full-scale  production  process.  Process  development  encompasses  all  the  work 
involved in the transition between these two phases.
Initial Discovery Process Final Commercial Production 
Process
Number of 
purification steps
15 7
Equipment Testtubes-1  liter flasks 2000-4000 gallon vessels
Batch size (output) ~ 1   gram 100-200 kg
Operators PhD chemists Technicians,  semi-skilled plant 
workers
Purity 1  %-10% 99.9%
Cost per kilo ~$20000-$50000/kg ~$3,500/kg
Criteria for process Biological activity of Cost; quality conformance with
design molecule; patent issues regulation; operability
Table  9.1  Comparison of initial  and commercial  production processes  (Pisano, 
1997)
225Process R&D can be split into two broad sections upstream, which encompasses 
fermentation  design and accounts  for roughly 20% of the cost and downstream, 
which is the actual purification process. Process R&D begins with the search for a 
manufacturing  process.  The  manufacturing  purification  process  (downstream 
processing),  involves the  use of sequential purification equipment to remove the 
impurities  from  the  feed  stream,  resulting  in  a  final  product  that  is  free  from 
contaminants  and  suitable  for  administration  to  humans.  The  majority  of 
biological drugs on the market use the  same  seven main purification methods in 
variable  order to  get to  a marketable  final  product.  These  are:  Cell  disruption, 
Centrifugation,  Filtration/Ultra-filtration,  Expanded  bed  processes,  Column 
chromatography and Precipitation (Bonneijea, et al.  1986).
At this  point  in the cycle,  only four pieces of data are available:  1) The  protein 
that  needs  to  be  produced;  2) The  gene  sequence  that codes the protein;  3) The 
host cell used to express the protein and 4) The method for isolating/purifying the 
protein within the laboratory.  The first step is the design of assays that accurately 
measure the quantity and purity of the protein.  The next stage is the design of a 
manufacture  scale  process  that  is  efficient and robust -  this  stage  is  called pilot 
development.
9.1.2  Pilot scale development
Traditionally  pilot  scale  studies have been exploratory  in nature.  This  is due to 
the fact that, at this point in time, very little will be known about the purification 
of the  candidate  drug.  Of particular importance  is  the  scale  of production;  this 
influences  the  performance  of a  biotech-process.  These  “scale-up”  effects  are 
difficult  to  predict  because  there  is  little  knowledge  about  what  environmental 
variables might affect the process.  The emphasis of process development is to 
get the process parameters defined as quickly as possible.
226Sets of pilot experiments are conducted to determine the influence on performance 
of a number of process parameters.  At this stage, problem solving also focuses on 
identifying  the  critical  factors  affecting  process  yields  and  product  quality. 
Getting  a  process  under  control  requires  that  a  significant  amount  of data  be 
generated over a large number of controlled pilot runs.
Fermentation design
Laboratory
scale w
purification
process
Preliminary 
process selection
Output from operation
Repeat several times
Pilot Pilot
batches batch
Purification yields 
Process parameters 
Product characteristics 
Economics 
Analytical methods
Identify and refine 
problem steps
Pilot production trials 
lOOL's  material 
Months for one  batch
Evaluation & 
Modification (1/10 
final scale)
Facilities & 
Equipment 
design
▼
Evaluate 
at  full 
scale
Optimise
process
V
Full scale trials
Figure 9.2  Traditional pilot scale process development scheme
9.1.3  The “historical” approach to process development
Considering the  fact that  pilot plant  studies  are  time consuming,  expensive  and 
require  dedicated  equipment,  the  traditional  attitude  among  biopharmaceutical 
companies  toward  process  optimisation  has  been  to  delay  it  until  there  was  a
227reasonable certainty that the drug would be approved.  In other words, companies 
hoped to avoid spending resources on drugs that would never make it to market. 
In practice, this meant investing heavily in process development/optimisation only 
when drugs got to Phase III clinical trials.  Process development was considered a 
success when it did not get in the way of product launch.  Creating a process that 
gave  the  drug  a  competitive  advantage  was  not  a  high  priority,  as  this  was 
considered  a  threat  to  the  aim  of keeping  process  development  off the  critical 
pathway time wise.  In the words of a traditional manager:  “If you try to do too 
much process development you will delay the launch.”
The challenge was framed in terms of optimising the initial process developed by 
discovery  research  scientists,  scaling  it  up  and  adapting  it  to  the  process 
environment.  Once  the  drug  reached  the  market,  the  focus  was  on  providing 
larger  manufacturing  facilities,  rather  than  optimising  the  process  in  order  to 
improve yields.  For a biopharmaceutical company, there are three main sources 
of competitive advantage:
1.  First to market
2.  High quality (in terms of purity, yield, dependability and flexibility)
3.  Low cost
At present each offers advantages that can only be exploited at the expense of one 
of the others.
1st to market
Optimal
process
Low  High quality
cost
Figure 9.3  Benefits of an optimised manufacturing process
228This  approach  used  to  make  sense  when  drugs  were  relatively  simple  to 
manufacture  and  process  development  involved  few  major  challenges.  FDA 
regulations also stated that the process did not need to be finalised until later on in 
the development cycle.
However,  the  industry  context  is  now  changing,  creating  challenges  for 
biopharmaceutical  companies.  The  financial  and  regulatory  environment  is 
creating  downward  pressure  on revenues  (caused by  shorter product life  cycles, 
pressure  by  governments  to  produce  cheaper  drugs  and  increased  competition) 
and upward pressure on manufacturing costs (caused by the increasing complexity 
of new drugs  and  stricter regulatory requirements).  As  a result leaving process 
development  until  the  last  minute  will  almost  certainly  lead  to  unaffordable 
delays.
This  changing  environment  has  caused  a  rethink  of  process  development 
strategies.  It  has  been  proved  that thorough  investigation  of the  manufacturing 
process  leads  to  improved  yields,  accelerates  throughput  and  reduces 
manufacturing  cycle  times.  These  improvements  all  lead  to  reduced  costs  of 
manufacture  and  potentially  provide  an  advantage  in  terms  of the  potential  for 
getting to market first with a new class of drug.
9.1.4  The current management problem
The  time  and  monetary  constraints  surrounding  pilot  plant  trials  preclude 
biopharmaceutical  companies  from  thoroughly  optimising  a  process.  The 
pressure to be first to market and to mitigate the risk of lost capital investment if a 
drug fails to get to market, out weighs the pressure of having a perfect purification 
process.  The  result  is  often  an  unwieldy,  inefficient,  and  costly 
manufacturing  process.  If  process  improvements  are  carried  out  after  the 
product  has  been  launched,  which  is  very  costly  and  time  consuming,  then the 
opportunity is missed to reap savings on production costs, since demand normally 
peaks early in product life cycle.  Therefore, improvements need to be made early 
on.  Also, regulatory constraints mean that any major process changes need to be
229validated and  approved  by the appropriate regulatory authority, a process that is 
by  itself time  consuming  and expensive.  However, the  high cost and long time 
line  of  pilot  studies  is  prohibitive  towards  carrying  out  extensive  trials  and 
providing  an  optimised  process  early  in  the  cycle,  when  the  drugs  chances  of 
reaching the  market are  less than 20%.  The result is that the biopharmaceutical 
companies are now faced with a conundrum; millions cannot be invested early in 
the drug development cycle to develop a manufacturing process, since the chances 
of it  getting  to  market  are  so  low.  Therefore,  the  biopharmaceutical  company 
chooses  to  burden  itself with  a  generic  un-optimised  manufacturing  process  in 
order to reduce time and costs.
9.2  Ultra Scale Sown As The Theoretical Solution To The Process
Development Conundrum
Ultra  Scale  Down  (USD)  mimics,  such as those described  in chapters three and 
four  offer  process  engineers  the  opportunity  to  recreate  the  conditions  of  a 
manufacturing scale purification process on a laboratory bench top.  At present a 
fermentation  design  mimic  has  not  been  built,  although  one  is  in  development 
(Lamping,  2003).  This  means that any purification process that utilises the unit 
operations that USD has the ability to mimic, can be investigated at the start of the 
development cycle.  This is at a fraction of the cost in terms of time, material and 
facilities.  The  results  from  these  scale  down  investigations  ensure  that process 
development is kept off the critical path and that a robust, effective purification 
process is delivered early on with a minimum number of pilot scale trials needed 
to  verify  it.  As  a result,  a biopharmaceutical  company can  be  first to  market 
with  a  low  cost and  high  quality process.  The complementary software allows 
results  from  individual  operations  to  be  integrated  into  one  whole  purification 
process  model.  This  allows  process  engineers  to  make  changes  to  one  unit 
operation  and  then  monitor  the  effect  on  the  whole  process  in  terms  of yield, 
efficiency and cost.
230Utilising USD technology has an effect on the drug development cycle, which is 
shown below:
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Regulatory approval
I  SI) Process  R&D. Pilot development and iiianuUicnirmc Mart-up
0  1
Figure 9.4  Proposed drug development cycle using ultra scale down technology
Process  R&D  is  no  longer  on  the  critical  path;  it  takes  less  time,  requires  a 
substantially smaller financial investment and delivers a more robust and efficient 
process.  This in turn helps to decrease the time to market by reducing the time 
spent at the regulatory approval stage.  A robust process that consistently delivers 
a purified product will take less time to gain approval than a process that has not 
been thoroughly investigated and optimised.
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9.3  Validation Of The “Crofab” Purification Process
CroFab is the trade name for Protherics anti-rattle snake venom.  This section will 
briefly discuss the validation of the purification process described throughout this 
thesis and  some of the  issues arising  from the use of Ultra Scale  Down  mimics 
during process development.
In order for a company to market a pharmaceutical product within a country, they 
must first obtain approval from the regulatory authorities governing the countries 
they wish to sell to.  An example is the Food and Drug Administration (FDA) of 
the United States of America; they require that the product and process be tested
232in  order  to  ensure  that  it  is  efficacious,  safe  for  human  use  and  that  the 
manufacturing  process  is  robust  and  reproducible.  Validation  provides 
documented  evidence  that  when  a  process  is  operated  under  the  defined 
conditions, a consistent level of performance that is acceptable will be obtained.
CroFab  process  development  was  undertaken  at  the  former  site  of Therapeutic 
Antibodies  UK  Ltd  (Tab  UK,  London)  and  transferred  to  large-scale  cGMP 
manufacture at Llandysul, Wales (Protherics UK Ltd).
Six conformance/consistency lots (2  sets of 3  batches) were produced within the 
cGMP facility at proposed production scale. Details of the licensed manufacturing 
and  process  validation  may  be  found  within the  Chemistry,  Manufacturing  and 
Controls  section  of  the  original  product  license  application  (volume  4  of 44, 
CroFab  original  PLA,  24  April  1998).  Stability  and  in  process  testing  was 
undertaken  using  analytical  methods  validated  according  to  current  ICH 
guidelines.  Product stability was assessed on 3 production scale batches. Product 
at various in process holding steps was stored at 2-8°C and evaluated by HPLC at 
4 week intervals over a 2 year period. Additional studies were undertaken at 27- 
33°C.  The  product  was  assessed  for  appearance,  colour,  clarity,  pH,  purity  and 
potency.  Two  prior approval  clinical  studies  were undertaken to assess  stability, 
efficacy and dosage of the final product.
As several volumes of the original CroFab license application are held within the 
Department of Regulatory affairs, Protherics  Inc  USA and due to confidentiality 
restrictions regarding the licensed product, further details of process validation are 
beyond  the  scope  of  this  thesis.  The  CroFab  purification  process  outlined  in 
Chapter 1   describes the current, validated method of GMP manufacture.
As  a whole  process  validation involves the  characterisation of each  stage of the 
purification  process  in  order  to  demonstrate  that  it  is  robust,  repeatable  and 
performs as intended; it should also demonstrate the limits of each step.  Cleaning 
validation also falls under this umbrella. The cleaning of each piece of equipment 
and the facility needs to be validated to demonstrate removal of proteins whether
233they  are  from  the  previous  process  or  the  environment.  It  also  needs  to 
demonstrate that no trace of the cleaning chemicals themselves remain.
Equipment validation can be split into two phases.  The installation qualification 
provides documented verification that the equipment has been installed inline with 
the  manufacturers  recommendations  and  establishes  confidence  that  the 
equipment is capable of consistently operating within the established limits.  The 
operational  qualification  provides  documented  evidence  that  the  equipment 
performs as intended over the anticipated operating ranges.
Test  methods  such  as  SDS-Page  or  Gel  Permeation  Chromatography  provide 
evidence of, for example: the purity, identity, concentration or biological activity 
of the protein of interest.  A test method validation study will have to be carried 
out which will demonstrate that the method is capable of determining the aspect 
being  examined,  for  example  the  concentration.  The  study  will  also  have  to 
demonstrate  that  the  method  is  repeatable  and  accurate.  The  study  involves 
characterising  the  method  including  aspects  such  as  its  limits  of operation  and 
interfering  chemicals.  Once  completed  the  test  method  validation  will 
demonstrate the applicability, repeatability and acceptability of the test.
The purification of CroFab involves eight distinct steps the precipitation step has 
been  chosen  to  demonstrate  how  a  process  step  might  be  validated.  The 
precipitation step is the first major purification step.  It is designed to remove the 
majority of the contaminating albumin and some other contaminating proteins in 
order  to  produce  a  feed  stream  suitable  for  chromatographic  purification 
operations.
In order to validate the purification step a characterisation study was undertaken 
which  addressed  the  parameters  influencing  the  precipitation  process.  These 
included;  the  amount of sodium  sulphate  used,  the  rate/mode  of addition of the 
sodium  sulphate,  the  type  of sodium  sulphate,  the temperature  of operation and 
the mixing conditions/time.  Each parameter was studied in order to define a range 
within  which  the  process  has  to  be  operated.  For  example  a  range  of sodium 
sulphate concentrations from ten to twenty percent (w/v) was studied.  The study
234determined  that  precipitation  occurs  from  12%  sodium  sulphate  upwards.  A 
working value of 18% was then chosen so that any small variation that may occur 
during routine manufacture will not impact the output of the process.  Each aspect 
was examined and an operational range set which is within the limits studied.  In 
practice the result of a well thought out and applied characterisation study will be 
a  purification  step  that  is  robust,  repeatable  and  satisfactory  to  the  governing 
agencies.
9.4  Regulatory Issues Arising From The Use Of Ultra Scale Down
Mimics During Process Development
Ultra  Scale  Down  mimics  such  as  those  developed  in  chapters  three  and  four 
might  enable  initial  process development work to be  carried out at a very small 
scale, which requires only very small quantities of material.  This would allow a 
company wishing to  develop and market a product to conduct more research on 
the  purification  process  should  it  wish  to.  This  in  turn  could  generate  more 
evidence that the manufacturing process is robust and reproducible since a number 
of experiments could be conducted testing the manufacturing process to the very 
limits of its design.
If however this information were to be submitted as part of the validation process 
the  Ultra  Scale  Down  mimics  would  first  have  to  be  validated.  This  would 
involve  not  only  the  standard  installation,  operation  and  performance 
qualifications  required  for  any  piece  of validated  equipment  but  also  that  the 
results generated by the small scale experiments be validated as being comparable 
to the results generated during a full scale manufacturing run.
In order to do this the manufacturer of any Ultra Scale Down device would have 
to provide evidence and details of the working ranges/conditions within which the 
device  has  been  tested  to  show  that  when  used  under  the  tested  operating 
conditions, it will generate results that compare to the full-scale process.
235In  practice,  within  the  biopharmaceutical  industry  this  may  not  be  possible 
because  every  process  is  different,  operated  under  different  conditions  with  a 
different  product.  Therefore,  the  ultra  scale  down  mimic  would  have  to  be 
validated  for  each  product,  process  and  condition.  A  restraint  which  may  limit 
their use to that of a research tool for many years to come.
Ultra scale down mimics have a great potential to provide a wealth of information 
about  a  manufacturing  process  but  during  the  validation  of  a  process  their 
usefulness  would  be  limited  by  the  fact  that  it  would  be  extremely  difficult  to 
validate,  that  the  information  generated,  accurately  mimics  what  occurs  at  the 
larger scale.
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25611  Appendix
11.1 Proformas
Date: 16/11/1999
Name:  Greg Neal Supervisor: Eli Keshavarz-Moore
Registration Date (1999/9/27) Advisor: Mike Hoare
Level: (EngD) (with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they  interact with each other,  resulting in a more  efficient,  less time  consuming 
purification process.  A  greater knowledge of how the purification steps  interact 
will  also  allow  results  produced  at  the  laboratory  bench  scale  to  be  more 
accurately  applied to  an  industrial  scale.  The  scale  down is  a powerful tool  for 
predicting  the  optimum  design  and  operation  of large  scale  complex  processes. 
It is particularly challenging because of poor scalability from  laboratory to pilot 
plant, and because of difficulties in the exploration of process optimisation.
Goals:
To  create  a  scale  down  mimic  of  the  pre-purification  steps  that  accurately 
describes  the  industrial  scale  process  utilised  by  Protherics,  and  to  study  the 
effects of engineering parameters in the application of process options.
257Conceptual Challenges:
The  behaviour  of  precipitates  in  the  centrifuge  has  a  large  impact  on  the 
clarification  and  separation  characteristics.  Precipitates  are  particularly 
susceptible to shear but the effects are system specific.
Results:
Protherics  produce  polyclonal  antibodies  in  bulk  and  final  dosage  form  for 
therapeutic use. The company’s products range from antidotes to snake venom to 
antibodies  against  anti-depressant  overdose.  They  are  the  world’s  biggest 
producer  of  anti  snake  venom.  The  company  distinguishes  itself  from  its 
competitors through the use of polyclonal rather than monoclonal antibodies.
At  present  the  serum  produced  by  immunised  sheep  is  processed  using  several 
different  techniques  ranging  from,  precipitation  and  centrifugation  to  affinity 
chromatography.  The  company wishes to  scale  up  its production from  100L to 
1000L and is investigating alternative process options.
A  two  week  visit  was  undertaken  in  order to  gain  first  hand  experience  of the 
production  of the  anti  snake  venom.  A  report  has  been produced  on this  visit 
detailing each step of the purification process.
Intellectual Property:
Investigation  into pre-purification steps  is  of value  as  eventually it should allow 
the process to be optimised so that valuable product is not lost during purification 
and it should allow the efficient scale up of the product.
Publications:
None
Previous milestones:
None
258Research targets:
6 months:
Understand the  purification process  used by Protherics with particular emphasis 
on the  precipitation  and  centrifugation  steps.  Mimic the precipitation step on a 
bench top scale in order to study the qualities of the process stream, and determine 
the characteristics of the precipitate.  The conditions of the precipitation step such 
as the precipitate used may be altered in order to study it further.
Milestones:
•  Calculate  the  sigma  value  for  both  Protherics  disc  stack  centrifuge  and the 
bench scale one.
•  Mimic  the  precipitation  stage  and  characterise  the  process  stream,  particle 
size, flow characteristics, density, viscosity and the density difference between 
the solution and the precipitate will be determined.
Research targets:
6 months to 1 year:
Understand  the  behaviour of the precipitate  in the  centrifuge  and create  a scale 
down  model  that  accurately  predicts  the  behaviour  of  the  industrial  scale 
centrifuge.  Study  the  interaction  between  the  precipitation  and  centrifugation 
steps  and  how  what  happens  in  these  steps  effects  the  process  further  down 
stream.
Milestones:
•  Create a model of the precipitates behaviour in the centrifuge
•  Mimic the centrifugation step on a small scale
259Training profile
Educational Background:  B.Sc (Hons) University of Wales, College of Cardiff 
Training profile: Lacks engineering background.
Year 1
Core Training:
Course or Management activity Dates * Progress & Assessment
Graduate school board skills 
e.g. Personal and Professional 
Management Skills 
PPSRP
Oct 99 to 
June 00
Lectures and workshops 
attended assessment is 
via course work and 
examination
Graduate school technical courses
e.g. Statistics
Statistics
14/01/00
24/03/00
Lectures and workshops 
attended assessment is 
via course work and 
examination
Department training modules 
e.g. Fermentation module 
Downstream Processing
Mar 00 to 
June 00
Downstream processing 
lectures plus course 
work and a final exam
Management activities 
Demonstratorship
Dec 99 to 
Mar 00
Student assessment 
Several training sessions 
attended
Workshops Attended 
e.g. Gene meetings
Shear
Total number of courses taken
* these may be checked
260Date:  14/07/00
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Mike Hoare
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they  interact with each  other,  resulting in a more  efficient,  less time  consuming 
purification process.  A greater knowledge of how the purification steps interact 
will  also  allow  results  produced  at  the  laboratory  bench  scale  to  be  more 
accurately  applied to  an  industrial  scale.  Scale  down experiments  are powerful 
tools  for predicting the  optimum  design and operation of a large  scale  complex 
process.  It  is  particularly  challenging  because  of  the  poor  scalability  from 
laboratory to pilot plant and because of difficulties in the exploration of process 
optimisation.
Goals:
To  create  a  scale  down  mimic  of  the  pre-purification  steps  that  accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a large  impact on the  clarification and  separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
261Results:
A scale down model of the precipitation process has been built which accurately 
mimics  the  industrial  scale  operation.  The  model  can  be  used  to  predict  what 
effects changes in the precipitation operation will have on the precipitate particles 
characteristics.  Material produced by the model can also be used to further study 
the purification process.
Intellectual Property:
Investigation  into pre-purification steps  and scale  down models  is  of value as it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early 
stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
Publications:
None.
Previous Milestones:
Understood  the  purification  process  used  by  Protherics,  particularly  the 
precipitation and centrifugation steps.  Mimicked the precipitation step on a bench 
top scale and determined the precipitate particles characteristics including, particle 
size, density, viscosity and percentage solids content.
Research targets:
Next 6 months:
Understand  he  behaviour  of the  precipitate  in  the  centrifuge  and  create  a  scale 
down model that accurately predicts the behaviour of the industrial scale machine. 
Study the  interaction between the precipitation and centrifugation steps and how 
what happens in these steps effects the process further down stream.
Milestones:
•  Understand how precipitate particles behave in a centrifuge and how their 
characteristics affect the performance of the centrifuge.
262•  Build  a  scale  down  model  of the  disc  stack  centrifuge  that  accurately 
mimics the industrial scale device.
Research Targets:
Next 6 months to 1 year:
Study  what  effect  alterations  in  the  precipitation  conditions  have  on  the 
centrifugation step and what knock on effect this has on chromatography stages. 
Study  what  effect  changes  in  engineering  parameters  during  the  centrifugation 
stage have on the performance of the centrifuge.  Produce a scale down model of a 
chromatography column.
Milestones:
•  Build a scale down chromatography column
•  Understand process interactions
263Training Profile
Course or Management 
activity
Dates * Progress & Assessment
Graduate school board skills 
e.g. Personal and Professional 
Management Skills 
PPSRP
Oct 99 to 
June 00
Completed awaiting result
Graduate school technical
courses
e.g. Statistics
Statistics
14/01/00
24/03/00
Completed awaiting 
results
Department training modules 
e.g. Fermentation module 
Downstream Processing
Mar 00 
to
June 00
Completed awaiting 
results
Management activities 
Demonstratorship
Dec 99 to 
Mar 00
Completed
Workshops Attended 
e.g. Gene meetings
Total number of courses taken
264Date: 14/11/00
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Mike Hoare
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they interact with each  other,  resulting in a more efficient,  less time consuming 
purification process.  A greater knowledge of how the purification steps interact 
will  also  allow  results  produced  at  the  laboratory  bench  scale  to  be  more 
accurately  applied to  an  industrial  scale.  Scale  down experiments  are powerful 
tools  for predicting  the  optimum  design and operation of a large  scale  complex 
process.  It  is  particularly  challenging  because  of  the  poor  scalability  from 
laboratory to pilot plant and because of difficulties in the exploration of process 
optimisation.
Goals:
To  create  a  scale  down  mimic  of  the  pre-purification  steps  that  accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a large  impact  on the  clarification and  separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
265Results:
Bioprocess design and optimisation customarily involves the use of pilot plant and 
industrial scale experiments to define the process and study the effect that changes 
to  the  process  have  on  the  level  of contaminants  or  yield  of product.  These 
studies  require  large  amounts  of time,  money  and material,  all  of which are  in 
short supply during the  initial stages of process design.  The use of scaled down 
laboratory models that accurately mimic the large scale process allow the process 
to be studied without the need for costly and material expensive pilot plant trials.
A  scaled down model  of the precipitation stage has been built which accurately 
mimics the  industrial  scale operation.  This model has been used to characterise 
the process stream, it has also been used to determine the effects, if any changes to 
the process will have on the precipitate particles and hence on operations further 
downstream.
Protherics  wish  to  change  from  liquid  precipitant  to  solid  in  order to  scale  up 
production.  This change to solid sodium sulphate has been studied and its effects 
are detailed below:
•  Increase in process stream viscosity
•  Increase in the amount of solid material
•  No change in particle size
The model  has  also  been used to  study the effects of higher shear levels during 
primary particle formation.  These were determined to be:
•  Increased process stream viscosity
•  Decreased particle size
•  Increased amount of solid material
Precipitant  produced  by  the  mimic  has  been  used  in  scale  down  centrifugation 
studies.  The  “in  house”  shear  device  is  being  used  to  mimic  a  disc  stack 
centrifuge and to study the effects of shear on particle size and biological activity.
266Intellectual Property:
Investigation  into pre-purification  steps  and scale  down models  is  of value as  it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early 
stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
Publications:
None
Previous Milestones:
Scale down mimic of disc stack centrifuge nearly complete, the scale down model 
of the  precipitation  stage  has  been  used  to  study  what  effects  changes  to  the 
process  set-up  have  on  the  characteristics  of  the  product,  i.e.  the  effect  of 
changing to solid precipitant and changes in mixing conditions.
Research targets:
Next 6 months:
Build a complete  picture  of the precipitation and centrifugation stage,  including 
mass  balances  and  visual  method  of tracking  the  process.  Use  this  picture  to 
optimise the process and study the effects of changes.  Produce the first paper on 
the scale down of precipitation and disc stack centrifugation.
Milestones:
•  Use  ELISA,  SDS-page  and total protein assays  to create a mass  balance 
and  track/visualise  exactly  what  is  happening  during  precipitation  and 
centrifugation.
•  Complete paper on scale down of precipitation and centrifugation.
•  Finish study on the effect of changing to a solid precipitant.
•  Finish study on the effects of shear on particle size and biological activity.
•  Determine the Zeta potential of the precipitate particles.
267Research Targets 
Next 6 months to 1 year:
Study  what  effect  alterations  in  the  precipitation  conditions  and  centrifugation 
stage  have  on  the  chromatography  step  and  how  the  stages  interact.  Produce 
second  paper  on  mixing  conditions  and  process  interactions.  Produce  a  scale 
down model of a chromatography column.
Milestones:
•  Second paper
•  Build a scale down chromatography column
•  Understand process interactions
268Training Profile
Course or Management 
activity
Dates * Progress & Assessment
Graduate school board 
skills
e.g. Personal and 
Professional Management 
Skills 
PPSRP
Oct 99 to 
June 00
Completed awarded pass 63%
Graduate school technical
courses
e.g. Statistics
Statistics
14/01/00
24/03/00
Completed awarded pass 63%
Department training 
modules
e.g. Downstream 
Processing
Bioprocess Management
Mar 00 to 
June 00
MarOl to 
June 01
Completed awarded  pass 
68%
In future
Management activities 
Demonstratorship
Nov 00 to 
Mar 01
One year completed starting 
second year
Workshops Attended 
e.g. Gene meetings
Total number of courses 
taken
269Date:  14/06/01
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Parviz Ayazi-Shamlou
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they  interact with  each  other,  resulting  in a more  efficient,  less time consuming 
purification process.  A  greater knowledge of how the purification steps  interact 
will  also  allow  results  produced  at  the  laboratory  bench  scale  to  be  more 
accurately  applied to  an  industrial  scale.  Scale  down experiments  are powerful 
tools  for predicting  the  optimum  design and operation of a large  scale  complex 
process.  It  is  particularly  challenging  because  of  the  poor  scalability  from 
laboratory to pilot plant and because of difficulties in the exploration of process 
optimisation.
Goals:
To  create  a  scale  down  mimic  of  the  pre-purification  steps  that  accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a large  impact  on the  clarification and separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
270Results:
A scale down model of the precipitation process has been built which accurately 
mimics  the  industrial  scale  operation.  The  model  can  be  used  to  predict  what 
effects changes in the precipitation operation will have on the precipitate particles 
characteristics.  Material produced by the model can also be used to further study 
the purification process.
The mimic has been used to study the effect that a change from liquid precipitant 
to solid has:
•  Increase the viscosity
•  Increase the percent solids
•  No change in particle size
It  has  also  been  used  to  study  the  effect  of higher  shear  levels  during primary 
particle formation:
•  Increased viscosity
•  Decreased particle size
•  Slightly increased percent solids
Precipitant  produced  by  the  mimic  has  been  used  in  scale  down  centrifugation 
studies.  The  “in  house”  shear  device  has  been  used  to  mimic  a  disc  stack 
centrifuge  and  to  study  the  effects  of  shear  on  particle  size  distribution  and 
biological activity.  The results are to be published in the first paper.
Intellectual Property:
Investigation  into  pre-purification steps and scale  down models  is  of value  as  it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early 
stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
271Publications:
Scale down of precipitation and centrifugation.  In preparation.
Previous Milestones:
Scale down mimic of disc stack centrifuge complete, the scale down model of the 
precipitation stage has been used to study what effects changes to the process set­
up have  on the  characteristics of the product,  i.e.  the effect of changing to solid 
precipitant and changes in mixing conditions, temperature etc.
ELISA,  SDS-page  and  total  protein  assays  have  been  used  to  create  a  mass 
balance  and  track/visualise  exactly  what  is  happening  during  precipitation  and 
centrifugation..
The study on the effect of changing to a solid precipitant has been finished 
Finished study on the effects of shear on particle size and biological activity
Research targets:
Next 6 months:
Finish  first  paper  on  scale  down  of precipitation  and  disc  stack  centrifugation. 
Complete three-month new venture development course at the London school of 
business.  Carry  out  study to  determine  solubility profile  of antibodies  in ovine 
serum. Investigate the effect of temperature on particle size and recoverability.
Milestones:
•  Paper finished
•  Course completed
•  Solubility profile determined
•  Effect of temperature determined
272Research Targets 
Next 6 months to 1 year:
Investigate  the  next  stage  in  the  purification  process  papain  digestion  and 
chromatography for a product in phase two clinical trials, find a way of removing 
the precipitation and centrifugation stage.
Milestones:
•  Complete model of papain digestion
•  Complete study into removing the precipitation and centrifugation stage
273Training Profile
Course  or  Management 
activity
Dates * Progress & Assessment
Graduate school board skills 
e.g.  Personal  and 
Professional  Management 
Skills 
PPSRP
Oct 99 to 
June 00
Completed awarded pass 63%
Graduate  school  technical
courses
e.g. Statistics
Statistics
14/01/00
24/03/00
Completed awarded pass 63%
Department  training 
modules
e.g. Downstream Processing 
Bioprocess validation 
Bioprocess management
Mar 00 to 
June 01 Completed awarded pass 68%
Completed
Completed
Management activities 
Demonstratorship
Nov 00 to 
Mar 01
Two years completed
New venture development at 
LBS
July  01- 
Sept 01
Biobusiness  plan 
competition
Sept  01- 
OctOl
Workshops Attended
274e.g. Gene meetings
Total  number  of  courses 
taken
275Date: 02/10/01
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Parviz Ayazi-Shamlou
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they interact with each  other,  resulting  in a more  efficient,  less time  consuming 
purification process.  A knowledge of how the purification steps interact will also 
allow results produced at the laboratory bench scale to be more accurately applied 
to an industrial  scale.  Scale down experiments are powerful tools for predicting 
the  optimum  design  and  operation  of  a  large  scale  complex  process.  It  is 
particularly  challenging  because  of the  poor scalability  from  laboratory to pilot 
plant and because of difficulties in the exploration of process optimisation.
Goals:
To create a scale down mimic of the downstream processing steps that accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a  large  impact on the  clarification and separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
276Results:
A scale down model of the precipitation and centrifugation stages has been built. 
This model has been validated against material provided by Protherics in order to 
prove the accuracy and validity of results.  The model can be used to predict what 
effects changes in the precipitation operation will have on the precipitate particles 
characteristics,  also  the  impact  of the  centrifugation  operation  can  be  assessed 
along with the effects  of changes  in the operating parameters of this stage.  The 
material produced by the model is representative of the feed stream produced at an 
industrial scale so all results can be applied to this scale, furthermore the material 
can also be used to study alternative purification options.
The mimic has been used to study the effect that a change from liquid precipitant 
to solid has:
•  Increase the viscosity
•  Increase the percent solids
•  No change in particle size
It  has  also  been  used  to  study  the  effect  of higher  shear  levels  during  primary 
particle formation:
•  Increased viscosity
•  Decreased particle size
•  Slightly increased percent solids
London Business School
A three-month course entitled new venture development was undertaken.  During 
the time spent at London Business School my teammates and myself developed a 
business plan for the commercialisation of Ultra Scale Down technology.
Intellectual Property
Investigation into  pre-purification steps  and scale  down models  is  of value as  it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early
277stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
Publications:
An  Ultra  Scale  Down  Approach  For  the  Prediction  of Full  Scale  Recovery  of 
ovine  Polyclonal  Immunoglobulins  Used  in  The  Manufacture  of Snake  Venom 
specific Fab Fragments (Final Draft)
Previous Milestones:
Scale down mimic of disc stack centrifuge complete, the scale down model of the 
precipitation stage has been used to study what effects changes to the process set­
up have  on the  characteristics  of the product,  i.e.  the effect of changing to solid 
precipitant and changes in mixing conditions, temperature etc.
ELISA,  SDS-page  and  total  protein  assays  have  been  used  to  create  a  mass 
balance  and  track/visualise  exactly  what  is  happening  during  precipitation  and 
centrifugation..
The study on the effect of changing to a solid precipitant has been finished 
Finished study on the effects of shear on particle size and biological activity 
Solubility study on the Fab fragments has been undertaken and finished. 
Three-month course at London Business School finished.
First paper has been completed.
Research targets:
Next 6 months:
Start  work  to  scale  down  filtration  and  study  this  purification  process  as  an 
alternative to centrifugation.
Milestones:
•  Complete scale down model
•  Study effect of feed stream (precipitant solution) on filtration
278Research Targets 
Next 6 months to 1 year:
Investigate alternatives to the existing purification process:
1.  Ultra scale down model of membrane filtration
2.  Ultra scale down model of chromatographic and papain digestion stages 
Milestones:
•  Complete model of membrane filtration
•  Complete model of chromatographic and papain digestion stages
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to
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280Biobusiness  plan 
competition
Sept  01- 
OctOl
Final stage qualifiers
Workshops Attended 
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281Date: 14/08/02
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Parviz Ayazi-Shamlou
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they interact with each  other,  resulting in a more  efficient,  less time consuming 
purification process.  A knowledge of how the purification steps interact will also 
allow results produced at the laboratory bench scale to be more accurately applied 
to an industrial  scale.  Scale down experiments are powerful tools for predicting 
the  optimum  design  and  operation  of  a  large  scale  complex  process.  It  is 
particularly  challenging  because  of the  poor  scalability  from  laboratory to  pilot 
plant and because of difficulties in the exploration of process optimisation.
Goals:
To create a scale down mimic of the downstream processing steps that accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a large  impact on the  clarification and  separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
282Results:
A scale down model of the precipitation and centrifugation stages has been built. 
This model has been validated against material provided by Protherics in order to 
prove the accuracy and validity of results.  The model can be used to predict what 
effects changes in the precipitation operation will have on the precipitate particles 
characteristics,  also  the  impact  of the  centrifugation  operation  can  be  assessed 
along with the  effects  of changes  in the operating parameters of this stage.  The 
material produced by the model is representative of the feed stream produced at an 
industrial scale so all results can be applied to this scale, furthermore the material 
can also be used to study alternative purification options.
The mimic has been used to study the effect that a change from liquid precipitant 
to solid has:
•  Increase the viscosity
•  Increase the percent solids
•  No change in particle size
It  has  also  been  used  to  study  the  effect  of higher  shear  levels  during  primary 
particle formation:
•  Increased viscosity
•  Decreased particle size
•  Slightly increased percent solids
Ultra Scale Down Filtration
A ultra scale down stirred cell filtration system has been used to study the effect 
of using filtration to remove the precipitated antibodies instead of centrifugation. 
Factorial design was used to design a series of experiment studying the effect of 
pressure  and  shear  rate  on permeate  flux rate.  The  yield of antibodies  and the 
purification profile has  also been determined and compared to the centrifugation 
route.  This work will form the basis of a second paper
283London Business School
A three-month course entitled new venture development was undertaken.  During 
the time spent at London Business School myself and my team mates developed a 
business plan for the commercialisation of Ultra Scale Down technology.
Intellectual Property
Investigation  into  pre-purification  steps  and scale  down models  is of value  as  it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early 
stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
Publications:
Neal G, Christies J, Keshavarz-Moore E, Ayazi Shamlou P. 2003. An ultra scale- 
down  approach  for  the  prediction  of  full-scale  recovery  of ovine  polycolonal 
immunoglobulins used in the manufacture of snake venom-specific fab fragment. 
Biotech Bioeng 81  (2):  149-157.
Previous Milestones:
Scale down mimic of disc stack centrifuge complete, the scale down model of the 
precipitation stage has been used to study what effects changes to the process set­
up have  on the  characteristics  of the product,  i.e.  the effect of changing to solid 
precipitant and changes in mixing conditions, temperature etc.
ELISA,  SDS-page  and  total  protein  assays  have  been  used  to  create  a  mass 
balance  and  track/visualise  exactly  what  is  happening  during  precipitation  and 
centrifugation..
The study on the effect of changing to a solid precipitant has been finished 
Finished study on the effects of shear on particle size and biological activity 
Solubility study on the Fab fragments has been undertaken and finished. 
Three-month course at London Business School finished.
First  paper  has  been  completed  and  accepted  for publication by  Biotechnology 
and Bioengineering
Ultra scale down of filtration process has been undertaken and finished
284Research targets:
Next 6 months:
Finish second paper on the effect of swapping from centrifugation to filtration on 
the downstream processing
Milestones:
•  Complete second paper
•  Produce an Ultra scale down model of chromatographic and papain digestion 
stages
Research Targets 
Next 6 months to 1 year:
•  Link  all  the  ultra  scale  down  mimics  together  to  form  a  whole  bioprocess 
model
•  Complete  an  economic  evaluation  of the  present  process  compared  to  the 
alternatives studied
•  Complete third paper on economics of process change
Milestones:
•  Production of whole bioprocess model
•  Completion of third paper
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286Date: 01/06/03
Name: Greg Neal  Supervisor: Eli Keshavarz-Moore
Registration date (1999/9/27)  Advisor: Parviz Ayazi-Shamlou
Level: (EngD with Protherics)
Project title:
A  study  of the  biopurification  steps  in  the  production  of polyclonal  antibody 
fragments for successful operation and scale-up.
Significance:
Investigation into the purification steps will lead to a better understanding of how 
they  interact with each other,  resulting in a more efficient,  less time  consuming 
purification process.  A knowledge of how the purification steps interact will also 
allow results produced at the laboratory bench scale to be more accurately applied 
to an industrial  scale.  Scale down experiments are powerful tools for predicting 
the  optimum  design  and  operation  of  a  large  scale  complex  process.  It  is 
particularly  challenging  because  of the  poor  scalability  from  laboratory to pilot 
plant and because of difficulties in the exploration of process optimisation.
Goals:
To create a scale down mimic of the downstream processing steps that accurately 
describes the industrial scale process utilised at Protherics, and to study the effects 
of engineering parameters in the application of process options.
Conceptual Challenges:
The characteristics of precipitate particles affect their behaviour in the centrifuge 
and have  a large  impact on the  clarification and  separation process.  Precipitate 
particles are particularly susceptible to shear but the effects are system specific.
287Results:
A scale down model of the precipitation and centrifugation stages has been built. 
This model has been validated against material provided by Protherics in order to 
prove the accuracy and validity of results.  The model can be used to predict what 
effects changes in the precipitation operation will have on the precipitate particles 
characteristics,  also  the  impact  of the  centrifugation  operation  can  be  assessed 
along with the  effects of changes  in the operating parameters of this stage.  The 
material produced by the model is representative of the feed stream produced at an 
industrial scale so all results can be applied to this scale, furthermore the material 
can also be used to study alternative purification options.
The mimic has been used to study the effect that a change from liquid precipitant 
to solid has:
•  Increase the viscosity
•  Increase the percent solids
•  No change in particle size
It  has  also  been  used  to  study  the  effect  of higher  shear  levels  during  primary 
particle formation:
•  Increased viscosity
•  Decreased particle size
•  Slightly increased percent solids
Ultra Scale Down Filtration
A ultra scale down stirred cell filtration system has been used to study the effect 
of using filtration to remove the precipitated antibodies instead of centrifugation. 
Factorial design was used to design a series of experiment studying the effect of 
pressure  and  shear rate  on permeate  flux rate.  The  yield of antibodies  and the 
purification profile has also been determined and compared to the centrifugation 
route.  This work will be published in a second paper
288Scale Down Chromatography
A small scale study of the equilibrium binding kinetics of ovine polyclonal IgG to 
Protein G has been conducted and the results used to build a mathematical model 
capable  of predicting  the  breakthrough  curves.  The  model  has  been  tested  by 
comparison with actual breakthrough curves produced under different conditions.
London Business School
A three-month course entitled new venture development was undertaken.  During 
the time spent at London Business School my team-mates and myself developed a 
business plan for the commercialisation of Ultra Scale Down technology.
Intellectual Property
Investigation  into  pre-purification  steps  and scale  down models  is  of value as it 
will  allow  processing  options  to  be  more  thoroughly  investigated  at  the  early 
stages of development when only small amount of material are available.  It will 
also reduce the amount of time it takes for a product to get to the market.
Publications:
Neal G, Christies J, Keshavarz-Moore E, Ayazi Shamlou P. 2003. An ultra scale- 
down  approach  for  the  prediction  of  full-scale  recovery  of ovine  polycolonal 
immunoglobulins used in the manufacture of snake venom-specific fab fragment. 
Biotech Bioeng 81  (2):  149-157.
Neal  G,  Francis  R,  Keshavarz-Moore E,  Ayazi  Shamlou P.  2004.  Separation of 
IgG  precipitate  from  contaminating  proteins  using  microfiltration.  Biotech  and 
Applied Biochem 39(2): 241-248.
Previous Milestones:
Scale down mimic of disc stack centrifuge complete, the scale down model of the 
precipitation stage has been used to study what effects changes to the process set­
up have  on the  characteristics of the product,  i.e.  the effect of changing to solid 
precipitant and changes in mixing conditions, temperature etc.
289ELISA,  SDS-page  and  total  protein  assays  have  been  used  to  create  a  mass 
balance  and  track/visualise  exactly  what  is  happening  during  precipitation  and 
centrifugation..
The study on the effect of changing to a solid precipitant has been finished 
Finished study on the effects of shear on particle size and biological activity 
Solubility study on the Fab fragments has been undertaken and finished. 
Three-month course at London Business School finished.
First  paper  has  been  completed  and  accepted  for publication  by  Biotechnology 
and Bioengineering
Ultra scale down of filtration process has been undertaken and finished.
Second paper ahs been completed and submitted.
Research targets:
Next 6 months:
Write up thesis
Milestones:
•  Complete Thesis
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